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Fatty acid deposition in non-adipose tissue leads to a cellular dysfunction known as lipotoxicity.  
Neutral lipid synthesis is known to protect against lipotoxicity but many additional pathways are 
likely to be integral in this process.  In order to identify pathways protective against lipid induced 
cell death, we performed a genome-wide unsaturated fatty acid (UFA) sensitivity screen in yeast.   
Of the ~5,500 gene mutants tested, we identified 156 which resulted in sensitivity to growth on 
media containing palmitoleate.  These genes identified many cellular processes, including 
vesicular trafficking, lipid metabolism and vacuolar protein sorting.   Deletion of three members 
of the GET complex, a complex essential for tail anchored protein insertion into the ER, caused 
vulnerability to fatty acids.  We went on to assess the role of GET3 in cellular lipid metabolism 
and found that ablation of GET3 results in a defect in vacuolar hydrolysis and a reduction in lipid 
droplet number; pathways which we hypothesize to be integrally related.  Furthermore, a major 
goal of this study was to find mammalian genes playing an integral role in pathways of 
lipoprotection.  Of the 156 gene deletions found to confer fatty acid sensitivity in yeast, 68 have 
been conserved in mammals.  We demonstrate that two of these mammalian orthologs, ARV1 
and ASNA1, are vulnerable to fatty acid treatment upon knockdown in the MIN6 pancreatic β-
cell line.  These mammalian genes, which were identified through the fatty acid sensitivity 
screen in yeast, are involved in lipid induced cellular dysfunction in pancreatic β-cells and, in the 
case of ARV1, hepatocytes.  Therefore, these genes likely play a role in the progression of the 
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CHAPTER 1: LITERATURE REVIEW 
 
The importance of obesity research has been increasing rapidly over the past century. For 
most of human history, obesity rarely occurred, and when it did was frequently associated with 




 century, the number of obese people increased 
due to increased food access and reduced physical activity, and the medical community began to 
identify health issues associated with excess weight gain.  These issues included shortness of 
breath, lethargy, depression, poor circulation and skin disorders [1, 2] as well as the primary 
comorbidities we now associate with obesity, type 2 diabetes (T2D) and cardiovascular disease 
(CVD) [3, 4]. 
In 1997 the World Health Organization (WHO) recognized obesity as a global epidemic 
and obesity and overweight have continued to grow to astounding numbers worldwide.  As of 
2008, the WHO estimated that 1.5 billion adults were overweight and  predict that the number of 
deaths in 2030 due to cardiovascular disease and diabetes will grow to 23.6 million and 3.4 
million,  respectively [5].   These metabolic diseases derive primarily from insulin resistance, 
intracellular lipid accumulation and the resulting cellular dysfunction.    
Obesity is associated with impaired insulin signaling in muscle, adipose and liver in 
addition to decreased glucose stimulated insulin release by pancreatic β-cells leading to broad 
insulin resistance.  Moreover, lipid spill over from adipose tissue during periods of caloric excess 
leads to lipid accumulation in non-adipose tissues, resulting in cellular dysfunction known as 
lipotoxicity.  Type 2 diabetes (T2D), nonalcoholic fatty liver disease (NAFLD), cardiac 
dysfunction and muscle insulin resistance are major lipotoxic diseases associated with lipid 
overload.  Studying the cellular processes and genetic components involved in the progression of 





Part I: Neutral lipid synthesis  
 Lipid imbalance is a characteristic feature of lipotoxic disease.  An accumulation of 
intracellular lipids in non-adipose tissue induces a lipid challenge, in which the cells are forced to 
store, or catabolize the excess free fatty acids (FFA).   Inability to properly process the incoming 
lipids by storage or oxidation results in lipid channeling into toxic pathways, such as ceramide 
biosynthesis and reactive oxygen species (ROS) production.  Furthermore, the lipid deposition is 
often associated with lipid induced cell death known as lipoapoptosis [6].  The first line of 
defense against excess intracellular lipids is the synthesis and storage of the neutral lipids, 
triglyceride (TG) and sterol ester (SE) [7]. 
    
Neutral lipid synthesis enzymes. Neutral lipids, such as triglycerides (TG) and sterol esters (SE), 
are a readily accessible storage form of fatty acids and sterols.  Both molecules are formed 
through esterification reactions, in which free sterols are acylated to form sterol ester while 
triglycerides are synthesized through the acylation of diacylglycerol (Fig 1-1). These lipids have 
a hydrophobic structure and are insoluble in the cytosol and unable to integrate into membranes 
at high molar concentrations.  Instead, TG and SE are mainly stored within a phospholipid 
monolayer, forming an organelle known as the lipid droplet (LD). The storage of lipids in the 
form of TG and SE allows a cell to survive periods of diminished nutrient availability and via 
their hydrolysis provides membrane building blocks, such as phospholipids and sterols, for 
cellular maintenance and energy.  Neutral lipid synthesis machinery has been well conserved 
between the budding yeast, Saccharomyces cerevisiae, and humans (Table 1-1) and studies in 






 Figure 1-1:  Neutral lipids are synthesized through acylation of sterol or 
diacylglycerol.  Figure originally published in Buhman. et al, 2001 [8].  
Esterification of diacylgerlycerol (DAG) and sterol occurs through the addition of 
a fatty acid molecule to a carboxyl group.     
 
There are two primary pathways of TG synthesis, the Kennedy pathway (also known as the 
glycerol phosphate pathway) and the monoacylglycerol (MG) pathway.  The MG pathway is 
found primarily in the small intestine, where it plays a major role in the synthesis of TG from 
dietary fat.  Diet derived monoacylglycerol and fatty acids enter the enterocytes where they are 
converted into DAG by an acyl-CoA:monoacylglycerol acyltransferase (MGAT) (Fig 1-2).  
Humans have three MGAT family members (MGAT1-3) but this pathway of DAG synthesis 
does not occur in yeast [9].   
As an alternate pathway, the Kennedy pathway, named after its founder,  functions in all 
eukaryotic cell types, including yeast (Fig 1-2).  The first step in this pathway is the acylation of 
glycerol-3-phosphate by an acyl-CoA:glycerol-sn-3-phosphate acyltransferase (GPAT).  In yeast, 




(LPA), is further acylated by an acyl-CoA:1-acylglycerol-sn-3-phosphatase (AGPAT), in yeast 
known as SLC1 and LOA1, to form phosphatidic acid (PA) [10].   PA is a central regulatory 
metabolite in the lipid biosynthesis pathway.  PA can be converted into cytidine diphosphate 
(CDP)-diacylglycerol, a key phospholipid precursor, or can be dephosphorylated by a 
phosphatidic acid phosphohydrolase (PAP) to form DAG.  There are three PAP enzymes in 
mammals, Lipin1-3, and one known yeast ortholog, the phosphoatidic acid hydrolase PAH1 [11].  
 
 
Figure 1-2: Triglyceride synthesis in mammals and yeast.  Enzymes indicated 
for mammals and yeast (in parenthesis) for each synthesis reaction.  Adapted from 





The final reaction in TG synthesis requires an acyltransferase enzyme, which catalyzes the 
acylation of diacylglycerol (DAG) (Fig 1-1).  In mammals, there are at least two DAG 
acyltransferase enzymes, DGAT1 and DGAT2 (Fig. 1-2 and Fig 1-3).  Both are found at the ER 
membrane, the site of LD biogenesis, and DGAT2 is also found on the surface of the lipid 
droplet [9].  Despite their similar function, these enzymes belong to two distinct gene families 
and do not share sequence homology (Table 1-1).   
Human DGAT1 is a member of the membrane bound O-acyltransferase (MBOAT) 
family, which includes the sterol esterifying acyl-coA:cholesterol acyltransferase (ACAT) 
enzymes and several enzymes responsible for catalyzying the transfer of fatty acyl moieties onto 
lipid and protein acceptors [9].  DGAT2 belongs to a gene family known as DAGAT, which 
includes six other human genes, the three acyl-coA:monoacylglycerol acytransferase genes 
(MGAT1-3) and the wax monoester synthases (NCBI Conserved Domain Database).  Both of 
these families have been conserved through evolution, with members existing in yeast and plants 
(Table 1-1) [13].  Though both function in TG synthesis, they differ in substrate specificity and 
activity.  DGAT2 has no known acyltransferase activity outside of TG synthesis, whereas 
DGAT1 is able to function as a acyl-CoA:retinol acyltransferase (ARAT), catalyzing the 
synthesis of retinyl esters from retinol, and as both an MGAT and monoester wax synthase in 
vitro [9].  DGAT1’s broad range of substrates is consistent with its known evolution.  DGAT1 
has two orthologs in yeast, Are1 and Are2, both of which function primarily as sterol esterifying 












S. cerevisiae ARE1 
ARE2 
DGA1 LRO1 
Lipid Product SE/TG TG SE/TG 
 
Table 1-1: Conservation of neutral lipid synthesis genes between budding yeast 
(S. cerevisiae) and humans.   Neutral lipid synthesis genes from both humans and 
yeast grouped by gene family.  Lipid products (Sterol ester (SE) or triglyceride 
(TG)) synthesized by the protein transcripts of these genes are also indicated.  
 
 In humans, DGAT1 is expressed ubiquitously, with the highest levels in the intestine, 
colon, testis and adrenal cortex and moderate levels in the heart, skeletal muscle and liver [15].  
DGAT2 is also found in all tissue types with specifically high levels of expression in the liver 
and adipose tissue [16]. The relative role of each DGAT in whole body TG synthesis has been 




 mice survive for only a 
few hours after birth, due to skin barrier abnormalities and have a severe (90%) drop in  total 
body TG [17].  In contrast, DGAT1 null mice are viable and have normal plasma TG levels with 
a decrease in adiposity and resistance to diet induced obesity (DIO) [18].  These studies indicate 
that DGAT2 is able to partially compensate for a loss in DGAT1 but not vice versa.  
In yeast, there are three distinct enzyme families that mediate TG synthesis.  The major TG 
synthesizing enzyme is LRO1, an acyl-coA independent acyltransferase (Fig. 1-2 and Fig 1-2) 
that requires phospholipids (preferentially phosphatidylcholine and phosphatidylethanolamine) 
as an acyl donor.  LRO1 is both a phospholipase and an acyltransferase [19] and is responsible 
for  the majority of TG synthesis during the log growth phase [13].  LRO1 has sequence 
conservation (27%) to the mammalian cholesterol esterification enzyme lecithin-cholesterol 




yeast ortholog of mammalian DGAT2, DGA1 (33% identical), functions as an acyl-
CoA:diacylgerlycerol acyltransferase, and mediates the majority of TG biosynthesis during 
stationary growth.  The double mutant dga1Δ lro1Δ possesses low levels (approximately 5% of 
control) of triglyceride synthesis, which can be accounted for by residual TG synthesis activity 
by the sterol esterifying enzyme ARE2 [14].    
 
 
Figure 1-3: Mammalian and yeast neutral lipid synthesis.  Neutral lipid 
synthesis requires action of acyl-coA:cholesterol acyltransferases (ACAT1/2) 
and acyl-coA:diacylglycerol acyltransferases (DGAT1/2) in mammals and 
ACAT related enzymes Are1/2 and the triglyceride synthesis enzymes Dga1p 
and Lro1p in yeast.  Lro1p is an acyl-CoA independent acyltransferase.  
 
Synthesis of sterol ester (SE) also requires an acyltransferase enzyme, which act on free 
sterols (Fig 1-1). This reaction is carried out by two related acyl-CoA:cholesterol 
acyltransferases, mammalian ACAT1 and ACAT2 (Fig. 1-1 and 1-3) and their yeast orthologs, 
the ACAT related enzymes 1 and 2 (Are1p and Are2p) (Fig. 1-3).  A double deletion of ARE1 




esterifying enzymes [21].  Intracellular sterol levels are under tight regulation and increasing free 
sterol is rapidly esterified for storage in the LD.  These esters can then be hydrolyzed, releasing 
free sterol for use in cellular membranes or steroid hormone synthesis [13].   
 
Triglyceride storage protects against lipotoxicity.  Compartmentalization of excess lipids as a 
storage form in LDs is able to protect the cell from lipotoxic effects.   Ablation of TG synthesis 
in both yeast and mammalian models results in severe lipotoxicity following unsaturated fatty 




 mice have increased toxic 
metabolites, DAG and fatty acyl-CoA, in nonadipose tissues consistent with the role of neutral 
lipid synthesis in lipotoxic disease prevention [24].  Interestingly, these mice remain insulin 
sensitive despite the rise in fatty acid metabolites.  Diverting lipids into TG storage is protective, 
as seen in mice overexpressing DGAT1 or DGAT2 in the liver.  These transgenic models 
develop fatty liver, but do not have hepatic insulin resistance, demonstrating that the synthesis 
and storage of TG shields against lipid induced cellular dysfunction in vivo [25].  
 
Part II: Eukaryotic Lipid Droplets  
In addition to a cells ability to synthesize neutral lipids, the biogenesis and homeostasis of the 
lipid droplet (LD) for neutral lipid storage is fundamental in adapting to intracellular lipid 
accumulation.  Discovered in the 1890s by Richard Altmann and E.B. Wilson [26, 27] , lipid 
droplets were largely ignored and considered as inert lipid depots for almost a century.  With 
increases in the prevalence of obesity related disease and advances in techniques in molecular 
biology, the LD is now considered a dynamic organelle integrally involved in the protection of 




The lipid droplet is composed of a phospholipid monolayer surrounding a neutral lipid core, 
made up of TG and sterol esters SE [28-31].   Lipid droplets are found in all eukaryotic cells and 
range greatly in size from less than 1 µm to 100 µm [32].  In humans, lipid droplets are 
prominently found in adipocytes where they provide long term energy storage and take up 
approximately 1/3 of the intracellular space [33].  The ratio of SE to TG stored in the LD differs 
greatly between cell types.  For example, LDs in adipose tissue are composed primarily of TG, 
whereas the steriodogenic cell types found in the adrenal gland, testis and ovary have LDs 
enriched in SE.  In addition to neutral lipids, LDs in the specialized hepatic steallate cells contain 
retinyl esters and act as the primary storage form for vitamin A.    Nearly equal amounts of TG 
and SE are found in LDs of the model organism S. cerevisiae (budding yeast).   
Beyond their role in lipid storage, LDs have been suggested to function as a temporary 
scaffold for proteins destined for degradation, as seen with the accumulation of α-synuclein on 
the LD surface in Parkinson’s disease [34].  This accumulation may serve to protect the cell from 
harmful cytosolic protein aggregation.  Additionally, recent work has uncovered a role for lipid 
droplets in the infectivity rate of viruses, such as the hepatitis C virus (HCV).  HCV hijacks the 
LD biogenesis machinery in order to assemble and replicate virus particles [35].  As an integral 
element for so many metabolic and infectious diseases, investigation into the basic biology of the 
LD provides valuable knowledge into the cellular mechanisms involved in these disorders.    
 
Lipid droplet associated proteins. The lipid droplet is decorated with an array of proteins, and 
several proteomic screens in both yeast and mammalian systems have compiled a comprehensive 
list of lipid droplet associated proteins [36-43] in order to shed light on the function of these 




protein family, made up of perilipin, adipophilin, TIP47, S3-12 and OXPAT, are important in the 
maintenance of LD structure. These proteins are able to regulate lipolysis and bind to the droplet 
via a four-helix bundle resembling that of Apolipoprotein E [44].  Similarly, plant oil droplets 
are surrounded by oleosin proteins, which cover the droplet and prevent coalescence [45].  Yeast 
lack orthologs to PAT and oleosin proteins, but do have several known lipid metabolism proteins 
localized to the LD surface, which regulate TG lipolysis and NL synthesis [46].   These proteins 
include TG synthesis enzyme DGA1 [47], SE biosynthesis enzymes ERG1, ERG6 and ERG7 
[36], TG lipases TGL1,3-5 [46] and the FA synthetase enzymes FAA1, FAA3 and FAA4 [36].   
Similarly, mammalian DGAT2 [48] and the TG lipase enzyme, adipose triglyceride lipase 
(ATGL) [49], are found on the LD surface and regulate droplet lipid levels.   
Furthermore, proteins involved in membrane-trafficking (RAB18 [50], ARF1 [51]) and 
fusion SNARE proteins (SNAP23 [52] and yeast USE1 [46]) have also been identified at the 
droplet surface and are proposed to be involved intracellular trafficking and fusion of LD.   
Another well-studied LD protein family known as the CIDE (cell death-inducing DFF45-like 
effector) family, includes three proteins, CIDEA, CIDEB and FSP27/CIDEC, which all reside on 
the droplet and all have integral roles in lipid droplet formation and energy homeostasis.   Mice 
deficient in each CIDE protein have a severe deficiency in white adipose LD formation and 
increased metabolic rate [53].    
 
Lipid droplet biogenesis.  LDs form rapidly within discrete regions of the ER in response to 
increased intracellular FAs, but the exact mechanism for LD biogenesis remains elusive.  Several 
observations support a model for lipid droplet formation at the ER membrane.  The phospholipid 




phosphatidylcholine (PC) and lower levels of phosphatidylethanolamine (PE) and 
phosphatidylinositol (PI) [54].  Additionally, many ER-associated proteins are also found at the 
surface of the lipid droplet, such as DGAT2 [48], and LDs are frequently found associated with 
the ER membrane [55].  The most supported hypothesis for lipid droplet biogenesis is that 
neutral lipids are synthesized within the ER bilayer at specialized sites and as the level of lipid 
increases beyond membrane capacity (2-4 mol %) the membrane leaflets begin to separate.  The 
lipid lens grows toward the cytosol at which point it reaches a critical mass and is able to 
separate from the ER into an independent organelle (Fig. 1-4 A).  Though the intermediate steps 
of this model have not been demonstrated experimentally, the phospholipid and protein 
composition of the LD in addition to the localization of NL synthesis genes at the ER are 
consistent with this explanation.    
There are two additional models, which have been proposed in LD biogenesis.  The 
“vesicular budding” model suggests that a membrane vesicle tethers to the ER and is filled with 
newly synthesized neutral lipids (Fig. 1-4 C) [30].  Corroborating this model, it has been found 
that knockdown of integral vesicular trafficking proteins alters LD formation [56, 57].  
Alternatively, the “bicelle” model posits that once neutral lipids are synthesized between the ER 
bilayer, the entire lipid lens is excised from the ER.  This leaves a transient hole in the ER 
membrane, which allows proteins typically sequestered in the ER lumen to leak into the cytosol 
(Fig. 1-4 B).  Although this model garners some support from studies that show that reassembled 
viruses escape from the ER lumen into the cytoplasm, the transient pores produced within the ER 







Figure 1-4: Three models of lipid droplet biogeneisis. Adapted from Walther 
T.C., and R.V. Farese, 2009 [30].  Synthesis of the NL triglyceride and sterol 
ester occurs at the ER membrane by neutral lipid synthesis enzymes (NLSE).  The 
3 models of LD formation are as follows: (A) NL build-up within the bilayer 
forms a lens which buds off as a mature droplet after reaching a critical size. (B) 
A second model is similar in that the NL forms a lens within the ER leaflets, but 
is excised from the ER as a “bicelle”.  The last model (C) involves a bilayer 
vesicle which binds to the ER and is filled by NLSE.  This lipid filling results in a 







Genome-wide knockout and knockdown screens have been used in the yeast S. cerevisiae 
and Drosophila S2 cells respectively, in order to identify genes necessary for lipid droplet 
biogenesis [56-59].   This work has identified very few genes having a major effect on LD 
formation, with many more gene knockouts or knockdowns causing a less pronounced, but still 
significantly altered LD morphology.  Two Drosophila RNAi screens identified the Arf1-COPI 
vesicular transport proteins [56, 57] as important regulators in the number and size of droplets.  
In addition, Guo et al., found that phospholipid biosynthesis proteins Cct1 and Cct2 play an 
important role in providing newly synthesized phospholipids to lipid droplet monolayers during 
growth [56].  The CCT (CTP:phosphocholine cytidylyltransferase) enzymes are reversibly 
targeted to the lipid droplet membrane, where they complete the rate limiting step of 
phosphatidylcholine synthesis and allow for membrane expansion .  Knockdown of the genes 
encoding these proteins results in decreased lipid droplet size due to defects in membrane growth 
[56].  
A yeast genome-wide lipid droplet morphology screen identified a seipin ortholog FLD1, 
which has increased levels of LD fusion after gene knockout [60].   The increased fusion in fld1Δ 
is due to a defect in lipolysis and impaired lipid droplet dynamics and Fld1p is thought to 
function as a lipid droplet scaffolding protein, moderating ER-lipid droplet interactions [61].  
Perhaps more notable than these individual proteins is the broad array of cellular pathways 
identified in these screens studies.  The diverse cellular pathways involved in lipid droplet 







PART III: Neutral lipid catabolism  
 
Intracellular TG levels are dependent on the balance between TG synthesis and 
catabolism.  Under normal conditions, metabolites formed from the breakdown of TG are 
utilized in signal transduction pathways, membrane biosynthesis and ATP production through β-
oxidation.   The mobilization of TG is particularly important during nutrient deprivation and is 
carried out by TG lipases, which cleave a fatty acid from glycerolipids [62].  Because the 
products of catabolism (DAG, FFA, PA) are also toxic to cells at excess levels, lipase activity 
may play an important role in the regulation of lipotoxic response.  Overexpression of the 
triglyceride lipase, hormone sensitivity lipase (HSL), in mouse pancreatic β-cells results in 
increased β-cell lipotoxicity and glucose intolerance [63].  Likewise, genome-wide association 
studies have identified a link between HSL gene polymorphisms and insulin resistance [64-67].   
Furthermore, maintaining tight control of adipocyte lipolysis is critical for whole body 
metabolism, and small changes in adipose lipolysis levels can have significant effects on 
circulating FFA [68] .   Insulin resistance of adipose tissue results in a deregulation of the 
lipolysis levels, increasing free fatty acids spill over into non-adipose tissues [6]. Therefore, 
mobilization of the triglyceride pool is an important factor in cellular lipid homeostasis and the 
progression of lipotoxic disease.   
 
Triglyceride lipolysis. Mechanisms of mammalian intracellular lipolysis have been studied 
extensively in the adipose and liver.  Degradation of TG is carried out by TG lipases, such as 




significant differences in tissue localization and substrate preference but are able to partially 
compensate for each other in adipose tissue, but not in other tissue types [69].   
ATGL is found in most tissues, with the highest expression in brown and white adipose 
tissue.  A deletion in ATGL induces a moderate obese phenotype in both mice [70] and 
Drosophila  [71], due to defective TG mobilization from adipocyte LD.  Likewise, adipose 
specific overexpression of ATGL results in a lean phenotype through increased TG hydrolysis 
activity [72].  With high TG specificity, ATGL initiates lipolysis by removal of the first FA from 
TG, followed by HSL hydrolysis of DAG  [73].  The protein CGI-58 (Comparative gene 
identification -58) is needed for full activation of ATGL, and interaction between these proteins 
increases TG hydrolysis activity by approximately 20 fold [74].  
HSL is critical for complete TG lipolysis, due to its ability to hydrolyze several different 
substrates, including TG, DAG and MAG [75].  HSL is found primarily in adipose tissue but is 
also found at low levels in skeletal muscle, pancreas and macrophages [76]. Phosphorylation of 
HSL by PKA promotes its translocation to the surface of the LD and enhances the lipolysis 
capacity [77].  HSL knockout mice have a 60% reduction in triglyceride lipase activities, and a 2 
fold increase in white adipose tissue size, but are not obese [78].  Additionally, HSL null mice 
have increased DAG accumulation, in adipose tissue, muscles and testis due to the integral role 
for HSL in DAG hydrolysis and have impaired insulin sensitivity [75].   
 In yeast, TG degradation occurs by the three proteins, triglyceride lipase 3, 4 and 5 
(TGL3, TGL4 (the ATGL ortholog) and TGL5) all of which are members of the patatin-domain 
containing family of esterases [79, 80].  These proteins are found at the phospholipid surface of 
the LD and all have similar structure, with a conserved sequence motif GXSXG and catalytic 




or TGL4 results in a significant TAG accumulation and altered cell cycle progression due to 
defects in membrane precursor availability [81].  A TGL5 deletion does not cause changes in TG 
hydrolysis but exhibits increased levels of very long chain fatty acids in TG [82].  All TGL 
mutants have decreased levels of sphingolipid biosynthesis and increased turnover of 
sphingolipids, suggesting that aberrations in lipolysis affect sphingolipid metabolism [83].    
 
Sterol ester hydrolysis.  Lipid droplet homeostasis also depends on the rate of sterol ester 
mobilization, a reaction which is carried out by sterol ester hydrolases to yield a fatty acid and a 
free sterol.  Three SE hydrolases, TGL1, YEH1 and YEH2 have been identified in yeast, two of 
which localize to the LD (TGL1 and YEH1) and one to the plasma membrane (YEH2) [12].  In 
mammals, sterol esters are hydrolyzed by the neutral cholesterol ester hydrolase (nCEH) and 
enzymatic activity of this enzyme is protective against foam cell formation and atherosclerosis 
[84].   
 
Lipophagy. Recent work has shown that autophagy plays an important role in lipid droplet 
metabolism and in a myriad of metabolic diseases including obesity, insulin resistance and T2D 
[85-87].   Autophagy, or “self-eating” is a lysosomal pathway used by a cell during periods of 
nutrient deprivation to recycle intracellular organelles and proteins. There are three classes of 
autophagic response, macroautophagy (for “bulk flow”), microautophagy (for cytosolic 
recycling) and chaperone mediated autophagy. In classical macroautophagy, autophagosomes 
sequester cytosolic organelles and proteins, and fuse with lysosomes to form an 
autophagolysosome.  The low pH and enzymes within the autophagolysosome degrade the 




nonspecific process, macroautophagy has been shown to have specific targeting capabilities for 
the mitochondria (mitophagy)[88], ER (reticulophagy) [89] and peroxisomes (pexophagy) [90].   
Macroautophagy can also specifically target lipid droplets for degradation, a process 
known as lipophagy.  During lipophagy, LDs are sequestered in autophagosomes which then 
fuse with lysosomes. The components of the LD are broken down by lysosomal lipases, freeing 
up FFAs for β-oxidation.  This process was first described in hepatocytes, where inhibition of 
autophagy caused decreased rates of lipolysis resulting in increased NL levels and  increased 
LDs [91].  Additionally, autophagy functions in the differentiation of cultured preadipocytes into 
mature adipocytes, with a block in autophagy resulting in decreased differentiation gene 
induction and reduced TG levels.  Blockage of autophagy in adipose tissues through ablation of 
the autophagy gene, ATG7,  results in decreased white adipose tissue  mass, decreased TG 
content and resistance to high fat diet induced insulin resistance [87].  The conflicting results in 
autophagy inhibition and TG levels in hepatocytes and adipocytes indicates that additional 
research regarding the connection between TG metabolism and autophagic flux is necessary.    
 
Fatty acid oxidation. Once TG breakdown has occurred, the major degradative pathway for FA 
is through β-oxidation [92].  Acyl-CoA molecules can enter into the mitochondria or 
peroxisomes where they are used for energy production through β-oxidation.  In mammalian 
cells, fatty acids are activated by acyl-coA synthetase to form an acetyl-CoA and transported 
across the mitochondrial membrane by carnitine-acyltransferase. The acyl-CoA is degraded by 
four fatty acid oxidation reactions, generating large quantities of ATP.  Fatty acid oxidation also 
occurs in peroxisomes, which generate H2O2 through the FA breakdown.  The peroxide produced 




for detoxification.  In yeast all β-oxidation occurs in the peroxisome, which uses β-oxidation to 
produce NADH and NADPH for the generation of energy [92].   
 
Part IV: Free fatty acid synthesis and uptake.  
In addition to triglyceride synthesis and catabolism, fatty acid uptake from the 
environment and de novo fatty acid synthesis play significant roles in the maintenance of 
intracellular lipid levels.   The balance of lipids can be described as an equation, with de novo 
lipogenesis and FA uptake increasing intracellular lipids and FA catabolism and utilization as 
degrading these lipids in the form of energy or membrane building blocks. Under conditions of 
increased circulating free fatty acids (FFA), intracellular FA uptake and accumulation occurs, 
requiring an increase in FA oxidation to maintain the lipid balance [93].  A similar increase in 
oxidation is needed to compensate for elevations in de novo FA synthesis. Without oxidative 
compensation, lipid accumulation occurs, initially as increased neutral lipid storage and 
eventually resulting in lipid induced cellular defects including ER stress, altered mitochondrial 
membrane integrity and apoptotic initiation.  
De novo lipogenesis. Fatty acid biogenesis through de novo lipogenesis requires acetyl-CoA 
which can be derived from multiple metabolic pathways, including glycolysis and pyruvate 
oxidation.  In mammals and yeast, two acetyl-CoA carboxylase (ACC) genes, cytosolic ACC1 
(yeast ACC1) and mitochondrial ACC2 (yeast HFA1) catalyze the initial step of FA synthesis 
through acetyl-CoA carboxylation forming the metabolic intermediate malonyl-CoA.  This 
process, which occurs through several catalytic steps, requires the action of one gene in 




fatty acid synthesis (FAS) enzymes catalyze the final steps of FA biosynthesis.  These fatty acids 
can then be elongated, by long chain elongases (mammalian ELOVL proteins and yeast ELO1, 
FEN1 and ELO3) and desaturated (mammalian stearoyl-CoA desaturase 1 (SCD1) and yeast 
OLE1) to meet cellular lipid requirements [94].   
 
Free fatty acid uptake. The alternate mode of intracellular fatty acid increase is through long 
chain fatty acids (LCFA) uptake. LCFAs are essentially insoluble in aqueous solutions, but when 
bound to proteins, such as albumin, can exist in an aqueous environment at much higher 
concentrations.  The two main mechanisms for fatty acid transport into cells are passive diffusion 
and protein-mediated transport.  Transfer of the lipid from the outer to the inner leaflet of the 
membrane has been shown to occur through a fatty acid ‘flip-flop’ [95].  Though this passive 
diffusion model of FA uptake is likely to occur to some degree, recent literature supports that the 
majority of FA uptake occurs through a protein mediated mechanism.    
Protein mediated lipid uptake takes place in one of two ways, through membrane bound 
fatty acid transporters or receptor mediated uptake of lipoprotein particles.  Fatty acid 
transporters function to sequester FA at the membrane for subsequent transport.  The major 
membrane bound fatty acid transporters in mammals are CD36, plasma membrane associated 
fatty acid-binding protein (FABPpm), the fatty acid transport protein family (FATP1-6) and 
caveolin [96].   
The mechanisms of fatty acid uptake in yeast are still unclear.  Like that described in 
mammals, one model is through a “flip-flop” entry, independent to protein transporters.  In 
addition, membrane bound proteins Faa1p, Faa4p and Fat1p have been implicated in fatty acid 




proteins activate FAs through addition of an acyl-CoA, which traps the FA within the cell [97-
99] 
Receptor mediated lipid uptake occurs through protein endocytosis of lipoprotein 
particles into cells, a process used by many mammalian cell types but not by yeast.  Lipoproteins 
are lipid-enriched particles made up of a neutral lipid core surrounded by a phospholipid 
monolayer, with a structure analogous to that of the LD.  Lipoproteins are classified into four 
main groups based on their characteristic density, chylomicrons having the lowest density, very 
low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins 
(HDL).  A distinguishing surface protein known as an apolipoprotein (apo) marks each 
lipoprotein class and acts in particle recognition [100]. 
After a meal, the enterocytes of the small intestine absorb cholesterol and TG and 
incorporates these lipids into a chylomicron with a single apo B48 protein. Chylomicrons are 
then secreted into the lymphatic and circulatory system where TG in the particle core is 
hydrolyzed by lipoprotein lipase (LPL) on the surface of the capillary endothelium.  The product 
of this hydrolysis, FFA, enters the adipose or muscle cells through the flip-flop or protein 
mediated transport mechanisms.  Chylomicron remnants are then taken up by the liver through 
receptor-mediated uptake through interaction with a cell surface protein known as the LDL 
receptor [100].    
The liver is able to package  and secrete TG and SE into a VLDL particle through 
lipidation of apo B100 in the ER of the hepatocytes.   Like chylomicrons, lipolysis of VLDL 
triglyceride occurs through LPL-dependent hydrolysis, and this lipolysis results in increasingly 
dense particles and an eventual conversion to LDL. Interaction between LDL and the LDL 




internalized, the vesicle fuses with the late endosome and lysosome, releasing sterols and FAs for 
cellular use [100]. The rise in circulating free fatty acids associated with obesity results in 
increased FFA flux through these protein mediated lipid uptake mechanisms and lipid 
accumulation due to increased uptake is a major determinant of lipotoxic disease progression.   
 
Part V:  Mammalian Lipotoxicity   
 
As previously discussed, lipotoxicity is defined as a cellular dysfunction triggered by the 
accumulation of fat in nonadipose tissue.  This term was first coined by Dr. Roger Unger in 1994 
when he described the role of FFA in the pathogenesis of type 2 diabetes in obese Zucker rats 
[101].  The most extreme example of lipotoxic disease occurs in complete lipodystrophy, where 
patients lack adipose tissue and lipids accumulate in ectopic tissues such as liver, muscle and 
pancreas [102].  Lipodystrophies can be either genetic or acquired, and are characterized by a 
loss or mislocalization of body fat and severe insulin resistance.  A similar increase in ectopic 
lipids has been shown to occur in obesity and has been observed in obese rodent models such as 
the high fat fed mouse [103] and Zucker rat [101].  
The lipotoxicity seen in lipodystrophy highlights the importance of adipocytes in protecting 
nonadipose tissue against insults of excess lipid exposure.  Adipocytes have evolved as a storage 
depot for fuel during extended periods of famine, in which excess calories are stored in the 
adipocyte LD and mobilized for use by other organs when nutrients are scarce.  Conversely, 
during periods of caloric excess, adipocytes buffer against increases in nutrient load through 
nutrient sequestration in the form of neutral lipids [104].  In addition to fat storage, adipocytes 




Normally, adipose is very insulin sensitive and small increases in insulin results in robust 
inhibition of lipolysis [105].   
  In many cases of obesity the adipocyte becomes dysfunctional and undergoes hypertrophy, 
experiences macrophage infiltration, and becomes insulin resistant.  This dysfunction likely 
result from an increase in ER stress and a failure in adequate cell proliferation, leading to both 
increased inflammatory adipokine and free fatty acid (FFA) release into circulation [106, 107].  
High circulating FFAs promote fat deposition into peripheral tissues such as pancreatic  cells, 
hepatocytes and muscle.    In an effort to attenuate lipotoxicity, these tissues increase lipid stores 
in the form of lipid droplets..  Although the LDs themselves are protective, an increase in lipid 
droplet number is indicative of an associated FA load.  With chronic exposure, nonesterified 
fatty acids (NEFA) are able to enter into toxic pathways, eventually causing cellular injury [108].   
 
Mammalian Mechanisms of Lipotoxicity:  The primary form of circulating FAs are long chain 
FAs (LCFA) containing 16 carbons or more, which can be classified as saturated, 
monounsaturated and polyunsaturated based on the number of double bonds.  The most abundant 
circulating fatty acids are the unsaturated fatty acids (UFAs) oleate (C18:1) and palmitoleate 
(C16:1) and the saturated fatty acids (SFAs) palmitate (C16:0) and stearate (C18:0).  In most 
mammalian tissue types UFA exposure increases TG synthesis and storage while SFAs enter into 
more toxic pathways, eventually resulting in lipotoxicity and lipid induced apoptosis 
(lipoapoptosis) [109-113].  Though typically less potent compared to SFA, UFAs have been 
shown to cause lipoapoptosis through alternate cellular pathways in certain cell types [114-124].  
 Evidence indicates that SFA induced lipotoxicity occurs through increased de novo 




a lipid molecule consisting of a sphingosine and a FA moity (typically palmitoly-CoA).  With 
increases in cellular palmitate, ceramide levels rise through the activity of the rate limiting 
enzyme serine palmitoyltransferase (SPT1).  Ceramides, like many sphingolipids, are signaling 
molecules involved in an array of cellular processes including cell proliferation and apoptosis 
[126].  Ceramide induces apoptosis through the formation of channels within the mitochondrial 
membrane, allowing for the release of mitochondrial apoptotic mediators, such as cytochrome c, 
and increased mitochondrial permeabilization [127] 
Ceramide independent pathways of SFA mediated lipotoxicity also occur, as seen with 
increased ROS [110, 111].   A rise in FAs increases ROS production via FA flux through β-
oxidation.  Newly formed ROS can react with mitochondrial DNA, proteins and lipids inducing 
oxidative damage and mitochondrial dysfunction. These effects result in a compromised 
mitochondrial membrane and release of pro-apoptotic factors resulting in a caspase dependent 
cell death cascade [125]. 
UFA has been shown to induce lipoapoptosis in various cell types, including HUVEC 
cells [116], the liver cell lines HepG2 [119] and McA-RH7777 [124] and primary rat β-cells 
[123].  Unlike SFA, this process involves the phosphorylation/dephosphorylation cycle of 
protein phosphatase type 2C and endoplasmic reticulum (ER) stress response.  Interestingly, 
genetic ablation of DGAT1 activity in CHO cells causes SFA and UFA to become equally toxic 
[7].  
ER stress response has proven to be important in both SFA and UFA induced lipotoxic 
dysfunction.  Classical ER stress occurs through an accumulation of misfolded proteins in the ER 
lumen and activation of PKR-like kinase (PERK), inositol-requirement enzyme 1 (IRE1) and 




through the dissociation of the ER chaperone immunoglobin heavy chain binding protein (BiP 
also known as GRP78) and leads to downstream signaling known as the unfolded protein 
response (UPR).  The UPR is an adaptive mechanism for restoration of ER function through 
decreasing cellular protein load and increasing the ER folding capacity.  If activation of these 
pathways is unable to restore ER homeostasis, pro-apoptotic pathways are initiated.  Activation 
of the pro-apoptotic factors, CHOP, JNK and caspase 12 as well as inhibition of the anti-
apoptotic Bcl-2 following prolonged ER stress lead to cell death [128].  
 In addition to misfolded proteins, both saturated and unsaturated FFAs are able to trigger 
ER stress [129-131] in part through decreased ER Ca
2+
 stores causing a secondary protein-
folding defect.   Additionally, palmitate is incorporated into lipid components in the ER where it 
disrupts the ER structure leading to a protein independent ER stress response [132].  
 Studies in rodent models have concluded that increased lipid exposure typical of obesity 
causes increased ER stress response marker expression in -cells, adipocytes and hepatocytes 
[133].   Pancreatic beta cells are particularly susceptible to ER stress due to their primary 
function in protein secretion and increased ER protein load [112].  Therapies that increase 
cellular resistance to ER stress could attenuate the lipotoxic cellular dysfunction in these tissues.  
Chaperone administration and attenuation of downstream UPR targets have been shown to 
increase ER protein folding capacity and correct for systemic insulin resistance, hepatic lipid 





Figure 1-5: Mammalian ER stress response pathways.  There are 3 branches of 
mammalian ER stress response.  Activation of these pathways occurs through the 
release of GRP78 from its binding partners (PERK, IRE1 and ATF6) in the ER.   
This initiates PERK dimerization and trans-auto-phosphorylation.  PERK then 
phosphorylates the α-subunit of elongation initiation factor 2 (eIF2) which results 
in decreased protein translation and the activation of proapoptotic CHOP.  
Similarly, upon activation, IRE1 oligomerizes and trans-auto-phosphorylates 
initiating splicing of the XBP1 transcript which can then translocate in the nucleus 
and bind to UPR response elements.  Lastly, movement of ATF6 from the ER to 
the Golgi occurs following GRP78 release.  At the Golgi, ATF6 undergos 
proteolysis, allowing it to translocate to the nucleus and activation UPR target 
genes.     
 
Type 2 Diabetes and pancreatic β cell failure. Type 2 Diabetes (T2D) is a disease characterized 
by defects in insulin action and insulin secretion.  Though obesity and overnutrition have been 




makeup in determining pancreatic -cell adaptation to glucose and FA excess.   Those with both 
increased circulating FFA and a pancreatic -cell susceptibility are the most prone to T2D.  
Genome-wide association studies (GWAS) have identified several gene variants responsible for 
this apparent susceptibility, including polymorphisms in the insulin receptor substrate IRS1 
[134], the -cell potassium subunit KCNJ11[135] and the gene encoding transcription factor-7 
like 2 (TCF7L2) [136].  
Under normal physiological conditions, the -cell responds to increases in circulating 
glucose with insulin release.  The circulating insulin then acts on liver, muscle and adipose to 
regulate carbohydrate and fat metabolism.  There are two phases to insulin release; the first is 
triggered in response to increased blood glucose levels stimulating the release of previously 
synthesized, docked, insulin containing secretory vesicles (Fig 1-6).  Glucose enters the -cell 
through the GLUT2 transporter, initiating the first phase of insulin secretion.  The rise in 
intracellular glucose causes increased glycolysis and mitochondrial respiration resulting in an 
increased ATP/ADP ratio in the cytosol. KATP channels close in response to the rise in ATP, 
triggering membrane depolarization and Ca
2+
 influx through voltage gated calcium channels.  
The Ca
2+
 signal then stimulates the release of insulin containing granules through exocytosis 
[137].  The second response step requires mobilization and priming of newly synthesized 
population of insulin granules to the plasma membrane for docking and fusion.   Approximately 
1% of the total number of granules present release insulin in the first phase whereas the second 





Figure 1-6: Mechanisms of glucose and fatty acid stimulated insulin secretion 
in pancreatic β-cells.  Role of glucose in insulin secretion stimulation and 
potentiation of the response with fatty acid or amino acid treatment.   
 
 In addition to glucose, several other molecules are able to stimulate insulin release.  
These include hormones and neurotransmitters, which bind to -cell membrane receptors and 
activate a neurohormonal activation pathway.  Fatty acids also serve as insulin secretagoges (Fig 
1-6) through glucose stimulated insulin stimulation (GSIS) potentiation by activation and 
binding to the fatty acid binding receptor GRP40.  Binding of FA to this receptor activates the 
Gαq-phospholipase C (PLC) pathway, triggering the release of luminal ER Ca
2+
 stores and 
subsequent increases in cytosolic Ca
2+




intermediates, such as DAG, have also been shown to alter acylation of insulin regulatory 
proteins and enhance insulin vesicle fusion.  Due to these effects, acute FA treatment improves 
insulin release with glucose stimulation, however chronic FFA exposure causes a reduction in 
GSIS, due to lipotoxic dysfunction.   
Defects in insulin secretion and -cell function may occur prior to the development of 
impaired glucose tolerance. In the pancreas of T2D patients, -cell volume is decreased by 
approximately 30% and frequently shows markers of apoptosis based on autopsy results [140, 
141].  Though significant, this loss in mass does explain the insulin response defect seen in T2D, 
rather -cell dysfunction in the remaining cells likely accounts for the full disease condition.  
Triglyceride accumulation in pancreatic islets is associated with β-cell loss, impaired insulin 
secretion and type 2 diabetes [142, 143].  Detailed studies on glucose stimulated insulin release 
in T2D patients and rodent models have shown that islets from diabetic donors have decreased 
glucose responsiveness, decreased insulin content and a defect in GSIS [144, 145].  In addition to 
impaired GSIS, T2D islets have decreased insulin content, decreased mature insulin granules, a 
reduction in insulin mRNA expression and increased levels of proapoptotic caspase3 and 8 
[142].  -cells are particularly sensitive to increased FFA levels due to their limited lipid storage 
capacity, driving excess lipids into toxic metabolic pathways (eg, ceramide and DAG synthesis).   
Chronic exposure to glucose (glucotoxicity) also causes some level of -cell dysfunction in 
model systems but the extent to which this occurs in humans is still undetermined [143].    
 
Nonalcoholic Fatty Liver Disease. In addition to pancreatic β-cell lipotoxicity, an accumulation 
of intracellular lipids in hepatocytes, known as nonalcoholic fatty liver disease (NAFLD), results 




early stages of hepatic steatosis as well as the progressive inflammatory stages of steatohepatitis 
(NASH) and cirrhosis [68].  The most common cause of NAFLD in the developed world is 
overnutrition and obesity and seventy-five percent of obese patients exibit some level of hepatic 
steatosis [146].   
 Excess levels of FFA or glucose have been shown to cause hepatic steatosis, with 
increased glucose channeling into the de novo FA synthesis pathway [147].  Both FFA and 
glucose uptake into the liver occurs by an insulin-independent mechanism. For this reason, an 
increased level of either metabolite in the circulation results in uptake by the liver regardless of 
circulating insulin.  Once within the cell, hepatic FFAs can be stored in the lipid droplet as TG, 
used as energy through β-oxidation, or assembled with apolipoprotein B 100 (ApoB) to form a 
very-low density lipoprotein (VLDL).  VLDL particles are then secreted into circulation, and are 
able to deliver lipids to peripheral tissues such as the adipocyte [68].   
Though one main function of the liver is to repackage lipids for distribution, it has a 
limited lipid storage capacity.  As the lipid level saturates lipid droplet storage, inflammatory and 
lipotoxic responses rise, furthering NAFLD disease progression.  On a molecular level, this 
hepatic lipid accumulation likely occurs through a combination of cellular changes.  Increased 
lipid uptake from circulation or elevated de novo lipogenesis increases lipid levels and defects in 
fatty acid oxidation or impaired lipoprotein secretion or synthesis decrease clearance of lipid 
from the liver.  
Insulin resistance is considered to be the primary source for these cellular alterations.  In 
order to understand the connection between insulin sensitivity and hepatic steatosis, the role of 
insulin in normal physiology will be briefly described.  In peripheral tissues such as the adipose 




glucose transporter 4 (GLUT4) transporters to the plasma membrane, resulting in increased 
glucose uptake.  Insulin is also able to decrease peripheral lipolysis through inactivation of 
hormone sensitive lipase (HSL).   In the liver, glucose uptake occurs through the insulin-
independent GLUT2 transporter, and therefore is unaffected by changing insulin levels.  Instead, 
hepatic insulin action results in the inhibition of gluconeogenesis through FOXO1 
phosphorylation, increased hepatic de novo lipogenesis and decreased levels of fatty acid 
oxidation [68].   
Insulin resistance in adipocytes results in a loss of insulin induced suppression of 
lipolysis, thus increasing levels of circulating albumin bound FFA. Hepatic uptake of free fatty 
acids from circulation is insulin independent, and therefore this rise in circulating FFA results in 
increased lipid uptake.  In the liver, there is a mixed insulin resistance characterized by impaired 
insulin mediated gluconeogenesis suppression, but no change in insulin stimulated de novo 
lipogenesis. The combination of increased FFA flux into the liver and increased lipogenesis 
results in hepatic lipid overload.  In order to lessen lipid load, the hepatocyte increases VLDL 
secretion but in many cases in unable to compensate for the chronically high levels of 
intracellular TG typically seen with type 2 diabetes [68].   
Lipid overload in the hepatocyte activates several signaling pathways altering cellular 
metabolism and increasing the susceptibility of the cell to damage.  This increased vulnerability 
is the result of impaired mitochondrial function and subsequent increases in oxidative stress.  
FFAs are able to increase the permeability of the mitochondrial membrane, increase ROS 
generation, induce ER stress response and increase JNK-dependent lipoapoptosis.   The oxidative 
stress resulting from the mitochondrial dysfunction is able to induce proinflammatory signaling 




Part VI: Yeast as model system for lipid disorders 
Many aspects of lipid metabolism and LD structure have been conserved across 
eukaryotic evolution. This conservation provides us with a useful and easily manipulated 
biological model to study complex pathways involved in human lipid disorders.   Genes that 
have been highly conserved across evolution are likely to be involved in essential cellular 
processes.  Being that lipid homeostasis is critical for cellular function, it is not surprising that 
there has been a high level of conservation in both sequence and function between integral lipid 
metabolism proteins of yeast and mammalian systems.  
 Yeast is a commonly used model organisms that is useful for the study of basic biological 
pathways due to its fast growth rate, availability of a deletion library containing a single deletion 
of all non-essential open reading frames (ORF), ease of genetic manipulation through use of 
homologous recombination or episomal plasmid transformation, and a high number of human 
orthologs [149]. The metabolic processes of NL synthesis (Table 1-1), β-oxidation, and lipolysis 
have an exceptional level of conservation and research using yeast has had a major impact on our 
current knowledge of eukaryotic lipid biology.  
 
Lipotoxicity in Yeast:  The process of lipotoxicity also occurs in yeast, and shares several 
parallels to mammalian lipid disorders.  Yeast undergoes cell death in response to exogenous 
fatty acids under certain genetic manipulations.  In yeast, a strain with deletions in all four of the 
genes encoding the NL-synthesis enzymes Are1p, Are2p, Dga1p and Lro1p contains no lipid 
droplets (Fig.  1-7) but is viable under normal growth conditions.  This mutant is highly sensitive 
to treatment with unsaturated fatty acids (UFA) such as oleate (C18:1) and palmitoleate (C16:1) 




150].   Following UFA supplementation, the NL-deficient strain shows increased oxidative stress 
and activation of the UPR, eventually leading to cell death.  Eliminating neutral lipid 
biosynthesis results in channeling of incoming FA into phospholipids, causing massive ER 
membrane proliferation and alterations in the phospholipid acyl chain composition [22]. Co-
supplementation of palmitate and oleate partially protects the NL-synthesis mutant from these 
defects, highlighting the importance of a balanced unsaturated/saturated fatty acid ratio in 
cellular function [23].   
Phosphatidic acid (PA) is an important central intermediate in TG and PL synthesis.  A 
mutation in the PA hydrolase, Pah1p, has markedly reduced levels in DAG and TG, and a 
channeling of lipids into phospholipid synthesis results in nuclear envelope expansion.  The 
defect in TG synthesis seen in pah1Δ renders the cell highly sensitive to UFA treatment, similar 
to that seen in the neutral lipid deficient strain [151].  Mutations in the mouse ortholog of PAH1, 
LPIN1, results in a lipodystrophy characterized by white adipose tissue loss, fatty liver, insulin 
resistance and hypertriglyceridemia [152].  Consistent with the mouse and yeast phenotype, the 
human LPIN1 gene has been linked to fat mass and glucose homeostasis through linkage studies 
[153].  
Though monounsaturated fatty acids (MUFAs) are the more toxic lipid in yeast, whereas 
SFAs are widely accepted as being more toxic in mammals, the lipotoxic mechanisms between 
the two organisms share many commonalities.   The resistance to palmitate toxicity in yeast is 
not due to a lack of uptake or incorporation.   FA profiling of yeast exposed to palmitoleate show 
that it is rapidly elongated and desaturated to match the cellular phospholipid requirements [154].   
Yeast with a desaturase activity defect have increased palmitate induced toxicity due to their 




endothelial cells overexpressing the mammalian desaturase SCD-1 rescues SFA induced 
lipotoxicity [155].  Collectively, these results indicate that desaturation of palmitate in both yeast 
and human systems is protective against SFA induced lipotoxicity and the composition of fatty 
acyl chains (both length and degree of desaturation) is important in maintaining membrane 
structure and cellular function.     
 
 
Figure 1-7: Neutral lipid deficient strain lacks all cytoplasmic lipid droplets and 
is sensitivity to unsaturated fatty acid treatment. (A) Lipid droplets from normal 
and the neutral lipid deficient strain (are1Δ are2Δ dga1Δ lro1Δ) were stained by 
the lipophilic dye, Nile Red.  (B) Cell growth in the presence of 0.5 mM 
palmitoleate in liquid rich media over time.  
 
 
Part VII: The Aims and Findings of this Thesis  
 
 
 The purpose of this thesis was to identify novel mammalian genes involved in the 




palmitoleate (C16:1) sensitivity screen, which identified genes deletions resulting in increased 
lipotoxicity.  From this screen, we determined that ablation of 156 genes result in a significant 
growth defect in response to unsaturated fatty acid treatment.  Of these genes, many encode 
proteins involved in lipid metabolism, mitochondrial respiration, mitochondrial fatty acid 
synthesis, vesicular trafficking, and histone modification.    
 From these genes we concentrated on those which have high evolutionary conservation 
between yeast and mammals in order to identify novel pathways involved in mammalian 
lipotoxicity.   We chose to focus on two conserved proteins, the tail-anchored protein insertion 
complex members, mammalian ASNA1 and yeast GET3, and the putative sterol transporters, 
mammalian and yeast ARV1.   In Chapter 3 we used the yeast model system to complete basic 
mechanistic studies on the role of GET3 in eukaryotic lipid metabolism and lipid droplet 
dynamics. We demonstrate that a loss in GET3 results in increased apoptosis in response to 
unsaturated fatty acid treatment, decreased neutral lipid synthesis and altered lipid droplet 
homeostasis due to defects in vacuolar nutrient recycling.  We also identify a relationship 
between GET3 and the yeast diacylglycerol acyltransferase, DGA1, in lipid droplet homeostasis.   
 In order to clarify a potential role for mammalian ASNA1 and ARV1 in lipotoxic disease, 
we took advantage of RNAi and adenoviral technology to knockdown and overexpress these 
genes in pancreatic β-cell line, MIN6, and the rat McA-RH7777 hepatoma cell line.  In Chapter 
4, we focus on the role of ASNA1 in lipid induced apoptosis and alterations in fatty acid effects 
on glucose stimulated insulin secretion (GSIS) in MIN6 cells.  We demonstrate that ASNA1 is 





In Chapter 5 we build upon research previously reported by Dr. Ying Liu, demonstrating 
that overexpression of human ARV1 in mouse liver induces hepatic lipid accumulation through 
increased TG synthesis [156].  We found that this lipid accumulation could not be explained by 
decreased VLDL secretion following ARV1 overexpression in McA-RH7777 hepatoma cells. We 
also report that knockdown of ARV1 in pancreatic β-cells results in decreased TG synthesis and 
increased apoptosis in response to both palmitate and palmitoleate and propose a model for the 
role of ARV1 in triglyceride homeostasis. Finally in Chapter 6 we discuss the potential 
mechanisms of GET3, ASNA1 and ARV1 in pathways of eukaryotic lipotoxicity and propose 














Chapter 2:  Identification of novel genes involved in 
 









Under conditions of excess lipid exposure, a cells primary line of defense is the 
esterification of fatty acids into neutral lipids and their subsequent storage in the lipid droplet.  
Lipid accumulation beyond the cells storage capacity results in a spillover of fatty acids into 
toxic metabolic pathways leading to lipotoxicity and apoptosis.  An accumulation of lipids in 
skeletal muscle, hepatocytes and pancreatic  cells is associated with the development of 
lipotoxic diseases such as type 2 diabetes and steatohepatitis.  Identification of gene mutants 
associated with a predisposition to fatty acid induced toxicity is essential in understanding the 
progression of these diseases.  In order to identify novel genes involved in eukaryotic 
lipotoxicity, we performed a genome-wide unsaturated fatty acid sensitivity screen using the 
model organism Saccharomyces cerevisiae.  Of the ~5,500 gene knockouts and knockdowns 
tested, we identified 156 gene mutant strains with significant sensitivity to the unsaturated fatty 
acid palmitoleate.  Of these genes, many are involved in lipid metabolism, vesicular trafficking, 
mitochondrial respiration and transcriptional regulation.   Additionally, 68 of the 156 yeast genes 
identified by the screen have been highly conserved throughout evolution, 11 of which have been 
previously associated with lipotoxic disease phenotypes in rodent models and/or human subjects.  
Therefore, this screen has identified novel genes and pathways involved in lipid homeostasis in 
both yeast and human systems, many of which are potential treatment targets for lipotoxic 





Ectopic fatty acid deposition in non-adipose tissues, such as pancreatic β-cells, muscle 
and liver, is strongly associated with obesity related diseases such as type 2 diabetes (T2D) and 
nonalcoholic fatty liver disease (NAFLD).  The limited lipid storage capacity of these tissues 
results in cellular dysfunction and apoptotic initiation, known as lipotoxicity and lipoapoptosis, 
respectively.  Lipotoxicity occurs in many mammalian cells types, including pancreatic β-cells 
[157-159] and hepatocytes [160, 161], as well as the eukaryotic model organisms Drosophila 
[162] and Saccharomyces cerevisiae [22, 163].    
Saturated fatty acids (SFA), such as palmitate are considered to be the primary toxic fatty 
acids (FAs) in mammalian cells [110, 111, 164, 165], but under certain circumstances, 





fibroblasts are as sensitive to UFA as they are to SFA due to their inability to channel 
UFA into triglyceride synthesis and lipid droplet (LD) storage [7].   Interestingly, wild type yeast 
are resistant to lipid induced cell death under normal growth conditions [22, 163, 166].  Ablation 
of all four neutral lipid synthesis enzymes (ARE1, ARE2, DGA1, and LRO1) however, results in 
severe sensitivity to the monounsaturated fatty acids oleate (C18:1) and palmitoleate (C16:1) 




fibroblast cells, in that the UFA induced 
lipotoxicity can be attributed to the neutral lipid synthesis defect.  
 Mechanisms of lipotoxicity in eukaryotic cells are still somewhat elusive, particularly the 
pathways of UFA-induced lipotoxicity.  The model organism, S. cerevisiae (‘yeast’), is a useful 
tool to examine these mechanisms due to its ease of use and the availability of a nearly complete 
(~96%) library of single deletion knockouts or knockdowns [167, 168].  The knockout library 




aspects of eukaryotic biology.  In the past, these screens have revealed genes integral for nutrient 
metabolism [169, 170], drug sensitivities [171, 172], cell cycle regulation [173] protein 
degradation pathways [174, 175], lipid droplet homeostasis [58-60] and fatty acid utilization 
[166, 176].   
In this study, we use a genome-wide screen in yeast to determine genes necessary for 
growth on the unsaturated fatty acid palmitoleate (C16:1).   Of the ~5,500 haploid gene mutants 
tested, 156 conferred sensitivity to fatty acid treatment compared to control.  We demonstrate 
that many protein transcripts of the palmitoleate sensitive genes are members of the same protein 
complex or function within the same biological pathway.   Additionally, forty four percent of the 





MATERIALS AND METHODS 
Yeast General.  Molecular biology and yeast procedures were performed according to 
conventional methods [177]. Complete (YPD; yeast extract, peptone, dextrose), synthetic 
complete (SC) and selective media were prepared as described previously [177].  All yeast 
strains used in this study were derived from s288C (Open Biosystems), with the exception of 
SCY2021 (are1::HIS3 are2::LEU2 dga1::URA3 lro1::URA3) which is derived from 
W303[178].   All single mutants were obtained from Open Biosystems Yeast Knock Out (YKO) 
Strain collection (Cat # YSC1053).  When indicated, fatty acids were added to media in 0.6% 
ethanol:tyloxapol (5:1, v/v) at the designated molar concentration (Sigma; palmitoleate and 
oleate as a 10% w/v stock in ethanol).  For liquid growth assays, overnight cultures were used to 
inoculate liquid media such that the starting optical density was 0.1 (A600 nm) and growth 
curves were obtained using a Microbiology Workstation Bioscreen C (Thermo Electron Corp.) 
and Research Express Bioscreen C software (Transgalactic Ltd).  Three isolates per genotype 
were normalized to an absorbance (OD600) of 0.1 and 10 μl of each strain was added to 290 μl 
of media per well and grown at 30° for 4 days and averaged in order to produce the final growth 
curve.  
 
Genome-Wide UFA Sensitivity Screen and Validation. The palmitoleate screen was carried out 
using the set of MATa haploid deletion strains (Open Biosystems) and a portion of essential gene 
knockdown DAmP (Decreased expression through mRNA perturbation) strains (Open 
Biosystems) maintained in the 96 well format setup by the supplier.  Frozen stocks were thawed 
and inoculated into YPD + 200 mg/liter geneticin G418 media in 96 well dishes using a singer 




water.  1 μl of the culture was pinned onto rectangular SC + 2% dextrose agar plates with and 
without 0.5 mM palmitoleate and grown for 2 days at 30°C .  Growth on plates was quantified 
using Image J software.  Growth normalization was done by dividing each colony size by the 
average growth of each on YPD. The normalized growth of each quadruplicate was then 
averaged to quantify the growth of each strain.  Differential growth was determined by using the 
log2 ratio between control plate values (SCD) and experimental plate values (SCD+ 
palmitoleate).  P-values comparing these normalized growth variables (‘calculated ratio’) were 
completed and a p<0.05 was considered as significant.    
 
Screen Validation using MATLAB Curve Analysis. Strains showing decreased growth on 
palmitoleate compared to fatty acid free media were then validated using the liquid growth assay.  
Growth curve variables obtained from this assay were then used to determine statistically 
significant changes in growth compared to a normal strain.  Three variables: maximum OD 
(A600), maximum growth rate (ΔA600/hr) and time at which maximum growth rate (in hours) 
were obtained using MATLAB numerical computing program for three isolates per genotype 
were normalized to wild type values and analyzed using ANOVA and t-tests against wild type 
values to determine significance.  
The MATLAB program was created to find the slope of the growth curve at each time 
point, and identify the maximum slope (or growth rate) for each triplicate in each strain.  The 
time (in hours) at which this slope was reached was also stored in a new matrix table.  Maximum 
OD was calculated as the highest OD600 value of the curve. Values of these variables were 
calculated for each individual growth curve and normalized to wild type control.  The values 





                   
 
                                        
 
       
 
 
Variable Glossary:  
WTSCD: Maximum growth rate for wild type strain in SCD media  
WTSCD + PO: Maximum growth rate for wild type strain in SCD media supplemented with 
palmitoleate 
WTnorm: Maximum growth rate of wild type in SCD normalized to SCD with palmitoleate 
xxxΔSCD: Maximum growth rate of growth for deletion strain in SCD media 
xxxΔSCD + PO: Maximum growth rate of growth for deletion strain in SCD media supplemented 
with palmitoleate 
xxxΔnorm: Maximum growth rate of deletion strain in SCD normalized to SCD with palmitoleate 
RateRatio: Ratio of normalized growth rates in deletion strain compared to wild type.  The 
higher this value, the more sensitive the deletion strain is to palmitoleate 
tSCD:  Time at which maximum growth rate occurs in SCD media 
tSCD + PO:  Time at which maximum growth rate occurs in SCD media with PO 
tnorm: Maximum growth rate time in SCD normalized to time in SCD with palmitoleate.   
TimeRatio:  Ratio of normalized time values in deletion strain compared to wild type. The larger 
this value the longer it takes for the deletion strain to reach log phase growth (lag).  
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ODSCD + PO: Maximum OD600 Absorbance value in SCD media with palmitoleate 
ODnorm: Maximum OD in SCD normalized to maximum OD in SCD + palmitoleate 
ODRatio: Ratio of normalized OD in deletion strain compared to wild type.  The lower this value 
the less saturated the culture with time.   
 
In subscreens testing for the sensitivity of each mutant in nystatin, myriocin, and temperature 
stress, only 74 gene deletions were tested.  These gene deletions are those, which had a 
significant difference in ‘Max OD’ and/or ‘Rate’ variables compared to control.     
 
Plating Assays.  Sensitivity to media containing fatty acids (0.5 mM palmitoleate, oleate, 
linoleate), Nystatin (2.5, 5, 10 and 15 μg/ml), myriocin (500 ng/ml) and temperature (16°C or 
37°C) were determined by serial dilutions of yeast strains after OD normalization.  Plates were 
incubated at 30°C, unless otherwise indicated, for 2 days.  Growth was compared to wild type 
grown under the same conditions.   
 
Fluorescence Microscopy.  Yeast cells were grown in specified media to saturation.   Lipid 
droplets were stained with Nile Red (1 μg/ml) (Sigma-Aldrich N3013) and visualized with a long 
pass GFP filter (excitation 440 nm).   All microscopy was performed using a Zeiss Axiovert 200 







A genome-wide screen identifies palmitoleate sensitive single mutants in yeast.  In yeast, a 
neutral lipid (NL) deficient are1Δ are2Δ dga1Δ lro1Δ strain was found to have a severe 
sensitivity to unsaturated fatty acids (UFA) but is unaffected by saturated fatty acid (SFA) 
treatment [22]. We therefore hypothesized that sensitivity of other mutant yeast strains to UFA 
would identify previously unreported lipotoxic pathways.   In order to determine additional genes 
important in yeast lipid tolerance, we performed a genome-wide screen for sensitivity to the 
monounsaturated fatty acid palmitoleate.   
We chose to carry out a fatty acid sensitivity screen in the yeast system for several 
reasons.  Multiple genome-wide screens have been completed in model organisms focusing on 
gene mutants resulting in altered lipid droplet morphology [56-60].  Surprisingly, there has been 
very little overlap in the genes identified by these screens and they have not been productive in 
terms of lipotoxic pathway identification.  The investigators focused on the role of two particular 
genes, the yeast seipin ortholog, FLD1, and the COPII vesicular trafficking complex, in the 
regulation of lipid droplet formation and size.  Furthermore, to our knowledge, no screen for 
mutants with increased susceptibility to fatty acid induced death has been completed in any 
organism and therefore this screen will provide a novel outlook on eukaryotic lipid metabolism.  
There have been two screens identifying mutants which are resistant to palmitate induced cell 
death in Chinese hamster ovary (CHO) cells, which demonstrate a role for the elongation factor 
1A-1 (eF1a1) and 3 small nucleolar RNAs (snoRNAs) in the resistance to lipotoxicity [179, 
180].   We hoped to complement these studies by examining lipotoxicity from a different angle, 
with an outcome of sensitivity versus resistance.  Lastly, the yeast model system is useful in the 




homeostatic pathways.  Moreover, the large number of human orthologs in yeast makes it a good 
model for the identification of genes involved human disease.  
The use of palmitoleate for the screen stemmed from the observation that NL-deficient 
yeast is more sensitive to palmitoleate (C16:1) than any other fatty acids tested (palmitate 
(C16:0), stearate (C18:0), myristate (C14:0), oleate (C18:1) and linoleate (C18:2) [22].  The 
haploid (MATa) deletion collection with deletions in ~4,800 nonessential genes and a 
knockdown DAmP (Decreased expression through mRNA perturbation) collection of ~700 
essential genes were plated on synthetic complete media with 2% dextrose +/- 0.5 mM 
palmitoleate.   
Growth sensitivity to palmitoleate was determined by comparing the normalized colony 
size on fatty acid containing media to no treatment media for each single deletion.  Analysis of 
each strain in quadruplicate found that 256 single deletion strains caused sensitivity (p<0.05) to 
palmitoleate compared to the wild type control, as measured by comparative growth rate (SCD 
versus SCD + palmitoleate) (Fig 2-2).  For screen validation, we grew each of these 256 deletion 
strains in rich liquid media (YPD) with and without 0.5 mM palmitoleate and monitored growth 
over a 4 day period (Fig 2-2).  Growth curves were analyzed using MATLAB software for 3 
variables; maximum optical density reading (“Max OD” in OD600), maximum rate of growth 
(“Max Rate” in OD600/hour) and time at which the maximum rate of growth was reached 
(“Time” in hours) (Figure 2-1).  These three variables were normalized to a wild type control and 
used to validate gene deletions with significant growth defects in palmitoleate containing media 
(see Methods for further explanation).  
We considered a significant increase in any of the three variables (Max Rate, Max OD or 




validation we narrowed down our list from 256 to 156 gene mutants with sensitivity to 
palmitoleate in both liquid and solid media (Table 2-1, Fig 2-2, Table S2-1).  Forty-seven of the 
156 genes identified have defects in at least two of the three growth variables.   The majority 
(136 gene mutants) of the 156 had a significant growth lag, in which the time to reach maximum 
growth rate (‘Time’) was increased compared to control.  Thirty-eight gene mutants had 
decreased maximum cell density (‘Max OD’) and forty-three had a significant defect in 
maximum growth rate (‘Rate’) (Table S2-1).    
Growth resembling that of wild type would have a “Time” of 0, a “Max Rate” of 1 and a 
“Max OD” of 1 (see Methods for details).  Gene mutants were ranked based on the sum of these 
variables (“Time” + “Max OD” + “Max Rate”) with the highest value indicating the most 
sensitive strain (Table S2-1).  A control curve without UFA sensitivity would have a variable 
sum equal to 2.  The highest variable summation value occurred with a deletion in ARV1, which 
had a variable sum of 47, making it the most sensitive strain identified in the collection (Table 
S2-1).  There were several strains that had a sum indicating wild type growth (~2) but because 
these mutants had significant values indicating a growth defect in at least one of the three 





Figure 2-1: Yeast growth curve variables for screen validation.  Schematic for 
growth curve analysis.  Values for each curve were calculated and normalized 







Figure 2-2:  Screen validation and follow-up methodology.  (1) Genome-wide 
screen of yeast knockout and knockdown collection on 0.5 mM palmitoleate.  256 
gene mutants were identified as being sensitive relative to wild type.  (2) Growth 
curve analysis in liquid media.  MATLAB program was used to determine 
statistical significance between mutant growth in 0.5 mM palmitoleate (see 
Methods for details).  156 gene mutants were validated as having significant 
sensitivity.  Of the 156 yeast genes, 68 have human orthologs.  (3)  Yeast and 
mammalian models will be used to determine the role of these genes in the basic 





Table 2-1: Deletion of 156 genes confers significant growth defects on 
palmitoleate A yeast deletion library containing haploid single deletion strains 
was plated on SCD ± 0.5 mM palmitoleate in quadruplicate.  Strain sensitivity 
was validated by growth curve analysis in liquid media with 0.5 mM palmitoleate. 
Cellular process determined using Saccharomyces Genome Database (SGD) Gene 
Ontology (GO) Slim Mapper 
 
 
Cellular Process Genes 
Amino Acid Metabolism ARO1 ARO2 TRP2 TRP5 
Carbohydrate Metabolism GCR2 HOC1 MNN4 TCO89 TPS1 
Cell Cycle  GRR1 HSL7 MRC1 NIP100 NPR3 SIC1 
Cellular Homeostasis SAG1 VMA1 VMA7 VMA21 
Cellular Respiration BCS1 CBP1 COX11 CYT1 MRPL51 PET309 QCR7 
QCR8 
Chromosome Organization  BUB1 CTF4 CTF8 HTB2 LGE1 NGG1 RTG2 VPS71 
Cofactor Metabolism CAT5 COQ3 COQ6 
Lipid Metabolism ARV1 CEM1 CSH1 DEP1 ETR1 FEN1 LOA1 MCT1 
SAC1 SCS7 
Mitochondrial Organization AEP1 ATP11 ATP25 CCE1 COX23 CRD1 GGC1 
IFM1 IMP2 MDM32 MRP10 MRPL7 PCP1 PET54 
PET117 PET123  
Protein Modification and 
Protein Folding 
 AIM22 KEX2 MDJ1 PFD1 SLI15 WSS1 
RNA/DNA Metabolism CBP2 COX18 ELP3 FRA2 GCN5 IES6 LDB7 LHP1 
LSM7 MEC3 MTF2 MSW1 NPL6 PHO23 PHO80 
QCR8 RAD6 RPB9 RPS14A RPS16A RRP8 RSC1 
RTF1 SHE3 SKY1 SLX8 SPT21 SRB8 SSN3 STP2 
YAF9 YNL296W 
Translation and Transcription AIM10 FES1 HAP3 MRPL9 RPL8A RPS28B RSM22 
RSM27 SNT1  
Transport FPS1 CTR1 ITR1 MTM1 SPF1 VPS61 VPS63 VPS64 
VPS69  
Vesicle Mediated Transport  EMP24 ERV14 GET1 GET2 GET3 GLO3 GOS1 
RIC1 PEP3 VPS51 VPS52 VRP1  
Unknown GFD2 MGR2 MTC1 SOV1 YBL094C YBL100C 
YBR144C YBR196C-A YDL009C YDL041W 
YDR149C YDR230W YDR417C YER084W YGR219W 
YHR009C YLR184W YLR202C YLR374C YML095C-A 






The liposensitivity screen confirms previously identified unsaturated fatty acid sensitive 
mutants.   Prior to this screen, several genes had been identified as causing sensitivity to 
unsaturated fatty acids [22, 151, 166, 181].   In order to ensure that our screen was consistent 
with these known phenotypes, we investigated if these mutants were also found by our screening 
methods.   Garbarino et al., determined that mutations in GET complex members GET2 and 
GET3 were vulnerable to growth on 0.5 mM palmitoleate in minimal media (SCD) [22].   As we 
expected, these knockout strains were also identified in our screen as having palmitoleate 
sensitivity (Table 2-1).  In addition, Fakas et al., showed that mutations in the phosphatidic acid 
hydrolase, PAH1, cause increased sensitivity to palmitoleate, oleate, and palmitate [151].   pah1Δ 
was not found by our screening methods only because it was not included in our yeast knockout 
library.  We tested this strain using our validation techniques and found that it too had a 
significantly increased sensitivity to UFA (Fig 2-5A).    
 Furthermore, two yeast screens assessing unsaturated fatty acid (UFA) utilization have 
been previously completed, both of which used oleate as a sole carbon source and identified 
several peroxisomal synthesis genes as integral in fatty acid utilization [166, 181].  The study 
completed by Lockshon et al. assessed viability defects in single mutant strains grown on UFA 
containing media lacking glucose [181] whereas Smith et al., investigated fatty acid utilization 
defects in strains by their ability to form  “clear zone” of used FA in the media [166].  The 
purpose of both studies was to identify genes necessary for fatty acid utilization and not for 
lipotoxic pathway identification.  Despite this difference, we did see moderate overlap (19 of 
156) between the genes found in our screen and these studies (Table 2-2). The majority of 




(FEN1, LOA1 and SAC1), cellular transport (SPF1, VPS64, VPS69) and RNA/DNA metabolism 
(LBD7, LSM7, NPL6, RSC1 and SPT21) (Table 2-2).   
 The overlap found between our screen and the two FA utilization screens is not 
particularly surprising.  Though their prime focus was in the determination of genes integral in 
fatty acid utilization as a sole carbon source, some genes which are highly sensitive to UFA may 
not be able survive on FA in the absence of glucose due to their liptoxic response.  Our screen is 
unique from these in that we focused on lipotoxicity, in which glucose was supplemented to the 
media and cells did not require FA utilization for viability.  Furthermore, our screen highlights 
the effect of glucose and lipid in combination (glucolipotoxicity) in eukartyoic systems as a 





Table 2-2: Overlap of palmitoleate sensitive gene mutants with previous fatty 
acid and lipid droplet genome-wide yeast screens.  A. Gene mutants identified in 
three lipid droplet morphology screens (Fei [58] Fei [60] and Szymanski [59]) and 
two oleate utilization studies (Lockshon [181] and Smith [166]) as having a lipid 
metabolism phenotype.  ‘More’ or ‘Less’ indicates the reported lipid droplet 
morphology change in the literature.  
 
 
Genes identified in 
palmitoleate 
sensitivity screen 











ARV1 More More    
BUB1 More     
CTF8     X 
FEN1    X X 
GET1 More     
GET2 Less     
GGC1    X  
LOA1   Smaller X  
LBD7     X 
LSM7     X 
NGG1     X 
NIP100    X  
NPL6     X 
RPL8A  Less  X  
RSC1     X 
SAC1  More  X  
SPF1    X X 
SPT21    X  
SSN3  More    
VMA1 Less  Larger   
VMA21 More More    
VPS51   More   
VPS64  More   X 
VPS69 More More  X X 
VPS71    X  
YAF9    X  







Effect of chain length and saturation on toxicity.  It has been well established that the level of 
toxicity of fatty acids is largely due to their degree of saturation and chain length [182-184].  In 
yeast lacking the neutral lipid (NL) synthesis enzymes (are1Δ are2Δ dga1Δ lro1Δ), both mono- 
and poly- unsaturated fatty acids are toxic (Fig 2-3A), but they are unaffected by treatment with 
saturated fatty acids (Fig 2-3B).  In order to determine if the gene mutants identified in this 
screen are vulnerable to only palmitoleate or if their sensitivity is a more general FA-mediated 
effect, we tested 74 gene mutants which had significant defect in either growth rate or maximum 
OD (defined in Materials and Methods) on media containing the saturated fatty acids myristate 
(C14:0) and palmitate (C16:0), the monounsaturated fatty acid oleate (C18:1) and the 
polyunsaturated fatty acid linoleate (C18:2).  We found that in general, the palmitoleate (C16:1) 
sensitive gene mutants had a less severe sensitivity phenotype to FAs with increased chain length 
(oleate, C18:1) and increased desaturation (linoleate, C18:2) (Figure 2-3A).   
Despite the robust sensitivity of the NL-deficient mutant to all unsaturated fatty acids 
tested, this strain is not vulnerable to saturated fatty acid treatment (Fig 2-3B). This is likely due 
to the ability of yeast to rapidly elongate and desaturate SFA to meet the cellular requirements 
for membrane phospholipids [22, 163].  UFAs are also integrated into the acyl-chains of 
membrane phospholipids, but do not undergo the alterations in chain length or saturation prior to 
integration [163].  Only one of the palmitoleate sensitive mutants, fen1, exhibited sensitivity to 
the saturated fatty acid palmitate (16:0) in both solid and liquid growth media (Fig 2-3B,C).  
FEN1 is a fatty acid elongase which mediates the elongation of fatty acids up to 24 carbons long. 
Of all of the yeast fatty acid elongases, FEN1 has the highest affinity for substrates with less than 
22 carbons, like palmitate (C16:0), palmitoleate (C16:1) and oleate (C18:1)  [185].  A balance in 




fluidity and cellular health and it has been proposed that the ability of palmitate to rescue oleate 
induced toxicity in the NL-deficient mutant is due to a restoration in the saturation balance of 
phospholipid acyl chains [23].  Similarly, yeast mutants with a defect in desaturase activity are 
sensitive to palmitate, likely due to their altered PL acyl chain balance [23].  The sensitivity of 
fen1Δ to both palmitoleate and palmitate can be explained by its inability to properly elongate 
exogenous FA to meet the cellular requirements of the cell and leading to an accumulation of 
acyl chains with the same chain length and a subsequent membrane phospholipid imbalance.  
 
Figure 2- 3: Toxicity of fatty acid depends on degree of unsaturation and chain length 
(A) Subset of palmitoleate sensitive gene mutants grown on media containing 0.5 mM of 
the monounsaturated oleate (18:1) and the polyunsaturated linoleate (18:2). (B) Single 
deletion mutants grown on 0.5 mM palmitate (16:0) (C) Growth curve of fen1Δ tested in 





Lipid droplet sub-screen.  Given that triglyceride storage in the form of lipid droplets is a cells 
primary defense against increased fatty acid exposure [22, 81, 186], we performed a lipid droplet 
screen of the 156 palmitoleate sensitive gene mutants.  We used this screening method to 
determine if palmitoleate sensitivity was due to defects in lipid droplet status.  Each single 
mutant was grown overnight in rich media (YPD) and stained with the lipophilic dye Nile Red, 
and images were classified as having less (Class I), control (Class II) or more (Class III) lipid 
droplets compared to a wild type (Fig 2-4).  89 of the 156 gene mutants screened (57%) had a 
normal number of droplets, 47 (30%) showing decreased droplet number and only 20 (13%) with 
increased lipid droplets (Table 2-3).     
 
Figure 2-4: Lipid droplet morphology sub-screen methodology. Single deletion 
mutants were grown overnight in YPD and stained with Nile Red to visualize 
lipid droplets.  Five or more images were captured and visual scoring was 
completed by three people in order to determine if the strains had abnormal lipid 











Table 2-3:  Lipid droplet phenotypes of palmitoleate sensitive single mutants. 
Classification of single deletion strains from palmitoleate sensitivity screen based on lipid 
droplet phenotype (more, less or control number of droplets).  Complexes or biological 




Genes identified by palmitoleate sensitivity screen Complexes 
Class I 
(Less) 
AEP1 AIM10 AIM22 ATP25 BCS1 CEM1 COQ3 
COX11 COX18 CTF4 CTR1 CYT1 ETR1 GCN5 
GET1 GET3 GGC1 GRR1 HTB2 IFM1 IMP2 LBD7 
LSM1 MDJ1 MRPL51 MRPL9 MSW1 MTF2 MTM1 
NPR3 PET117 PET309 QCR8 RPS28B RSM22 
SAG1 SOV1 SSN3 VMA1 WSS1 YBL100C YLR202C 
YMR135W-A YNL198C YOR331C YPR153W 
Fatty Acid Synthesis 
GET complex 





ARO1 ARO2 ATP11 ARV1 BUB1 CAT5 CBP1 CCE1 
COQ6 CRD1 CSH1 CTF8 DEP1 ELP3 EMP24 
ERV14 FPS1 FRA2 GCR2 GET2 GFD2 GLO3 
GOS1 HOC1 HSL7 IES6 ITR1 KEX2 LGE1 LHP1 
LSM7 MCT1 MDM32  MEC3 MGR2 MNN4 MRC1 
MRP10 MRPL7 MTC1 NGG1 NIP100 NPL6 PCP1 
PEP3 PET54 PHO23 PHO80 RAD6 RIC1 RPB9 
RPS14A RPS16A RRP8 RSM27 RTF1 RTG2 SAC1 
SCS7  SHE3 SIC1 SKY1 SLI15 SNT1 SPF1 SPT2 
SPT21 TCO89 TPS1 TRP2 TRP5 VMA21 VMA7 
VPS52 VPS63 VRP1 YAF9 YBL094C YBR144C 
YDL009C YDL041W YDR149C YDR417C YER084W 












CBP1 FEN1 FES1  HAP3 LOA1  PFD1 PGI1 
RPL8A RSC1 SLX8 SRB8 VPS51 VPS61 VPS64  
VPS69 VPS71 VPS72 YL096C-B YLR374C 
YNL296W 




The proteins encoded by these genes tended to group within the droplet phenotype 
categories based on their biological process or protein complex (Table 2-3).   Gene mutants with 
protein transcripts involved in fatty acid synthesis and members of the cytochrome bc or 
vesicular GET complex have decreased droplet number while those with altered amino acid, 




genes needed for histone deacetylation also had normal lipid droplet number.  Only those genes 
belonging to the class B vacuolar mutant family or SWR1 complex had increased lipid droplet 
number upon mutation. (Table 2-3)  
There have been three previously published yeast genome-wide screens using neutral 
lipid dyes Nile Red [58, 60] or BODIPY 493/503 [59] to determine single gene deletion alleles 
resulting in altered lipid droplet morphology.  Through comparison of our palmitoleate screen 
with these previous studies, we find 12 of 156 gene mutants have been previously reported to 
have altered lipid droplet morphology (Table 2-2).  Of these 12, we independently identified 7 to 
have a LD phenotype in our Nile Red sub-screen.  There is surprisingly little overlap within 
these morphology screens, indicating that even slight changes in growth conditions can cause 
significant alterations in lipid droplet morphology and the subjectivity of morphology screens 
may lead to high variability.  
This screen also demonstrates that there are many pathways that do not affect LD 
biogenesis that can alter lipid vulnerability.  To determine if mutants known to affect LD 
morphology cause changes in lipid vulnerability, we tested four single gene deletions known to 
cause severe defects in LD morphology in yeast (pah1Δ [187], fld1Δ [60], tgl3Δ [81], 
snf1Δ[188]) for palmitoleate sensitivity.  We found that all except for one (pah1Δ) had normal 
growth with FA treatment (Fig 2-5).    Mutations in the phosphatidic acid hydrolase, PAH1, 
causes a smaller number of larger droplets due to its role in diacylglyceride (DAG) synthesis and 
targeting of neutral lipids into the lipid droplet [187].  Triglycerides accumulate within the ER 
bilayer of pah1Δ, possibly contributing to its sensitivity to unsaturated fatty acids [151] (Fig 2-




The three other genes inducing changes in LD morphology are FLD1[60], TGL1 [81] and 
SNF1 [188].  FLD1 is an ortholog of human seipin, a gene associated with congential 
lipodystrophy.  Deletion of FLD1 results in giant lipid droplets, likely due to increased fusion 
[60] or defects in the ER lipid droplet contact sites [59] (Figure 2-5C).  Deletion in the 
triglyceride lipase, TGL3, causes increased lipid droplets due to decreased triglyceride turnover  
[80] (Figure 2-5B).  Lastly, SNF1 is a central kinase regulating the transcription of glucose-
repressed genes [188].  Deletion of SNF1 causes a massive increase in lipid droplet number when 
grown in minimal media (SCD) (Figure 2-5E).   Despite the significant changes in lipid droplet 
morphology, deletion in any of these genes did not alter the sensitivity of cells to treatment with 
palmitoleate (Fig 2-5B-D).   Together, this data demonstrates that although an essential 
protective mechanism against intracellular lipid accumulation, sensitivity to palmitoleate also 
occurs through pathways that do not alter NL-storage or synthesis.  Additionally, changing LD 
morphology or size does not predict an associated effect on the lipotoxic vulnerability of the cell.  
Studying these pathways that effect lipotoxicity independent from neutral lipid synthesis is 










Figure 2-5: Defects in lipid droplet morphology does not always predict 
sensitivity to exogenous fatty acid.   Growth curves of four single deletion strains 
(pah1Δ, fld1Δ, tgl3Δ, snf1Δ) known to cause defects in lipid droplet morphology 
in liquid (A-C) YPD with and without 0.5 mM palmitoleate (C16:1).  (A) pah1Δ 
grown overnight in YPD and stained with Nile Red to confirm lipid droplet 
defects.  (B) Oil Red O image of lipid droplet defects in tgl3Δ obtained from 
(Kohlwein et.al).  (C) Nile Red images of fld1Δ [60].  (D) Serial dilutions of wild 
type and snf1Δ on YPD with and without 0.5 mM palmitoleate (C16:1).  (E) Lipid 




Unsaturated fatty acid sensitive strains share several other sensitivity phenotypes.  The 74  
genes that had significant defects in “Max OD” and “Rate” growth curve variables, were tested 
under several additional growth conditions known to target sterol, sphingolipid and cellular 
stress pathways.  We chose these conditions based on the known connections between fatty acid 
metabolism and other lipid pathways in order to gain insight into how these genes may be 
functioning in lipotoxicity.   
 
Targeting sterol homeostasis with nystatin treatment.  In yeast, oleate causes major changes in 
membrane phospholipid composition and increases membrane fluidity, which is thought to be a 
major cause of oleate induced toxicity [23].  Under conditions of oleate treatment, triglyceride 
synthesis and lipid droplet formation is increased but sterol ester (SE) synthesis is decreased 
through inhibition of the sterol acyltransferase, Are2p.   It has been proposed that the inhibition 
of sterol esterification compensates for the changes in membrane fluidity, through an 
accumulation of membrane free sterols inducing increased membrane rigidity [189].    Therefore, 
defects in sterol homeostasis or an inability to properly regulate membrane SE levels could alter 
a cells ability to properly respond to UFA treatment.   
In order to determine if palmitoleate sensitive mutants were defective in sterol 
metabolism, we used the polyene antibiotic, nystatin, which induces defects in the plasma 
membrane through binding of the drug with membrane free sterols.  This binding results in the 
formation of transmembrane channels composed of polyene and sterol molecules followed by 
intracellular ion and metabolite leakage through these channels, leading to cellular dysfunction 
and death [190].  Consistent with the interaction between nystatin and sterol homeostasis, a 




We tested the palmitoleate sensitive strains on several concentrations of nystatin (2.5, 5, 10 and 
15 g/ml) and found that the 66% of the 74 mutants tested were sensitive to nystatin compared to 
wild type (Fig 2-6 and Table S2-3).  Screens for polyene antibiotic sensitivity in yeast have 
identified genes important in not only sterol homeostasis, but have also revealed a potential role 
for fatty acid pathways [191] and antioxidative defense mechanisms [192] in nystatin 
vulnerability.   The commonality in gene deletions conferring sensitivity to both palmitoleate and 
nystatin are consistent with these previous studies, and demonstrate an interesting connection 
between FA-induced lipotoxicity and sterol metabolism.  
 
Focusing on defects in sphingolipid metabolism using myriocin treatment. Sphingolipids are 
integrally involved in lipotoxicity, particularly in response to saturated fatty acid treatment [111].   
Increased saturated fatty acids (SFAs) can enter the ceramide biosynthesis pathway, through 
action of serine palmitolytransferase (SPT).  Ceramide is a potent inducer of apoptosis, and acts 
through the formation of channels in the mitochondrial membrane leading to protein release and 
mitochondrial permeabilization.    Due to the role of sphingolipid metabolism in lipotoxicity and 
apoptosis, we tested the palmitoleate sensitive mutant strains for defects in sphingolipid 
homeostasis using the serine palmitolytransferase (SPT) inhibitor, myriocin.   
Inhibition of the yeast SPT enzymes with myriocin blocks the rate-limiting step of 
sphingolipid biosynthesis, and depletes the cell of ceramide and complex sphingolipids IPC, 
MIPC and M(IP)2C [193]. Gene deletions vulnerable to myriocin are likely involved in an 
integral sphingolipid related pathway. Growth of the palmitoleate sensitive deletions on myriocin 
supplemented media caused growth inhibition in only three mutant strains, aep1Δ, get3Δ and 




surprising that there is little overlap between palmitoleate sensitive deletions and those inducing 
myriocin sensitivity and demonstrates that palmitoleate induced cell death in yeast is likely a 
ceramide independent process.   
 
Targeting a mutant’s ability to adapt to temperature stress.  Adaptation to increased or 
decreased temperature depends on the “heat-shock” or “cold-shock” response respectively.  
These response mechanisms serve to alter gene expression for conservation of cellular function.  
Adaptive response to a shift in growth temperature includes alteration in sterol concentrations in 
the plasma membrane and modification of membrane phospholipid fatty acyl chains, both of 
which affect membrane fluidity.  For instance, in response to cold stress in yeast, PL synthesis 
genes INO1 and OPI3 are upregulated and there is an immediate increase in the expression of the 
FA-desaturase OLE1 [194, 195].  Action by these enzymes causes a small decrease in saturated 
phospholipid acyl chains and an increase in total unsaturated acyl chains, with increased C16:1 










Figure 2-6: Gene mutations conferring sensitivity to palmitoleate sensitivity 
also have altered basal unfolded protein response (UPR) induction nystatin and 
cold sensitivity. (A)Top 80 16:0 sensitive mutants plated on rich media containing 
2.5-15 μg/ml nystatin X myriocin and also under growth conditions of cold (16°) 
and heat (37°) stress for 3 days.  Deletions were found to be sensitive to nystatin 
cold stress or in many cases both.  (B) Gene hits from screen were compared to a 
HAC1 reporter screen in yeast tested for altered levels of basal UPR in single 
deletions [197]  ~30% of palmtioleate sensitive hits were also identified in this 
screen.  (C) Example of nystatin sensitivity in a subset of gene single deletions.   
 
Since the response to a shift in temperature is so reliant on UFA levels and the integration 
of unsaturated fatty acyl-chains into membrane phospholipids, mutant strains sensitive to 
palmitoleate due to altered membrane FA composition may also be vulnerable to changes in 




conditions of temperature stress, we grew serial dilutions of each strain in high (37C) and low 
(16C) growth temperatures.   Of the mutant strains tested, sixty-seven percent were sensitive to 
low temperature growth (16C) (Fig 2-6 A and Table S2-3).  The overlap between the 
palmitoleate sensitivity and cold sensitivity indicate that these strains have a defect in the ability 
to properly modulate the acyl chain distribution, membrane fluidity, and/or stress response 
associated with both lipid influx and cold shock.    
 Alternatively, there was a small number (10%) of palmitoleate sensitive mutants also 
sensitive to high temperature growth (Fig 2-6 A and Table S2-3).  Mirroring cold shock 
response, growth of yeast at high temperatures is correlated with decreased unsaturation of lipids 
in order to counter the more “fluid” state of membranes at higher temperatures [198].  Heat 
shock induces a general down regulation of transcription for energy conservation, and an 
accumulation of trehalose and glycogen [199].  It is unclear why we see an obvious difference in 
susceptibility of palmitoleate sensitive single deletions to heat vs. cold stress but perhaps genes 
necessary for cold resistance are more reliant on unsaturated fatty acid detoxification and stress 
response mechanisms than heat stress.   
 
Lipotoxicity and the UPR.   ER stress is involved in both saturated and unsaturated fatty induced 
toxicity in both mammalian [142, 164] and yeast systems [22, 154].  Induction of ER stress 
typically occurs due to an accumulation of unfolded proteins, but can also be triggered by FFAs 
[129].  In yeast, ER stress induction occurs through stimulation of the transmembrane sensor 
Ire1p resulting in an activation of the Hac1p transcription factor [200].   Hac1p transcriptionally 
upregulates unfolded protein response (UPR) genes in order to adapt to altered ER homeostasis 




the yeast knockout library and identified several hundred gene knockouts causing significantly 
altered levels of UPR [197].   There was a significant overlap (28%) between gene mutants 
found to be palmitoleate sensitive in this screen with those found to affect the UPR (Fig 2-6B 
and Table S2-3).    
 Together, these sub-screens demonstrate that many gene deletions inducing palmitoleate 
sensitivity are also sensitive to drugs targeting membrane sterols (nystatin) and conditions 
inducing alterations in membrane fluidity (16C growth) but are not sensitive to an inhibition in 
ceramide biosynthesis (myriocin treatment).   In addition, almost thirty percent of palmitoleate 
sensitive mutants had altered levels of UPR, a factor which likely contributes to their lipotoxic 
vulnerability.   
 
Biological categories of palmitoleate sensitive gene deletions.  The cellular processes 
represented most by the genes found causing palmitoleate sensitivity upon mutation include 
mitochondrial organization, RNA and DNA metabolism, cellular and vesicular transport, lipid 
metabolism, cellular respiration and a large number of genes with unknown function (Table 2-1 
and Fig 2-7).   Of the twenty-six genes with unknown function, three dubious open reading 
frames (ORF) overlap or are chromosomally adjacent to recognized yeast genes also identified in 
our screen.   For example, the start codons between YER084W and GET3 (YER083C) are 
separated by only 34 base pairs (bp).  The other two dubious open reading frames overlap with 
known genes, with a 16 bp overlap between YNL198C and GCR2 (YNL199C) and a 302 bp 
overlap between MRPL9 (YGR220C) and YGR219C.  Therefore, these dubious ORF may alter 
the expression of their overlapping genes, and the palmitoleate sensitivities may instead be due 




More detailed analysis of the 156 gene deletions revealed that 48 encode proteins from 12 
protein complexes (Fig 2-7), implicating a role of these complexes in yeast lipid metabolism.  Of 
the complexes identified, six are involved in RNA and DNA metabolism including the chromatin 
remodeling complexes SWR-1/INO80, and RSC; the histone acetyl/deacetylation complexes 
Rpd3L and SAGA-like (SILK); and the spliceosomal protein complex U6 snRNP.  Additionally, 
genes encoding proteins involved in the cellular respiration complexes III and IV, both 
mitochondrial and cytoplasmic ribosomes and two vesicular trafficking complexes (GARP and 
GET) were identified as playing a role in protection against palmitoleate induced cell death (Fig 
2-7).   If a complex is involved in lipotoxic processes, we expect that a mutation in any part of 
the complex would impact palmitoleate sensitivity.  Therefore, independent identification of 
several complex members increases screen confidence and highlights the importance of each 






Figure 2-7 Yeast protein complexes represented by palmitoleate screen and 
grouped by cellular function.  Complex information obtained from 
Saccharomyces genome database (SGD).   
 
Lipid metabolism and transport. Past studies have highlighted the importance of triglyceride 
synthesis [7, 22, 23], fatty acid desaturation [155, 202-204] and elongation [202] in the 
maintenance of cellular function during periods of excess fatty acid exposure.  Consequently, it 
is not surprising that mutations in multiple genes encoding lipid metabolism proteins cause 




multiple metabolic pathways, including sphingolipid biosynthesis, lipid transport, mitochondrial 
fatty acid synthesis and phospholipid regulation.   
 
Sterol and sphingolipid metabolism. The putative sterol transporter, ARV1, was the most 
sensitive deletion mutant identified by this screen (Table S2-1).  As seen with the NL-deficient 
strain, arv1Δ was completely inviable in media containing 0.5 mM palmitoleate.  Knockout of 
ARV1 induces a defect in sterol transport from the ER to the plasma membrane, resulting in 
sterol accumulation in the ER membrane and a constitutively active unfolded protein response 
(UPR) [205, 206].    In addition to this gene effecting sterol transport, two sphingolipid 
metabolism genes, CSH1 and SCS7, are sensitive to palmitoleate upon deletion (Table 2-1and 
Table S2-1).  Protein transcripts of these genes are involved in the synthesis and hydroxylation of 
the long chain sphingolipids IPC, MIPC and M(IP)2C [207].   Sphingolipids and sterols been 
implicated in mammalian toxicity, with increased ceramide [111] and free sterols inducing cell 
death [206].  It is likely that mutations in these genes sensitize cells to lipid induced apoptosis 
through similar pathways to FA induced toxicity, including mitochondrial permeabilization 
[127], increased reactive oxygen species production [125] and the induction of ER stress[129].   
 
Fatty acid modification. Modification of fatty acids through desaturation and elongation are 
common mechanisms of cellular adaptation to lipid load through their ability to moderate the 
levels of membrane lipid species [22, 23] and regulate channeling of FA into TG stores [7].   
Knockout of the fatty acid elongase FEN1 and the acyl-CoA dependent lysophosphatidic acid 
acyltransferase (LPAAT), LOA1, results in decreased viability with palmitoleate exposure (Table 




central lipid metabolite phosphatidic acid (PA) [10].    Though no other phospholipid synthesis 
gene mutants exhibited palmitoleate sensitivity, our screen identified a phospholipid gene 
regulator, transcription factor DEP1 as important in the response to FA accumulation (Table 2-1 
and Table S2-2).   Mutations in these FA modification genes results in altered FA composition 
and storage within the cell both of which are necessary processes for protection against excess 
lipid load.   
Alterations in acyl chain ratios (in either chain length or degree of unsaturation) or defects in 
pathways of lipid storage can result in oxidative damage [208] and ER stress [23, 80, 129] .   
 
Mitochondrial fatty acid synthesis.  In addition to cytosolic lipid metabolism genes, mutations in 
the mitochondrial localized fatty acid synthase (FAS) II confer sensitivity to palmitoleate, as 
identified by our screen.  The mitochondrial FAS II complex differs from the eukaryotic FAS I 
system in that independent polypeptides enzymes carry out each reaction step and a deletion in 
any complex member results in a cell deficient in respiratory function [209].  Three of the five 
major FAS II enzymes were identified by our screen as being important regulators of 
palmitoleate tolerance.  These enzymes are the predicted malonyl-CoA:ACP transferase 
(MCT1), the 3-ketoacyl-ACP synthase condensing enzyme (CEM1) and enoyl thioester 
reductase (ETR1)  [209] (Table 2-1and Table S2-2).  The end product of this pathway is the 8 
carbon saturated fatty acid, octanoic acid (C18:0).  Mitochondrial membrane phospholipid 
composition is altered in yeast with disrupted FAS II, supporting the idea that fatty acids 
synthesized by this complex are able to integrate into phospholipid acyl chains [210].   We 




membrane content and mitochondrial integrity, which is further compromised by a rise in 
intracellular UFA, leading to apoptotic initiation.  
  
Mitochondrial Respiration. Reactive oxygen species (ROS) exist as either oxidants (such as 
hydrogen peroxide H2O2
- 
) or as reductants (such as superoxide O2
-
) and high levels of ROS can 
induce significant oxidative damage.  These molecules are the major toxic metabolites 
responsible for lipid induced cellular dysfunction.  Mitochondria are integral to eukaryotic 
lipotoxicity, and mitochondrial dysfunction results in the release of pro-apoptotic factors which 
initiate the cell death cascade [183].  ROS are produced during aerobic respiration, mainly 
through the leakage of electrons from the mitochondrial respiratory chain [211].  Mutations in 
key respiratory chain proteins are associated with increased mitochondrial reactive oxygen 
species production (ROS) and this rise in ROS is particularly high in mutants affecting the 
functions of respiratory chain complex III and IV [212].   We found that deletions in genes from 
both complex III and IV conferred sensitive to growth on palmitoleate.  Three of the cytochrome 
bc1 (complex III) associated genes, cytochrome C1 (CYT1), and two ubiquinol cytochrome c 
reductase complex members (QCR7 and QCR8) were found by our screen to induce palmitoleate 
sensitivity upon deletion.  Moreover, four gene deletions whose corresponding proteins are 
involved in respiratory complex IV function, COX11, COX18, COX23 and PET117, were 
identified by our screen (Table 2-1and Table S2-2).  Increased ROS resulting from deletions in 
these genes likely increase the cells susceptibility to lipid induced ROS production.  
 
 Vesicular trafficking.  Vesicles are responsible for the transport of protein cargos between 




GTPases for vesicle fusion and SNAREs for membrane tethering [213] .   Screens for lipid 
droplet defects in yeast and Drosophila have demonstrated a relationship between vesicular 
trafficking and lipid droplet homeostasis [56, 57, 59, 60].   Knockdowns in components of the 
COPI machinery in Drosophila S2 cells results in larger, more dispersed droplets [56, 57] and 
blockage of retrograde trafficking (COPII) in yeast causes a lipid droplet accumulation, likely as 
a protective mechanism against secretory stress.    
In this screen, deletions in genes encoding proteins of two vesicular trafficking 
complexes, GARP and GET, were found to be vulnerable to growth on palmitoleate containing 
media (Fig 2-7).  The Golgi-Associated Retrograde Protein (GARP) complex is involved in 
endosomal tethering from the endosome to the Golgi, a key step in retrograde trafficking [214]. 
The GET, or Golgi to ER Trafficking, complex was initially described through a yeast secretory 
pathway screen as an important mediator of retrograde trafficking [215], but has now been 
identified as a required complex for tail anchored protein insertion [216]. Tail anchored (TA) 
proteins contain a C-terminal hydrophobic domain and an N-terminal cytosolic domain, and lack 
a signal peptide for organelle targeting.  Instead, ER localized TA proteins require the GET 
machinery (Get1-3p) for targeting and insertion into the ER, by a signal recognition particle 
(SRP) independent mechanism [216].     
Both the GET and GARP complexes have a role in retrograde vesicular transport, 
particularly in endosomal trafficking pathways.  In addition to its role in TA protein insertion, 
Get3 functions as an endosomal gunanine nucleotide exchange factor.   Get3p facilitated binding 
of GTP to the guanine nucleotide binding protein (G-protein) Gpa1 at the endosome initiates the 
production of phosphatidylinositol-3-phosphate [217], which has been implicated in endosomal 




plays an important role in cellular processes requiring endosomal trafficking.  The identification 
of these complexes in our screen introduces a potential role for endosomes in lipid homeostasis.  
 Vesicular transport is necessary for the exchange of lipids and proteins between 
organelles. Defects in trafficking causes protein mislocalization, induces the unfolded protein 
response (UPR) and increases cellular stress [22]. To date, it is unclear if the lipid droplet 
morphology phenotypes observed in vesicular transport mutants are due to a broad membrane 
trafficking defect or specific to particular complexes.    These results indicate that palmitoleate 
sensitivity is specific to these complexes (GARP and GET) and not a general defect of altered 
cellular trafficking.   
 
Vacuolar protein secretion mutants. VPS mutants are characterized as single deletions causing a 
sorting defect of the vacuolar glycoprotein carboxypeptidase Y (CPY) resulting in CPY 
secretion.  Vacuolar proteins, such as CPY, are first inserted into the ER, travel to the Golgi 
through the secretory pathway and are sorted through the Golgi to the vacuole [219, 220].  The 
61 VPS mutants have been grouped into 5 classes based on their vacuolar morphology, which 
can be visualized by fluorescent vacuolar membrane stains such as FM4-64 [221].  Class A has 
normal vacuolar morphology with three to ten sub-compartments within the cytosol.  Class B has 
fragmented vacuolar structure, with twenty or more vacuole-like compartments.  Class C mutants 
have no vacuolar structure whereas class D mutants have defects in vacuolar segregation 
resulting in a single large vacuole.  Class E mutants have large prevacuolar compartments due to 
defects in the formation of intralumenal vesicles at the multivesicular body (MVB).  Lastly, class 
F mutants have a central vacuole surrounded by many fragmented vacuolar structures [222] .  




screen, we re-plated 61 VPS mutants [223] on palmitoleate to check for additional gene deletions 
that result in fatty acid sensitivity within this protein family.   
This screen validated our original hits and identified several additional palmitoleate 
sensitive VPS deletions including the GARP complex members, VPS53 and VPS54, Class D 
mutants VPS15 and VPS45 and Class C mutants VPS16 and VPS18 (Fig S2-2 and Table 2-4).  
The class B VPS mutants had the highest number of gene knockouts causing increased 
palmitoleate sensitivity (Table 2-4).  These include the GARP complex members VPS51, 52, 53 
and 54 as well as LOA1, VPS69, VPS71, VPS72 and VPS73.  NL-deficient yeast have highly 
fragmented vacuoles, characteristic of that seen in Class B VPS mutants [23] and a similar 
vacuolar phenotype has been reported in mutants defective in fatty acid elongation [224], 
phosphatidic acid hydrolysis [225] and phospholipase C metabolism [226].   Defects in vacuolar 
fusion are evidently associated with altered lipid homeostasis though the mechanism explaining 






Table 2-4:  Sensitivity of vacuolar protein sorting (VPS) mutants to 
palmitoleate.  Sensitivity phenotype indicated as either completely inviable (++) 
or sensitive (+) compared to wild type, ‘--’ indicates normal growth.   See Figure 







VPS Class Gene 
Sensitivity 
phenotype 
VPS Class Gene 
Sensitivity 
phenotype 







VPS10 -- VPS16  VPS26 -- 
VPS13 -- VPS18   VPS62 -- 
VPS29 -- VPS33 -- VPS65  
VPS30 -- 
Class D 
VPS2 -- VPS68 -- 
VPS35 -- VPS3 -- 
VPS38 -- VPS6 -- 
VPS55 -- VPS8 -- 
VPS63  VPS9 -- 
VPS70 -- VPS15  
VPS74 -- VPS19 -- 
Class B 
VPS5 -- VPS21 -- 




VPS39 -- VPS20 -- 
VPS41 -- VPS22 -- 
VPS43 -- VPS23 -- 
VPS51  VPS24 -- 
VPS52  VPS25 -- 
VPS53  VPS27 -- 
VPS54  VPS28 -- 
VPS64 -- VPS31 -- 
VPS66  VPS32 -- 
VPS69  VPS36 -- 
VPS71  VPS37 -- 
VPS72  VPS44 -- 
VPS73  VPS46 -- 





Histone modification, acetylation and deacetylation.  In response to oleate exposure, cells alter 
their gene expression profile through the induction of genes required for fatty acid metabolism 
[227].  These gene expression changes result in increased peroxisomal β-oxidation, decreased 
protein translation and repressed glycolysis in order to adapt to the new source of energy [227-
229].  Transcriptional regulation controls these changing expression patterns through chromatin 
remodeling processes controlled by chromatin binding of the histone variant Htz1p.  Movement 
of Htz1p (H2A.Z) onto the nucleosome in exchange for the chromatin bound histone H2A 
requires the SWR1 complex [230].  This screen identified knockouts of three SWR1 complex 
members, YAF9, VPS71 and VPS72 as being sensitive to palmitoleate (Table 2-1 and Table S2-
2).   In addition, transcriptional activation of a portion of oleate responsive promoters requires 
the acetylation of Htz1p by Gcn5p/Esa1p [230].  A deletion in GCN5 also had a significant 
growth defect on palmitoleate containing media (Table 2-1) further supporting a role for Htz1p 
transcriptional regulation in the activation of pathways protective against lipotoxicity.   
 Histone acetylation status contributes to gene activation and expression pathways, and is 
controlled through histone acetylases (HATs) and deacetylases  (HDACs). We have found that 9 
of the yeast genes associated with sensitivity to palmitoleate have histone acyltransferase or 
deaclyltransferase activity (Table 2-1 and Fig 2-2).    Genes encoding the histone deacyltases 
HDAC complex, Rpd3L (PHO1 and DEP1), are sensitive to palmitoleate upon deletion (Fig 2-
2). The Rpd3-L complex is required for repression and induction of Environmental Stress 
Response (ESR) genes under several different conditions, lack of which causes major defects in 
the initiation of stress response.  Additionally, three of the palmitoleate sensitive deletion strains 




(Fig 2-2).  This complex is required for gene regulation under conditions of mitochondrial 
dysfunction [231].    
 Together the identification of the Htz1 associated proteins (SWR-complex and GCN5) as 
well as the HAT and HDAC genes from this screen demonstrates that a proper transcriptional 
response to palmitoleate treatment may be necessary for the induction of protective pathways 





 In this study, we identified novel genes and pathways integral in the protection against 
lipid induced cell death in the yeast model organism S. cerevisiae. Our screen is unique in that 
we focused on sensitivity to lipids in rich media containing both glucose and fatty acids, a 
condition which caused severe toxicity in the NL deficient mutant (are1Δ are2Δ dga1Δ lro1Δ).   
Ablation of the triglyceride synthesis enzyme DGAT1 in mouse fibroblasts results in severe 
sensitivity to unsaturated fatty acids, similar to that seen in the NL-deficient yeast strain [7, 22, 
23].  Unsaturated fatty acids have also been shown to induce toxicity in some mammalian cell 
types including liver cell lines [119, 124] and primary rat pancreatic β- cells [123] without 
genetic manipulation.  The concentration needed to induce toxicity with UFA tends to be greater 
(~1.0 mM) than that needed to induce toxicity with SFA (~0.25 mM) but gene mutations 
resulting in sensitivity to either UFA or SFA will increases susceptibility for lipotoxic disease 
progression.  Thus identification of mammalian genes involved in these processes is crucial in 
understanding the genetics of obesity related disease.  
 A primary goal of this study was in the identification of mammalian genes that play a role 
in lipotoxic diseases such as type 2 diabetes.  Using methods of sequence alignment (NCBI: 
Basic Local Alignment Search Tool) we determined that a large proportion of the 156 yeast 
genes identified by this screen have been conserved throughout evolution with 68 (44%) genes 
having human and murine orthologs (Table S2-2).  Since the concentration of fatty acid used in 
this study (0.5 mM) is at a level of similar to that normally occurring in human serum [232] 
many of these orthologs may have a similar fatty acid sensitivity upon knockdown in mammalian 




 Eleven of these orthologs have been previously associated with metabolic diseases, 
diabetic phenotypes or stress induced apoptosis (Table 2-5).   This provides an interesting 
connection between known metabolic genes and lipotoxic pathways and provides a potential 
mechanism for these associations.  The diabetic phenotypes linked to these orthologs include 
defects in glucose homeostasis, altered insulin secretion, and genetic association with T2D in 
human populations.  ASNA1, the GET3 ortholog, was shown to positively regulate insulin 
secretion in both C. elegans and mammalian pancreatic β-cells [233] though the mechanism of 
this regulation is still unclear.  Moreover, altered expression of the mouse ortholog of yeast 
palmitoleate sensitive gene, ITR1 (mouse GLUT2) results in pancreatic β-cells dysfunction. 
Specifically, mammalian GLUT2 is an insulin-independent glucose transporter integral in 
glucose sensing in pancreatic β-cells.  Inactivation of GLUT2 in mice by homologous 
recombination resulted in hyperglycemia, hypoinsulinemia and high plasma free FA [234].  
 Genome-wide association studies reported polymorphisms in mammalian orthologs of 
PCP1 (presenilin associated, rhomboid-like (PARL), IFM1 (mitochondrial initiation factor 2 
(MTIF2)) and FEN1 (elongation of very long chain fatty acids protein 6 (ELOVL6)) to be 
associated with increased risk for type 2 diabetes [235, 236].  The identification of the yeast 
orthologs of these genes in our screen indicates a potential connection between the diabetic 
phenotypes associated with these mammalian genes and cellular dysfunction due to increased 
lipid sensitivity.   
The mammalian ortholog of yeast GCN5 (also known as GCN5) is a histone 
acyltransferase (HAT) that directly acetylates peroxisomal proliferators gamma coactivators 
PGC1α and PGC1β [237, 238].  The PGC1 family of transcriptional coactivators is involved in 




metabolic disorders.  GCN5 repression of PGC1β in primary skeletal muscle cells results in 
decreased GLUT4 expression and reduced insulin mediated glucose transport [237].   
Table 2-5:  Mammalian orthologs of screen identified yeast genes previously 
associated with glucose homeostasis insulin secretion dyslipidemia or oxidative 
stress. Associations determined through the National Center for Biotechnology 
(NCBI) database National Human Genome Research Institute catalog of 
published genome-wide association studies (genome.gov) and HuGE Navigator 







Previous associations with the metabolic 
syndrome 
GET3 ASNA1 (46.5%) 
ASNA-1 positively regulates insulin secretion in C. 
elegans and mammalian cells. [233] 
PCP1 PARL (32.3%) 
Leu262Val polymorphism of PARL is ssociated with 
earlier onset of T2D [235] 
ARV1 ARV1 
Decreased expression of ARV1 results in cholesterol 
retention in the endoplasmic reticulum and abnormal 
bile acid metabolism. [239] 
GCN5 GCN5 (46%) 
GCN5-mediated transcriptional control of the metabolic 
coactivator PGC1β through lysine acetylation  [237] 
FPS1 AQP9 (28%) 
Gene expression of paired abdominal adipose AQP7 
and liver AQP9 in patients with morbid obesity: 
relationship with glucose abnormalities. [240] 
IFM1 MTIF2 (36%) 
Genetic association analysis of 13 nuclear-encoded 
mitochondrial candidate genes with type II diabetes 
mellitus: the DAMAGE study. [241] 
ITR1 GLUT2 (27%) 
GLUT2 was thus demonstrated to be required to 
maintain normal glucose homeostasis and normal 
function and development of the endocrine pancreas 
[234] 
MDJ1 DNAJB9 (46%) 
MDG1/ERdj4 an ER-resident DnaJ family member 
suppresses cell death induced by ER stress. [242] 
FEN1 ELOVL6 (30.6%) 
ELOVL6 genetic variation is related to insulin 
sensitivity[236] 
MGR2 ROMO1 (43%) 
Serum deprivation-induced reactive oxygen species 
production is mediated by Romo1 [243] 
ETR1 MECR (36.4%) 
Structural enzymological studies of 2-enoyl thioester 
reductase of the human mitochondrial FAS II pathway: 






 As seen with the yeast system (Fig 2-7), many of the human orthologs can be grouped 
into the cellular processes of DNA and RNA metabolism, mitochondrial respiration and 
vesicular trafficking (Fig 2-8).  Several deletions of yeast mitochondrial respiration complex III 
and IV members and genes essential for mitochondrial DNA maintenance were identified as 
palmitoleate sensitive by our screen (Table 2-1 and Table S2-2).  Mammalian mitochondrial 
respiratory genes BCS1L, COX11 and COX18 genes have all been conserved in sequence and 
function to their yeast orthologs BCS1 (50% identity), COX11 (54% identity) and COX18 
(24.7% identity) (Table S2-2). Furthermore, the retrograde trafficking SNARE, GOSR1 and the 
vesicular trafficking GTPase, Arfgap2 were also found to have high sequence identity to two 
genes identified by our screen, GOS1 and GLO3.  Deletions in these genes results in vesicular 
trafficking defects, specifically in retrograde (Golgi to ER) transport, and likely function in lipid 
metabolism similarly to the yeast system.   
 Yeast is a powerful model system for studying mammalian lipid disorders due to the high 
evolutionary conservation of lipid metabolism machinery [149].  Regardless, there is an obvious 
difference in the vulnerability of yeast and mammals to saturated fatty acids (SFA) such as 
palmitate.   SFA are considered more toxic than UFA in mammalian cells [182], whereas yeast 
are resistant to SFA induced cell death [22, 23].  This resistance may be explained by yeasts 
ability to rapidly elongate and desaturate SFAs to meet the requirements of the cell [23].   
 Despite this obvious difference, there are many parallels in the mechanisms of 
lipotoxicity between yeast and mammals.   For instance, deletion of the yeast fatty acid elongase, 
FEN1, results in sensitivity to the SFA, palmitate, likely due to its inability to properly elongate 
fatty acids and maintain “normal” proportions of phospholipid acyl-chain species (ie C16:C18 




ELOVL6, increases SFA sensitivity in pancreatic β-cells through increased elongation of 
palmitate to stearate [202].  Altered acyl-chain ratios have been shown to cause major changes in 
membrane fluidity and increase vulnerability to ER stress [176] and regulation of FA elongation 
in both yeast and mammalian systems increases levels of lipotoxicity.   Moreover, disruption of 
the yeast phospholipid synthesis through deletions in the phosphatidylethanolamine 
methyltransferase (PEMT) genes, OPI3 or CHO2, in a TG-deficient (dga1Δ lro1Δ) background 
results in a marked sensitivity to 0.5 mM palmitate.  This further highlights the essential 
connection between neutral lipid and phospholipid synthesis, where loss of both results in fatty 
acid vulnerability [22].   
In conclusion, this screen has identified a comprehensive list of eukaryotic gene deletions 
resulting in UFA sensitivity and provided new information regarding pathways essential in 
cellular response to lipid accumulation.  In addition, we have implicated 68 mammalian genes in 
lipotoxic disease through sequence homology, 55 of which are unprecedented.  Future research 
into the role of these genes in human metabolic disease is necessary, and may provide significant 









Figure 2-8: Mammalian orthologs represented by palmitoleate screen grouped 
by cellular function.  Biological function information from National Center for 
























Golgi to endoplasmic reticulum trafficking protein, GET3, plays an  
 








 A genome-wide palmitoleate sensitivity screen in yeast identified the Golgi to ER 
Trafficking (GET) complex as having an important role in yeast lipid metabolism and 
lipotoxicity.  The GET complex is integral to tail-anchored protein insertion into the ER 
membrane and ablation of this complex results in inefficient protein insertion and localization.  
Due to its high evolutionary conservation we focused on the cytosolic member of the complex, 
Get3p.  Deletion of GET3 causes a reduction in lipid droplet number, decreased neutral lipid 
synthesis and a vulnerability to palmitoleate-induced apoptosis.  Additionally, a double mutant 
lacking both GET3 and the triglyceride synthesis gene DGA1 had a significant reduction in lipid 
droplet number compared to both single deletion strains.  This decrease is not due to a reduction 
in neutral lipid mass, but instead appears to be due to a subcellular mislocalization of neutral 
lipids, with an accumulation of lipid droplet-like structures in the vacuole of the get3Δ dga1Δ 
double mutant.  We also demonstrate that get3Δ mutants have a reduction in autophagic flux, as 
measured by GFP-ATG8 cleavage and decreased survival under nitrogen starvation condition, 
indicating defective autophagosome flux.  This defect is likely due to abnormal vacuolar 
lipolysis, as protease activity and vacuolar pH were both normal in these mutants.  GET3 is also 
a guanine nucleotide exchange factor (GEF), extending its role beyond tail anchored protein 
insertion.  As a GEF, GET3 activates an endosomal signaling cascade which has been implicated 
in endosomal maturation and trafficking.  We suggest that a deletion in GET3 results in 
decreased trafficking of a vacuolar lipase through a block in endosomal maturation, causing 








Baker’s yeast (Saccharomyces cerevisiae) is an excellent tool for the identification and 
characterization of novel pathways involved in mammalian lipotoxicity and lipid droplet 
biogenesis due to the evolutionary conservation of lipid metabolic mechanisms.   Yeast neutral 
lipid enzymes and many lipid droplet associated proteins have been conserved in both sequence 
and function to their mammalian counterparts [8, 13, 20].  The ACAT related enzymes Are1p 
and Are2p are responsible for all sterol esterification [245] whereas diacylglycerol esterification 
is mediated by LRO1 (a lecticin-acyl-CoA acyltransferase (LCAT) ortholog) during logarithmic 
growth [246]and DGA1 (the sole DGAT2 ortholog) during stationary phase [14].  Ablation of all 
four yeast neutral lipid synthesis genes (ARE1, ARE2, DGA1 and LRO1)  results in a complete 
loss of cytosolic lipid droplets and a pronounced sensitivity to unsaturated fatty acids (UFA) [22, 
23].  Quadruple mutations are unlikely to occur in nature, and thus a yeast screen for single 
mutants conferring sensitivity to the UFA palmitoleate (C16:1) was completed in order to 
identify genes involved in the mechanisms of lipotoxicity.  From this screen, we identified 156 
gene deletions with increased sensitivity to the UFA (chapter 2).  Of these deletions, several 
genes are known to encode proteins involved in vesicular trafficking were identified, particularly 
the GARP endosomal tethering complex and the GET complex.  The three primary members of 
the GET complex (GET1-3) were identified as conferring sensitivity to palmitoleate upon 
deletion, and thus function in an important mechanism involved in fatty acid tolerance.   
The GET complex was initially identified in an epistatic miniarray profile (E-MAP) 
method designed to identify gene clusters likely involved in the same biological pathway.  This 
group showed that the three GET complex members (Get1-3) are functionally related and act 




found to be essential in mediating the post-translational insertion of tail-anchored (TA) proteins 
into the ER membrane [216].   TA protein insertion is independent and distinct from the classical 
signal recognition particle (SRP)-dependent pathway which is the primary mode of insertion for 
the majority of ER membrane proteins.  TA proteins are characterized by a single 30 residue C-
terminal transmembrane domain (TMD) and an N-terminal cytosolic domain and make up 3-5% 
of all membrane proteins [247].  The cytosolic member of the complex, Get3p, binds the TA 
protein TMDs through a large, hydrophobic, composite groove and subsequently tethers to the 
N-terminus of the ER resident protein Get2 [248, 249]. Get1, which is found tightly associated to 
Get2 at the ER membrane, mediates TA protein release into the membrane by forcing the 
transition of Get3 from a closed to an open conformation [250] (Fig 3-1).   
More recently, two additional GET complex members were identified, Get4p and Get5p 
[197].  Together with the scaffolding protein, Sgt2p, these proteins form the TMD recognition 
complex (TRC), and are able to differentiate between the mitochondrial and the ER TA-protein 
TMD sequences. The C-terminal domain of Sgt2 recognizes TA proteins, and following this 
recognition, Get4 and Get5 facilitate the transfer of ER TA proteins to Get3 [251] (Fig 3-1).  
Knockout of either GET4 or GET5 caused mislocalization of the TA proteins Sed5p-GFP from 
Golgi to a diffuse pattern as well as a relocalization of Pex15 to the mitochondria [248].   
 Our palmitoleate sensitivity screen indicated a link between the GET complex members 
and lipid homeostasis.  We chose to specifically focus on the role of Get3p in lipid metabolism 
due to its high evolutionary conservation, with orthologs in all eukaryotes [252].  The goal of this 
study was to determine by what means mutations in GET3 alter lipotoxicity and lipid droplet 




droplet homeostasis resulting from a GET3 deletion are due to slowed vacuole turnover and are 
independent of tail anchored protein misinsertion. 
 
 
Figure 3-1: Tail anchored protein insertion into the endoplasmic reticulum by 
the GET complex machinery. The transmembrane domain recognition complex 
(TRC) made up of Get4p, Get5p and Sgt2p recognizes newly synthesized tail 
anchored proteins and directs them to Get3p which subsequently localizes to the 
ER membrane.  Get3p then docks to the membrane bound Get1p and Get2p and 
together these proteins insert the protein into the membrane and Get3p is released 










MATERIALS AND METHODS 
 
Yeast General.  Molecular biology and yeast procedures were performed according to 
conventional methods.  Complete (YPD; yeast extract, peptone, dextrose), synthetic complete 
(SC), selective media and 5-fluoroorotic acid (5-FOA) were prepared as described previously 
[177].  All yeast strains (Table 3-1) used in this study were derived from s288C (Open 
Biosystems), with the exception of SCY2021 (are1::HIS3 are2::LEU2 dga1::URA3 
lro1::URA3) which is derived from W303[178].   All single mutants were obtained from Open 
Biosystems Yeast Knock Out Strain collection (Cat # YSC1053).   Double mutants were 
generated using the one-step PCR-mediated gene disruption protocol [253] in which PCR 
products containing 20 nucleotides of the selection cassette (Kluyveromyces lactis URA3 or 
Nourseothricin resistance cassette) and 50 nucleotides of the gene specific sequence were 
generated prior to transformation.  PCR products and plasmids were introduced into the host 
strain via lithium acetate transformation [254] followed by selection and PCR confirmation.  
ATG8-GFP [255] and SEC63-RFP [256] plasmids were a kind gift of Dr. Elizabeth Miller.  
When indicated, fatty acids were added to media in 0.6% ethanol:tyloxapol (5:1, v/v) with the 






Table 3-1: Yeast strains used in these studies.  All Strains except for SCY325 
and SCY3256 have a BY4741 background 
 
 
Yeast Strain Genotype 
BY7471  
Wild Type 
Normal  MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
get1Δ (ygl020cΔ) get1Δ::KANMX 
get2Δ (ygl083cΔ) get2Δ::KANMX 
get3Δ (ydl100cΔ) get3Δ::KANMX 
dga1Δ (yor425cΔ) dga1Δ::KANMX 
lro1Δ (ynr008wΔ) lro1Δ::KANMX 
arv1Δ (ylr242cΔ) arv1Δ::KANMX 
ybl100cΔ ybl100cΔ::KANMX 
gos1Δ (yhl031cΔ) gos1Δ::KANMX 
SCY 3370 dga1Δ::URA3 get3Δ::KANMX 
SCY 3384 dga1Δ::KANMX get2Δ::URA3 
SCY 3391 dga1Δ::KANMX get1Δ::URA3 
SCY 3416 dga1Δ::URA3 get3Δ::KANMX lro1Δ::NAT 
SCY 3411 dga1Δ::KANMX get2Δ::URA3 lro1Δ::NAT 
SCY 3408 dga1Δ::KANMX get1Δ::URA3 lro1Δ::NAT 
SCY 3407 lro1Δ::NAT get3Δ::KANMX  
SCY 3405 lro1Δ::NAT get2Δ::KANMX  
SCY 3402 lro1Δ::NAT get1Δ::KANMX  
 SCY 3421 dga1Δ::KANMX lro1Δ::NAT 
SCY 3423 dga1Δ get3Δ::KANMX  (5-FOA  URA3 disruption of SCY 3370) 
SCY 3427  dga1Δ get3Δ::KANMX lro1Δ::NAT  
(5-FOA  URA3 disruption of SCY 3416) 
SCY 325 W-303normal 




 Growth Assays. Yeast strains were plated in serial dilutions from overnight cultures and grown 
at 30°C for 3 days.  For liquid growth assays, overnight cultures were used to inoculate liquid 
media such that the starting optical density was 0.1 (A600 nm) and growth curves were obtained 
using a Microbiology Workstation Bioscreen C (Thermo Electron Corp.) and Research Express 
Bioscreen C software (Transgalactic Ltd).  Three isolates per genotype were normalized to an 
Absorbance (OD600) of 0.1 and 10 μl of each strain was added to 290 μl of media per well and 
grown at 30° for 4 days and averaged in order to produce the final growth curve.  
 
Apoptosis Assays. Yeast apoptosis was assessed using Annexin V binding and propidium 
idodine staining using the FITC Annexin V/Dead Cell apoptosis kit (Molecular probes V13242).  
Cells were washed with sorbitol buffer (1.2 M Sorbitol, 0.5 mM Magnesium Cloride, 35 mM 
Potassium Acetate ph 6.8), digested with 5.5% gluculase and 15 U/ml lyticase in sorbitol buffer 
and resuspended in Annexin/PI for 20 minutes [257].   
 
Fluorescence Microscopy. Yeast cells were grown in specified media overnight or to log phase 
growth (OD600= 0.4-0.8) when specified.  For lipid droplet analysis, cells were stained with Nile 
Red (1 μg/ml) (Sigma-Aldrich N3013) and visualized with a long pass GFP filter (excitation 440 
nm).  For quantification, 10 frames 0.25 μm apart were captured and displayed as maximum 
intensity projections.  Lipid droplets were counted for 6 frames per strain, with 15-30 cells in 
each frame.  Statistical analysis was carried out by comparing variation within frames. C1-
BODIPY 500/510-C12, BODIPY 493/503, FM4-64, and CMAC-Arg were all purchased from 
Molecular Probes (Invitrogen).  Cells treated with the neutral lipid stain BODIPY 493/503 were 




PBS prior to visualization. The long-chain fatty acid analog C1-BODIPY 500/510-C12 was 
added from a 5 mM ethanolic stock to 1 ml of cells at a final concentration of 50 µM and 
incubated for 60 seconds followed by 3 washes in 50 µM fatty acid-free BSA (Sigma-Aldrich) in 
PBS [258]. Vacuolar staining was carried out using FM 4-64 (Molecular Probes) lipophic dye as 
previously described [259].  Briefly, cells were incubated for 2 hours in YPD with 0.03 µM 
FM4-64, washed once with ddH2O and visualized using a Texas red filter. CMAC-Arg (7-
amino-4-chloromethylcouramrin, L-arginine-amide) was used as a probe for veast vacuolar 
protease cleavage (Molecular Probes, Y-7531) as per the manufacturer’s instructions.   For Oil 
red O staining, cells were fixed in 4% formaldehyde in PBS for 20 minutes and washed twice in 
PBS.  The cells were then stained with 0.2% Oil Red O (Sigma) in H2O:isopropanol (1:1) for 15 
minutes followed by fluorescent imaging. All microscopy was performed using a Zeiss Axiovert 
200 M using a 63x oil immersion objective and images taken by a Hamamatsu Orca-ER camera.   
 
Lipid Analysis and Metabolic Labeling. Yeast lipid labeling was performed using [9,10- 
3
H] 
Oleic acid and [9,10- 
3
H]palmitic acid (PerkinElmer Life Sciences) labeling by growth with 0.1 
μCi/ml overnight at 30°C.  Lipids were isolated by hexane/isopropyl alcohol (2:1) organic 
extraction of dried cell pellets and resolved by TLC in petroleum ether/diethyl ether/acetic acid 
(84:15:1).  Lipids were then detected using iodine staining and quantified with scintillation 
counting [14].   Phospholipids were separated using a 2 solvent system.  Lipids were extracted as 
described above, resolved first in ether:diethyl ether:acetic acid (84:15:1), followed by a second 





Subcellular fractionation.  Membranes were prepared from cells grown for 18 hours in YPD 
with [9,10- 
3
H] Oleic acid and organelle fractionation was completed as previously described 
[205].  200 µl of each fractions was resuspended in H2O:isopropanol (4:1) followed by extraction 
twice with hexane and analysis by TLC separation and scintillation counting.  15 µl of each 
fraction were used for western blot analysis of marker proteins.  Protein extracts from yeast or 
mammalian samples were applied to 12% SDS-PAGE gels and transferred to nitrocellulose 
membranes.  Membranes were then blotted with corresponding primary antibodies and 
secondary antibodies, and proteins bands were detected by ECL immunodetection system.   
 
Electron microscopy. Cells were grown to mid-log phase, prefixed in glutaraldehyde and 
postfixed in potassium permanganate.  They were then dehydrated by graded ethanol series and 
embedded in Spurr’s resin [260].  Cells were thick sectioned and stained with Reynold’s lead 
citrate followed by visualization on a transmission electron microscope [261].   
 
Autophagy assay.  A GFP-ATG8 plasmid was transformed into indicated strains and grown in 
SCD-URA to mid-log followed by 3 hours of starvation in nitrogen deficient SD-N medium 
(0.17% yeast nitrogen base without amino acids and ammonium sulfate, 2% glucose).  Cells 
were visualized via fluorescent microscopy and protein was isolated as previously described 
[89].  Protein concentrations were determined by BCA assay (Bio-Rad) and 20 µg total protein 
was loaded onto a 12% SDS-PAGE gel and separated by electrophoresis.  Proteins were 
transferred to nitrocellulose and analyzed by Western blotting techniques suing a mouse anti-





Nitrogen starvation growth. Log phase growth cultures grown in YPD were shifted to nitrogen 
deficient media (SD-N) and grown for 8 days.  Viability was measured by plating aliquots on 








Mutations in GET complex members confer sensitivity to the unsaturated fatty acid 
palmitoleate.  We previously identified single deletions in GET1-3 in the genome-wide fatty acid 
sensitivity screen as being sensitive to the monounsaturated fatty acid palmitoleate (chapter 2).  
We validated these results on liquid and solid media and found that all three mutants were 
sensitive to 0.5 mM palmitoleate (C16:1) but were not sensitive to oleate (C18:1) or palmitate 
(C16:0) (Fig 3-2A-C).  Two additional GET complex members, GET4 and GET5, were not 
identified by our screen, but were tested for palmitoleate sensitivity through serial dilution 
growth on 0.5 mM palmitoleate.  In contrast to the other complex member deletions, these 
mutants did not show any sign of sensitivity to any of the fatty acids tested (Fig 3-2C).   Get4p 
and Get5p are members of the transmembrane domain recognition complex (TRC), along with 
the scaffolding protein, Sgt2p [247].   The lack of sensitivity of these mutants to palmitoleate 
treatment indicates that these genes are dispensable in the GET complex dependent lipid 
metabolism pathway.   
GET3 has been exceptionally well conserved over evolutionary time, with orthologs 
existing in all eukartyotes and some prokaryotes [252].  For this reason, we chose to focus 
primarily on the role of GET3 in eukaryotic pathways of lipotoxicity.  Treatment of get3Δ with 
0.5 mM palmitoleate for five hours resulted in increased cell death, as measured by Annexin V 
staining of externalized phosphatidylserine and internalization of propidium iodide (PI) (Fig 3-
3A).   
Quantification of Annexin V/PI positive cells found a significant increase in both 
Annexin V and PI staining in palmitoleate treated GET3 mutants (7.9% Annexin + and 10.8% PI 




3A,B).  Overnight treatment with valproic acid was used as a positive control for yeast apoptosis, 
causing death in 100% of cells within the collected frames (Fig 3-3A).  Valproic acid is an 
inhibitor of histone deacetylases (HDACs) in mammalian cells [263] and induces yeast apoptosis 
dependent on the caspase-like protein Yca1p [264].    We observed a majority of dead cells (PI+) 
costained with Annexin V, indicating an apoptotic response (Fig 3-3).  A similar apoptotic 
response was reported in NL-deficient mutants treated with unsaturated fatty acids [22]. 
 
Figure 3-2: Mutations in GET1-3 result in sensitivity to palmitoleate in liquid 
and solid media.  (A,B) Growth curve analysis using Bioscreen C workstation in 
YPD ± 0.5 mM palmitoleate (16:1). 4Δ refers to the neutral lipid deficient are1Δ 
are2Δ dga1Δ lro1 strain.  (C) Growth on solid media (YPD ± 0.5 mM indicated 





Condition Annexin V PI 
Wild Type 2.1% (±0.31) 2.6% (±0.53) 
get3Δ 2.3% (±0.62) 1.9% (±0.51) 
Wild Type + Palmitoleate 3.2% (±0.93) 3.6% (±0.48) 
get3Δ + Palmitoleate 7.9% (±1.11)* 10.8% (±1.05)* 
 
Figure 3-3: Palmitoleate treatment causes increased apoptosis and cell death in 
get3Δ.    (A) Annexin/PI staining of yeast grown overnight in YPD or YPD + 0.5 
mM palmiolteate.  Control cells incubated overnight with 25 μM Valproate was 
used as a positive control for apoptosis [264].  (B) Quantification of Annexin and 
PI positive cells as a percent of total cells (>500 cells per strain). Asterisks 
indicates statistical significance (p<0.05) compared to control in the same 





Knockout of GET3 results in a reduction in lipid droplets.  Lipid droplet formation and storage 
plays an integral role in the cells ability to survive conditions of fatty acid accumulation [7, 22, 
23].   In order to determine if increased fatty acid sensitivity in GET3 mutants was due to defects 
in LD formation or stability, cytosolic lipid droplets were stained using the lipophilic dye, Nile 
Red (Fig 3-4A). The number of lipid droplets per cell after overnight growth in rich media were 
counted and we found that a deletion in GET3 resulted in a 31% decrease in lipid droplet number 
(3.83 ± 0.15) compared to a normal control (5.55 ± 0.47) (Fig 3-4B).   
 Synthetic lethality screens focusing on genes encoding proteins involved in the early 
secretory pathway identified an interaction between the gene encoding the diacylglycerol 
acyltransferase enzyme, Dga1p , and GET2 [22, 215].  This interaction indicates a potential link 
between TG synthesis and GET complex dependent mechanisms.  We validated this, and found 
that the double deletion of get2∆ dga1∆ did result in a growth defect under normal growth 
conditions (data not shown).  For this reason, we hypothesized that knockout of both DGA1 and 
members of the GET complex may exacerbate the lipid phenotypes in these strains.  
Consequently, a double deletion of get3∆ dga1∆ resulted in a 75% reduction in the number 
cytoplasmic lipid droplets (1.38 ± 0.12 per cell), which was not associated with an increase in 
lipid droplet size (Fig 3-4A,B).  The lipid droplet deficiency in get3Δ dga1Δ was significantly 








Figure 3-4: The get3∆ dga1∆ double mutant has a significant reduction lipid 
droplet number (A) Neutral lipid staining of GET3 and DGA1 mutants using 
Nile Red dye (B) Average number of lipid droplets per cell, >50 cells counted in 
at least 7 frames per strain * p-value < 0.01 compared to wild type, # p-value 
<0.05 compared to dga1Δ and get3Δ (C) Growth of GET3 and DGA1 mutants in 
YPD + 0.5 mM palmitoleate for 3 days.  The 4Δ neutral lipid deficient strain 
(are1Δ are2Δ dga1Δ lro1Δ) was used as a positive control for palmitoleate 




Since all three members of the GET complex are involved in the same process of tail 
anchored protein insertion into the ER membrane, single deletions of each gene often cause 
similar cellular defects and phenotypes [216].  Furthermore, in addition to DGA1, there is an 
alternate yeast TG synthesis enzyme, LRO1 [14, 246]. Knockout of either DGA1 or LRO1 
decreases triglyceride synthesis and could potentially affect lipid droplet morphology similarly.  
In order to assess if the reduction in LDs is specific to the GET3 DGA1 double mutation, we 
made all 6 mutant combinations of a single TG synthesis gene knockout on a GET mutant 
background (get1Δ dga1Δ, get1Δ lro1Δ, get2Δ dga1Δ, get2Δ lro1Δ, get3Δ dga1Δ and get3Δ 
lro1Δ).  We then stained each strain for lipid droplets in order to determine if any other knockout 
combinations caused a similar phenotype to that seen in get3Δ dga1Δ strains.  The get3Δ dga1Δ 
double mutant was the only mutant combination causing a significant decrease in LD number, 
demonstrating that the defect is specific to these genes and not a general consequence of a GET 
complex or TG synthesis deficiency (Fig 3-5).    
The triple deletion of get3Δ dga1Δ lro1Δ had an even more striking reduction in LD 
number compared to both get3Δ and dga1Δ lro1Δ with many cells having no visible lipid 
droplets (Fig 3-5).  This does not occur however, in either get1Δ dga1Δ lro1Δ or get2Δ dga1Δ 
lro1Δ (Fig 3-5).  The double deletion of DGA1 and LRO1 is essentially TG deficient, with a 
greater than 95% reduction in TG synthesis, though a low level of TG synthesis remains through 
Are1p and Are2p activity [14].  In this strain sterol esterification is still intact.  Therefore, the 
almost complete lack of LD in get3Δ dga1Δ lro1Δ indicates that the additional deletion of GET3 
in the TG “deficient” background is due to either decreased in lipid droplet biogenesis or an 
increase in LD catabolism.  This effect is specific to GET3 and the removal of other neutral lipid 






Figure 3-5: The lipid droplet defect seen in a GET3 mutant does not occur in 
GET1 or GET2 knockout strains. The GET3 mutants with additional DGA1 
deletion has a severe lipid droplet phenotype, which is not seen with other GET 
complex/DAG acyltransferase double mutants Neutral lipid staining using Nile 
Red of all GET complex and TG synthesis enzyme knockout combinations, after 
overnight growth at 30° in YPD.  







Despite the significant loss in lipid droplets in get3Δ dga1Δ, sensitivity to palmitoleate 
treatment was not further increased compared to the GET3 single deletion (Fig 3-4C).   In fact, 
double mutants of LRO1 or DGA1 in any GET mutant background did not exacerbate the 
palmitoleate sensitivity (Fig S3-1).   From this, we determined that the GET3 deletion causes 
major aberrations in lipid metabolism, which manifests as a defect in neutral lipid storage and 
increased palmitoleate sensitivity.  Though an additional mutation in DGA1 does not exacerbate 
the palmitoleate sensitivity, the further reduction in lipid droplets in the double deletion 
emphasizes the role of GET3 in lipid droplet homeostasis.  This finding also highlights the 
concept that though important in the protection against lipotoxicity, a reduction in lipid droplet 
number does not always predict an increase in fatty acid sensitivity.   
 
GET3 induced lipid droplet defect is not due to decreased cellular neutral lipid levels.  As the 
primary location of NL storage, decreased LD number is typically associated with lower levels 
of NLs.  Therefore, the severe lack of lipid droplets in get3Δ dga1Δ may occur through a 
decrease in cellular triglyceride or sterol ester.   Lipid levels were measured using lipid 
extraction techniques followed by densitometry of thin layer chromatography (TLC) separated 
lipid species.  There was no significant decrease in TG or SE mass in any of the mutants (Fig 3-
6).  Consequently, despite their lack in LD storage, these cells did not have decreased NL mass 
compared to control.   This result is consistent with the growth curve data (Fig 3-4) which 
demonstrates that decreased lipid droplet number in get3Δ dga1Δ did not result in an increase in 
vulnerability of this strain to exogenous fatty acids compared to either single deletion (get3Δ or 
dga1Δ).  If neutral lipid synthesis was significantly decreased in the double mutant compared to 




demonstrate that the FA-sensitivity in the GET mutants may not be related to the lipid droplet 
phenotype occurring upon deletion of GET3.  
Regardless of normal NL mass, the levels of SE and TG synthesis were decreased in 




H]palmitate incorporation into 
neutral lipids (Fig 3-7).  Cells were grown in rich media overnight with fatty acid label, and 
following lipid extraction each fatty acid species (phospholipid, diacylglycerol, free fatty acid, 
triglyceride and sterol ester) was quantified by scintillation counting.  The average percent of 
radiolabeled oleate incorporated into either SE or TG was decreased for both get3Δ dga1Δ and 
get3Δ during steady state overnight growth (Fig 3-7A).   Palmitate incorporation was also 
decreased in all three mutants when grown with label overnight (Fig 3-7B).  Alternatively, a 
three hour pulse at saturation phase with radiolabeled oleate showed a decrease in TG synthesis 
for dga1Δ and get3Δ dga1Δ, but not for the GET3 single deletion (Fig 3-7C).  This is likely due 
to the role of Dga1p in TG synthesis during the saturation growth phase [14].  A deletion in 
GET3 results in decreased NL synthesis during log growth phase growth  [22], whereas a 
mutation in DGA1 results in decreased TG synthesis during saturation (Fig 3-7C).  Together, 
these results indicate that TG and SE synthesis is decreased throughout growth in the GET3 
DGA1 double mutant.  The concurrent decrease in TG and SE synthesis with normal NL mass 
occurring in GET3 mutants indicates that there is a likely reduction in NL turnover.  
Analysis of [
3
H]oleate incorporation into other lipid species separated by TLC 
(diacylglycerol, free fatty acids and phospholipid) found that phospholipid (PL) synthesis levels 
were significantly increased in both get3Δ and get1Δ dga1Δ (Fig 3-7 D).  The PL species 
separated out by this method of TLC contains multiple phospholipid types, characterized by their 




phosphatidylserine (PS), phosphatidylinositol (PI) and diphosphatidylglycerol (DPG).   To 
dissect out if a specific phospholipid type was responsible for the rise in total PL synthesis, we 
further separated the phospholipid species using a two solvent system followed by quantification 
of radiolabeled oleate incorporation into each PL type.  This quantification indicated that the rise 
in PL synthesis seen in GET3 mutants is due to a general increase in fatty acid flux through the 
phospholipid synthesis pathway, with increases in four phospholipid types; diphosphatidyl 
glycerol (DPG), phosphatidylinositol (PI), phosphatidylserine (PS) and phosphatidylcholine (PC) 








Figure 3-6: The get3∆ dga1∆ double mutant does not cause a decrease in 
neutral lipid mass. Lipid mass, as measured by species density of iodine stained 
TLC plate separation of extracted lipids. Iodine binds to double bonds in fatty 
acids.  ‘p’ indicates p value of statistical significance compared to wild type (WT) 





Figure 3-7: get3∆ mutants have decreased neutral lipid synthesis levels. Levels 





H]palmitate (B) incorporation into neutral lipids after overnight growth with 
labeling media.(C) [
3
H]oleate incorporation during 3 hour pulse at saturation.  (D) 
Increased [
3
H]oleate into phospholipids (PL) occurs with decreased [
3
H]oleate 
incorporation into neutral lipids (NL= sterol ester + triglyceride) in both GET3 
mutants.  (*) indicates significance (p<0.05) compared to wild type, (#) indicates 






Figure 3-8: get3∆ mutants have increased oleate incorporation into 
phospholipids. The decrease in oleate incorporation into neutral lipid synthesis 
seen in GET3 mutants is counterbalanced by increased incorporation into 
phospholipid species.  Asterisks indicate significance (p<0.05) compared to wild 
type (WT).  Phospholipid species; DPG: diphosphatidylglycerol PE: 










Figure 3-9: Use of BODIPY fatty acid analog indicates lipid localization 
changes in get3∆ and dga1∆ mutants.  BODIPY fatty acid analog (C1-BODIPY 
500/510-C12) shows decreased incorporation of fatty acids into lipid droplets in 
get3Δ dga1Δ.  Cells were treated with BODIPY 500/510 for 1 minute followed by 
3 washes in 50 µM fatty acid free BSA in PBS.  
 
 For visualization of fatty acid uptake, incorporation and localization in live cells, we used 
a fluorescent BODIPY conjugated long chain fatty acid (C1-BODIPY 500/510-C12). The fatty 
acid conjugate, dodecanoic acid, is a precursor for PL and NL biosynthesis and long term 
labeling (>1 hour) stains lipid droplets in yeast [265].  Additionally, short term incubation (~2 
minute) with this analog has been used to monitor FA uptake and localization in mammalian 
cells [266].  Incubation of GET3 and DGA1 mutants with C1-BODIPY 500/510-C12 for 1 
minute followed by fluorescent microscopy results in lipid droplet staining in wild type and 
get3Δ.  Alternatively, lipid droplet and membrane staining occurred in dga1Δ and only 





Figure 3-10:  get3∆ and dga1∆ mutants have increased BODIPY fatty acid 
membrane staining after preincubation with monounsaturated fatty acids. 
BODIPY fatty acid analog (C1-BODIPY 500/510-C12) staining for 1 minute after 
3 hour incubation in (A) 0.1 mM palmitoleate or (B) 0.5 mM oleate.  
 
Pretreatment of cells with 0.1 mM palmitoleate or oleate for 3 hours resulted in increased 
membrane and cytosolic staining in both dga1Δ and get3Δ dga1Δ likely due to the DGA1 




also occurs in the palmitoleate treated GET3 mutant, while wild type has mainly LD staining 
under all treatment conditions, with some membrane staining following oleate incubation (Fig 3-
10).  These results show that fatty acid incorporation into the LD is slowed in GET3 and DGA1 
mutants when pretreated with monounsaturated fatty acids (MUFA) oleate or palmitoleate.  The 
fluorescent membrane staining seen in these mutants could be due to either incorporation of the 
BODIPY-FA into phospholipid acyl chains or through synthesis into TG.  In either case, 
[
3
H]oleate incorporation and C1-BODIPY 500/510-C1 demonstrates that fatty acid flux into LD 
storage is slowed with deletions in GET3 and/or DGA1.   
GET3 mutants have altered triglyceride subcellular localization.  The 75% decrease in LD 
number accompanied by normal NL levels suggests a defect in LD formation in get3Δ dga1Δ.  
The current model of lipid droplet biogenesis posits that NL synthesis occurs in specific regions 
the ER bilayer and buds off of the ER to form an independent organelle [30].  A similar 
phenotype of normal NL mass with reduced LD number occurs with deletion of the phosphatidic 
acid hydrolase, PAH1.   This mutation results in a buildup of TG in the ER bilayer due to 
defective channeling of TG into the budding lipid droplet structure.  The TG accumulation in the 
ER was visualized by both BODIPY 493/503 fluorescence and electron microscopy (EM) as 
lipid filled ER rings [187].  In order to determine if a similar mechanism of defective LD 
budding was occurring in our GET3 mutants, we analyzed electron micrographs of these strains 
and looked for fatty buildup within the ER membrane.  We saw no such accumulation in any of 
our mutants, demonstrating that the decrease in LD seen in get3Δ dga1Δ is likely not due to an 
accumulation of NL within the ER bilayer (Fig 3-11).   
Further analysis of the electron microscopy (EM) images indicate an increase in 




both dga1Δ and get3Δ dga1Δ (Fig 3-11 and 3-12A, black arrows).  Vacuoles with associated 
lipid droplets were counted for each genotype and we found that over 40% of cells had vacuolar 
lipids in both DGA1 deletion strains, while wild type and get3Δ had less than 20% (Fig 3-12B).   
The increased number of lipid droplet-like structures in the dga1Δ single mutant was surprising, 
and indicate a preferential movement of lipid to the vacuole in this strain.  Lipid droplets located 
within or in tight association with the yeast vacuole and mammalian lysosome have been 
reported in lysosomal hydrolase inhibited hepatocytes [91], in yeast mutants of the trafficking 
genes ARF1 [267]and SEC13 [268], and in a mutant of the yeast lipid phosphatase, SAC1 [269].   
 
Figure 3-11: Electron Microscopy of get3∆ and dga1∆ mutants.  Thin section 
EM of control, dga1Δ, get3Δ, and get3Δ dga1Δ.  Two images shown per strain.  
N, nucleus; V, vacuole; white arrowheads indicate lipid droplets and black arrows 
indicate lipid droplet-like structures within the vacuole.   
 
In addition to vacuolar associated lipid droplets, membrane-like structures were found 
within a portion (16%) of the vacuolar lipid only in the GET3 DGA1 double mutant and not in 




membrane recycling through autophagy [89].  Autophagy is a process involved in the 
degradation of cellular products and organelles through lysosomal hydrolysis and plays a 
particularly important role under starvation conditions.  There are three modes of autophagy, 
macroautophagy, microautophagy and chaperone mediates autophagy. Microautopahgy occurs 
through nonspecific cytoplasmic invagination by the autophagosome while chaperone mediated 
autophagy targets only specific peptide sequences for degradation. Macroautophagy, from here 
on referred to simply as “autophagy” is a selective process in which particular organelles, such as 
the mitochondria or lipid droplet, are targeted and sequestered by the autophagosome [90].  This 
mode of autophagy has been recently implicated in the degradation of hepatic lipids [91] and in 















Figure 3-12: Electron Microscopy of get3∆ and dga1∆ mutants indicates 
increased lipid droplet association with the vacuole and internal membrane 
structures in the GET3 DGA1 double mutant.  (A) Abnormal structures in the 
get3Δ dga1Δ include increased lipid droplets in vacuoles (black arrows) and the 
presence of membranes structures inside vacuolar lipid droplets (white 
arrowheads).   (B,C) Quantification of these structures in all four genotypes.   (B) 
Percent of cells imaged with vacuolar associated internal lipids.  (C) Percent of 







Since the GET3 DGA1double mutant has membrane accumulation within the vacuole, we 
went on to assess the vacuolar structure and lipid association using fluorescent probes.  Staining 
of the vacuolar membrane with, FM4-64 did not indicate any obvious vacuolar phenotypes in 
any of the GET3, or DGA1 mutants (Fig 3-13).  Co-staining with the neutral lipid stain BODIPY 
493/503 showed a close interaction between vacuoles and lipid droplets in all strains (Fig 3-13), 
but the localization of droplets within the vacuole could not be deciphered using this method.  
 
Figure 3-13: Vacuolar membrane marker FM4-64 demonstrates normal 
vacuolar morphology in get3∆ and dga1∆ mutants.  Log phase (OD600~ 0.4-
0.8) cells were labeled for 90 minutes with 0.03 mM FM4-64 in YPD and for 30 




To further rule out an accumulation of NL within the ER membrane, we transformed 
cells with a plasmid containing the fluorescent ER marker Sec63-RFP and co-stained with the 
neutral lipid stain BODIPY 493/503 (Fig 3-14).  In agreement with the EM results, we saw no 
obvious accumulation of lipids within the ER bilayer in any strain.  Consistent with previous 
work [55] lipid droplets were found in frequent association with the ER membrane in all strains.  
Additionally, all mutants had normal Sec63-RFP localization and ER structure (Fig 3-14), 
despite known vesicular trafficking defects characteristic of GET mutants [215].   
 
Figure 3-14: Neutral lipids do not colocalize with the ER membrane in get3∆ 
and dga1∆ mutants.  Co-localization of neutral lipids and the ER membrane 
using the neutral lipid dye BODIPY 493/503 and the fluorescent ER marker 




As an alternate method for the determination of subcellular TG localization, we labeled 
all four strains overnight with [
3
H]oleate and completed a whole cell membrane fractionation.  
The thirteen fractions were grouped into their associated organelles, based on organelle specific 
marker proteins (Fig 3-14).   As expected from Nile Red staining, levels of TG in the lipid 
droplet fractions were significantly decreased in both get3Δ and get3Δ dga1Δ compared to wild 
type and dga1Δ.  The TG levels were increased throughout several other membrane fractions, 
including those associated with the golgi, vacuole and cortical ER/plasma membrane marker 
proteins (Fig 3-15).  The TG within these mutants is dispersed throughout several membrane 
fractions in the cell, but the exact localization of this storage is still unclear.   What is clear from 
these results is that TG in the GET3 mutants is localized to non-LD structures within the cell.  
Based on the EM data (Fig 3-11 and Fig 3-12), it appears that this localization likely occurs 






Figure 3-15: get3Δ causes mislocalization of cellular triglyceride Total cell 
fractionation using renograffin and grouped based on associated organelle.  Cells 
were labeled for 16 hours with [H]oleate.  Western blots of all strains for 
organelle specific proteins Sec61 (ER), Sec22 (ER and Golgi), Pma1 (Plasma 
Membrane). Lipid droplet fractions were based on wild type neutral lipid levels.  
Fraction 1 (F1) was not associated with any tested organelle.  
 
 
Lipid structures within the GET3 DGA1 double mutant can be explained by decreased 
vacuolar lipid turnover.  The yeast vacuole is the primary site of degradation and cellular 
recycling. An accumulation of vacuolar lipid could occur through either an increase in vacuolar 




defect in vacuolar hydrolase activity [270].   Vacuolar directed trafficking occurs through either 
macroautophgy or the biosynthetic Cvt pathway (Fig 3-22).  These pathways share many 
mechanistic similarities.  Both form at the phagophore assembly site (PAS), after which the 
membrane expands to form a vesicle, taking up vacuolar specific hydrolases in Cvt trafficking or 
targeting whole organelles as seen in macroautophagy.  These vesicles fuse with the vacuole 
through use of the autophagy machinery leading to whole organelle degradation and nutrient 
recycling.  The accumulation of internal membranes within the vacuole seen in the EM images of 
get3Δ dga1Δ (Fig 3-12) could potentially occur through increased autophagy resulting in a rise in 
LD associated autophagosome transport to the vacuole.   
A commonly used method for the determination of yeast autophagy is through the 
transformation of a GFP-Atg8 fusion plasmid [255].  Atg8p, the yeast ortholog of mammalian 
LC3, is an early mediator of autophagosome formation and its expression increases in response 
to autophagy induction [271, 272]. ATG8p exists as a cytosolic protein until lipidation, after 
which it accumulates in pre-autophagosomal structures (PASs).  These structures can be 
visualized by fluorescence microscopy in cells expressing the GFP-ATG8 plasmid (Fig 3-14 b).  
In addition to PAS visualization, the GFP-Atg8p fusion protein can be used as a marker for 
vacuolar processing.  When autophagosomes lyse to vacuoles, GFP is released from Atg8 
through proteolytic cleavage, which can be detected by Western blot.  Figure 3-16 shows that 
autophagy induced by nitrogen starvation (SD-N) increases GFP-ATG8 cleavage in both wild 
type and dga1Δ while starvation induced proteolytic cleavage was not detected in either get3Δ or 
get3Δ dga1Δ (Fig 3-16A).  In agreement with these results fluorescence microscopy under 
nitrogen starvation conditions also shows an accumulation of GFP-Atg8 bodies in get3Δ dga1 





Figure 3-16: Mutation in GET3 results in decreased GFP-ATG8 vacuolar 
processing under conditions of nitrogen starvation. Strains were transformed 
with a plasmid containing GFP-ATG8 protein and grown to log phase in SCD 
media followed by 3 hours incubation in nitrogen starvation media (SD-N).  Cells 
were harvested for protein preparation and protein extract was analyzed by 
Western blot using antibodies specific against GFP.  Equal protein concentrations 
were loaded into each lane.  (B,C) Cells grown  in the conditions described above 





Similar defects in proteolytic cleavage have been reported in the vacuolar protease 
deficient, vps4Δ pep4Δ and in the vacuolar lipase mutant atg15Δ resulting in an accumulation of 
autophagic bodies within the vacuole [89, 262].  Therefore, it is possible that the GET3 mutants 
are defective in vacuolar hydrolysis resulting in decreased autophagosome breakdown.   
The hydrolytic defects occurring in both vacuolar protease deficient (vps4Δ pep4Δ) and 
vacuolar lipase deficient (atg15Δ) strains results in a block in autophagy due to a failure in 
autophagosome breakdown.   The inability to breakdown autophagic bodies results in an 
inviability under conditions that require nutrient recycling for survival.  Therefore both of these 
vacuolar hydrolysis mutant strains have decreased percent survival in nitrogen deficient (SD-N) 
media compared to control [89, 262].  In order to determine if the GET3 mutants also had 
decreased survival due to defects in vacuolar hydrolysis, we grew all four strains in YPD media 
to log phase (OD ~ 0.5) and transferred the cells to SD-N media for 8 days.  Every 2-3 days we 
plated an aliquot of cells on solid YPD media to assess survival during starvation.  Consistent 
with the defect in GFP-ATG8 processing, both get3Δ and get3Δ dga1Δhad a significant 
reduction in percent survival under nitrogen deficient conditions compared to both wild type and 
dga1Δ.  Decreased survival in SD-N indicates that mutations in GET3 result in a defect in 
nutrient recycling, which could occur through a decrease in autophagic induction or reduced 





Figure 3-17: GET3 mutants have reduced survival rates under nitrogen 
starvation conditions. Cells were grown to log-phase (OD ~ 0.5) and transferred 
to SD-N media for 8 days.  Plating of cell aliquots on YPD plates were completed 
every 2-3 days and grown for 2 days at 30°C.  Colonies were counted in order to 
assess culture viability and percent survival.  WT indicates wild type control.   
 
Breakdown of the autophagosomes is necessary for survival under starvation conditions 
because it allows vacuolar hydrolases access to its internal contents for nutrient recycling.   The 
breakdown of autophagosomes depends on action of proteinase A (yeast Pep4p) [273] and B 
(yeast Prb1) [274] and vacuolar acidification [275].  To test for vacuolar protease activity, we 
used the vacuolar lumen specific marker, CMAC-Arg (7-amino-4-choloromethylcoumarin, L-
arginine-amide).  CMAC-Arg is a coumarin-based vacuolar marker conjugated to L-Arginine, 
and is nonfluorescent until cleaved by vacuolar proteases, after which it fluoresces a bright blue.  
Treatment of these cells with CMAC-Arg under normal (Fig 3-18) and nitrogen starvation 
conditions (Fig 3-19) demonstrates that the vacuoles of GET3 and DGA1 mutants have normal 
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have proper CMAC-Arg cleavage, which would be evident through a lack of vacuolar 
fluorescence.  This also indicates that these mutants have normal vacuolar acidification.  
In addition to vacuolar proteases, vacuolar lipases are known to degrade lipids and 
breakdown autophagic bodies in yeast [262] and mammalian cells [276].  The yeast vacuolar 
lipase Atg15p is a membrane bound lipase and knockout of ATG15 results in an accumulation of 
autophagic bodies in the vacuole, but normal vacuolar pH [277].  Atg15p is transported to the 
vacuole from the ER through the multivescular body (MVB) pathway and is blocked in VPS 
Class E mutants [277].  Defective localization of Atg15p, due to deletion in GET3, could explain 
the vacuolar processing defects and decreased survival rate with starvation and thus must be 
tested in these strains.   








Figure 3-18: Probe for vacuole protease activity indicates that GET3 mutants 
properly hydrolyze proteins under normal conditions.  Strains were grown in 
minimal media (SCD) and re-suspended in 10 mM HEPES (ph 7.4) with 5% 
glucose containing 100 µM CMAC-Arg for 30 minutes and visualized by 
fluorescence microscopy.  Blue fluorescence indicates protease cleavage of 
Arginine conjugate and activation of the coumarin-based fluorescence.  Lipid 













Figure 3-19: Probe for vacuole protease activity indicates that GET3 mutants 
properly hydrolyze proteins in nitrogen deficient conditions.  Strains were grown 
for 2 hours in nitrogen deficient media and re-suspended in 10 mM HEPES (ph 
7.4) with 5% glucose containing 100 µM CMAC-Arg for 30 minutes and 
visualized by fluorescence microscopy.  Blue fluorescence indicates protease 
cleavage of Arginine conjugate and activation of the coumarin-based 
fluorescence.  Lipid droplets were stained with BODIPY 493/503 neutral lipid 





Lipid droplets within the vacuolar are not shown through BODIPY or Nile Red staining.  
Despite the increase in vacuolar associated lipid droplets seen by EM, we were unable to localize 




The yeast vacuole has a pH of approximately 5.5 dependent on growth conditions [278] and 
some fluorescent probes, particularly green fluorescent proteins (GFPs), are known to have 
reduced signal in the vacuole due to the low pH conditions [279].   We first considered that was 
the lack of fluorescent staining was due to a similar acid-induced signal reduction.  Studies 
determining pH effects on Nile Red fluorescence indicate that a pH between 4.5 and 8.5 causes 
little change in relative fluorescent intensity [280].    Additionally, in C. elegans, BODIPY and 
Nile Red probes are able to fluoresce in acidic lysosomal-related organelles (LROs), despite the 
low pH [281].  It is therefore unlikely that the acidic environment of yeast vacuoles is 
responsible for these contradictory results.   
 Although vacuolar lipid association and accumulation visualized by EM has been 
reported in yeast [267-269], to our knowledge, no study has demonstrated vacuolar lipid droplets 
through fluorescence staining in this organism.   In order to decipher if we were not capturing all 
cellular neutral lipids using these fluorescent dyes, we also used the lypophilic dye Oil Red O 
following cell fixation. We did not see droplet-like structures in the vacuole by these methods, 
but did find increased fluorescence within a structure reminiscent of the vacuole in the GET3 
DGA1 double mutant, which was not seen in either single deletion strain (Fig 3-20).  The 
staining was not localized within a punctate structure, but was instead a diffuse appearance.  This 
diffuse pattern may explain we did not see vacuolar staining using either BODIPY or Nile Red, 
which may require a higher signal density for visualization.  Alternatively, lipid staining in the 
vacuole may require cell fixation for visualization.  These results confirm that there is an 
increase in neutral lipids in a “non-lipid droplet” structure in get3∆ dga1∆, most likely within the 
vacuolar lumen, though a vacuolar co-stain is required with Oil Red O to determine exact 






Figure 3-20: Oil red O staining demonstrates subcellular staining of non-lipid 
droplet structures in the get3∆ dga1∆ double mutant. Cells grown overnight in 
YPD and fixed after which they were incubated in Oil red O for 10 minutes 
followed by fluorescent imaging. Lower pane with get3∆ dga1∆ is a 2x 




Deletions in tail-anchored proteins does not recapitulate GET3 mutant lipid phenotypes.  The 
GET complex is involved in protein localization of at least 50 different proteins, and therefore 
knockout mutations of these genes results in broad cellular defects.   A deletion of the cytosolic 
GET3 causes a mislocaliztion of tail-anchored proteins, which is exacerbated in both get1Δ and 




get3Δ is due to the accumulation of cytosolic Get3-TA protein aggregates in GET1/2 knockouts, 
leading to an extensive depletion of TA proteins.  In the GET3 deletion, these aggregates do not 
occur, though efficient insertion into the ER membrane is still somewhat impaired.  Deficiency 
in GET3 results in a less specific targeting of TA proteins and insertion into non-ER membranes.  
Get3p is therefore critical in accurate targeting of TA-proteins to the ER membrane, but lack of 
Get3p does not deplete the cell of these proteins like that seen in get1Δ and get2Δ.   
Being that a major function of Get3p is its role in the movement of tail-anchored proteins 
from the ribosome to the ER for insertion into the ER membrane, we tested for palmitoleate 
sensitivity in all known non-mitochondrial yeast tail anchored gene mutants (44 knockouts or 
DaMP strains) to determine if the lipid phenotypes in the GET3 mutants could be easily 
explained by altered tail anchored protein localization.  Of the 44 genes, mutations in two 
resulted in increased sensitivity to palmitoleate, both of which had been already identified by our 
genome-wide screen (gos1Δ and ybl100cΔ) (Table 3-2, chapter 2).  Both gos1Δ and ybl100cΔ 
had a similar growth defect as get3Δ in media containing 0.5 mM palmitoleate (Table S3-1 and 
Fig 3-21A) but neither have a defect in TG synthesis measured by [
3
H] oleate incorporation (Fig 
3-21B).  Furthermore, ablation of DGA1 in either gos1Δ or ybl100cΔ did not phenocopy the 
severe LD defect observed in get3Δ dga1Δ (Fig 3-22).  Together, these results indicate that the 
lipid metabolism defects in GET3 mutants are not explained by the mislocalization of a single 
known tail anchored protein, however we cannot rule out the possibility that inefficient targeting 







Figure 3-21: Two genes encoding tail anchored proteins, GOS1 and YBL100C, 
are sensitive to palmitoleate treatment (A) 44 known tail anchored proteins were 
tested for 16:1 sensitivity in liquid media and found that both ybl100cΔ and gos1Δ 
have sensitivity similar to GET family knockouts.  (B) [
3
H]-Oleate labeling of 
ybl100cΔ and gos1Δ. (C) Neutral lipid staining of gos1Δ dga1Δ and ybl100cΔ 








Figure 3-22: Knockout of DGA1 in a gos1Δ or ybl100cΔ background does not 
phenocopy the get3∆ dga1∆ double mutant lipid droplet defect. Double 
mutations gos1Δ dga1Δ and ybl100cΔ dga1Δ were stained for lipid droplets using 
Nile Red after overnight growth in rich media (YPD).  Both double mutant strains 







In this study, we have identified a novel role for Get3p in lipid homeostasis, which 
appears to be independent of GET3 mediated defects in tail-anchored protein insertion.  We 
propose that this effect is not due to inefficient insertion of tail anchored proteins for two 
reasons; the contrasting lipid droplet phenotypes in get3Δ and get1Δ or get2Δ as well as the lack 
of overlap in lipid droplet morphology in double mutants of tail anchored protein genes in a 
GET3 deletion background.  
Results demonstrating that the lipid droplet defect occurring in the get3Δ dga1Δ double 
deletion is specific to GET3, and does not occur in deletions of either GET1 or GET2  (Fig 3-4) 
supports the idea that this phenotype is not due to TA protein misinsertion.  Each GET complex 
member plays a different role in tail-anchored protein insertion; with cytosolic Get3p binding to 
newly synthesized TA-proteins and anchoring to ER localized Get1p and Get2p, which together 
insert the protein into the membrane (Fig 3-1). Ablation of either GET1 or GET2 results in a 
general loss in tail anchored proteins throughout the cell, due not only to improper insertion but 
also to an aggregation of TA proteins bound to cytosolic Get3p.  A GET3 deletion does not have 
protein aggregate build up, but does have an inefficient insertion of ER tail anchored proteins, 
resulting in protein insertion into multiple membranes.  Studies of GET complex deletions have 
focused on the pleiotropic phenotypes caused by deletions in either GET1 or GET2, due to their 
marked sensitivities to multiple growth conditions.   Knockout of GET3 has less growth 
sensitivities compared to knockouts in the other two complex members, due to the continued 
insertion of TA proteins [216], thus phenotypes which are dependent on GET complex function 
should occur in all GET mutants, but especially in get1∆ and get2∆.   For example, Schuldiner et 




temperatures.  Both  get1∆ and get2∆ have these same sensitivity phenotypes, but get3Δ was 
shown to have either no growth defect or a less severe phenotype under all conditions [216].  
Therefore, because we do not see the same deficiency in lipid droplets in get1∆ dga1∆ or get2∆ 
dga1∆, it is unlikely that the defect is due to GET complex dysfunction.   
Furthermore, the two tail anchored protein gene deletions found to be palmitoleate 
sensitive, GOS1 and YBL100C, did not cause a significant reduction in LD number with an 
additional deletion of DGA1.  If these proteins were responsible for the LD defect characteristic 
of get3Δ dga1Δ, we would expect double deletions of DGA1 and YBL100C or GOS1 to 
phenocopy the 75% reduction in LD number (Fig 3-22).   As previously mentioned, many of the 
phenotypes resulting from a deletion in GET1 or GET2 can be easily explained by the extensive 
defects in TA protein insertion including sensitivity to copper, tunicamycin, heat and 
hydroxyurea [216].  Therefore, we originally assumed that the lipid metabolism defects 
occurring in get3Δ were due to TA protein misinsertion into membranes of other organelles, such 
as the mitochondria and Golgi.  Our analysis of lipid phenotypes in TA protein mutants does not 
support this explanation and therefore, it is unlikely that the lipid phenotype can be explained by 
protein misinsertion. Nonetheless, at this point we cannot conclude that the GET3 lipid 
phenotypes are unrelated to mislocalization of a combination of TA proteins (ie gos1Δ 
ybl100cΔ).  
If the lipid droplet defects resulting from a deletion in GET3 are not due to TA protein 
misinsertion, then Get3p must play an alternate role in cellular homeostasis.  In addition to 
protein insertion pathways, Get3p has been identified as a guanine nucleotide exchange factor 
(GEF) for the guanine nucleotide binding protein (G protein), Gpa1p [217].  G proteins are 




downstream signal transduction pathways.  Typically, receptor activated G-proteins consist of 
three complex members the Gα, Gβ and Gγ which are localized to the plasma membrane where 
they respond to external stimuli.  In addition to plasma membrane localized G proteins, G 
proteins are also found on intracellular compartments where they play a role in trafficking [282].  
Activation of a G protein-coupled receptor (GPCR) occurs through guanine nucleotide exchange 
(GDP for a GTP) by GEF proteins at the Gα subunit.  This exchange triggers Gβγ activation and 
the stimulation of downstream signaling cascades.  Yeast Gpa1p is localized to both the plasma 
membrane and endosome, where it functions in external pheromone response and endosomal 
phosphatidylinositide-3-phosphate (PtdIns-3-P) production [218].  Gpa1p co-localizes with 
Vps34p and Vps15p at the endosome, which have been proposed to function as the Gγ and Gβ, 
respectively [283].  Consistent with G protein function, Gpa1p localizes with Vps34p/Vps1p5 in 
a guanine nucleotide dependent manner and GTP bound Gpa1p leads to increased PtdIns-3-P 
production by the yeast phosphoinositide-3-kinase, Vps34p [284] (Fig 3-23).  Get3p is a non-
receptor GEF which binds to Gpa1p directly and accelerates the exchange of guanine for signal 
activation [217].  Therefore a deletion in GET3 would result in decreased nucleotide exchange, 
causing a reduction in endosomal PtdIns-3-P production.  
Levels of PtdIns-3-P at the endosome are involved in the recruitment of proteins to the 
membrane [285] and have been implicated in the multivesicular body (MVB) formation and 
vesicular trafficking [286].  A role for phosphatidylinositides in endosomal trafficking, has been 
shown through PtdIns-3-Kinase inhibition in human melanoma cells and selective modification 
of PtdIns-3-P in endosomes of HeLa cells causing slowed endosome maturation and reduced 
protein flux through the endosome [287, 288].   Protein sorting from the Golgi to the vacuole 




late endosomes and MVB; the “ALP” pathway, which bypasses the endosome completely; and 
trafficking through the early endosome requiring maturation into the late endosome and MVB 
for vacuolar transport (Fig 3-23).   An appealing explanation for the nutrient recycling and lipid 
droplet defect occurring in get3Δ can be inferred from the role of Get3p in guanine nucleotide 
exchange and activation of the Gap1p/Vps15p/Vps34p G protein complex leading to PtdIns-3-P 
synthesis.  The deletion in GET3 likely result in defective endosomal maturation, from the early 
endosome to the late endosome, due to reduced PtdIns-3-P production and a subsequent decrease 
in protein trafficking from the early endosome to the vacuole (Fig 3-23).   This defect in protein 
trafficking may contribute to the lipid droplet phenotypes characterized by a GET3 mutant.  
Of the three complex members, GET3 has been the most highly conserved compared to 
either GET1 or GET2 [289].  As all three proteins play an integral role in tail anchored protein 
insertion, the high level of conservation in GET3 may be due to its dual role in tail anchored 
protein insertion and endosomal trafficking, though a role for the mammalian ortholog of GET3, 
ASNA1, in guanine nucleotide exchange has not yet been reported.  Since these proteins contain 
similar structures and domains, this additional protein function cannot be ruled out and further 
research regarding the role of GET3 and ASNA1 in endosomal trafficking and maturation is 





Figure 3-23:  Role of GET3 in endosomal maturation and vesicular trafficking.  
Protein trafficking pathways from the late golgi include (1) the ALP pathway, 
which sorts proteins including ALP and Vam3p to the vacuole independent to 
MVB sorting (2) the CPY pathway which moves proteins from the golgi through 
the late endosome or MVB to the vacuole (the vacuolar hydrolase, CPS, and 
proteins destined for vacuolar degradation such as Ste2p), (3) movement from the 
golgi to the early endosome [223].  Additional pathways for vacuolar targeting 
include the cytoplasm to vacuole targeting (Cvt) pathway, which delivers the 
hydrolase Ape1 to the vacuole and pathways of autophagy, including 
microautophagy, chaperone mediated autophagy and macroautophagy.  Adapted 




The reduction in neutral lipid turnover (Fig 3-6, Fig 3-7), decreased autophagosome body 
processing (Fig 3-16) and reduced survival under starvation conditions (Fig 3-17) indicate that 
GET3 mutants are unable to properly recycle nutrients through pathways of vacuolar hydrolysis.  
Protein hydrolysis of CMAC-Arg was functional in both GET3 and DGA1 mutants (Fig 3-18 and 
Fig 3-19) indicating efficient localization and function of vacuolar proteases and normal vacuolar 
pH.  Despite normal proteolysis, targeting of a vacuolar lipase, such as Atg15p, may be altered in 
GET3 mutants.   Proteins which traffic through the early endosome to the vacuole are appealing 
targets to explain the slowed nutrient turnover in a GET3 mutant due to its role in endosomal 
PtdIns-3-P production.  Soluble vacuolar proteases and vacuolar ATPases are sorted through the 
MVB to the vacuole through the CPY pathway.  It has been suggested that a group of proteins 
are first trafficked to early endosomes and through endosomal maturation enter the same MVB 
pathway for vacuolar targeting (Fig 3-23).   We suggest that it is this latter pathway which 
requires the transition from early to late endosomes that is targeted by Get3p.  The only 
identified yeast vacuolar lipase, Atg15p, requires the MVB pathway for vacuolar targeting and 
may utilize this early endosome trafficking pathway [277].   In summary, we propose that the 
decrease in endosomal PtdIns-3-P production resulting from ablation of GET3 may cause 
decreased vacuolar lipase (Atg15p) trafficking to the vacuole and reduced autophagic body 
turnover.   A role for Get3p/Gpa1p in vacuolar turnover is further supported by a genome-wide 
screen identifying gene deletions with reduced viability in conditions of nutrient deprivation.  
This screen found that deletions in GET3, GPA1, VPS15 and VPS34, have decreased survival in 
low nutrient conditions but did not identify any other GET mutants with this phenotype [290].  
Furthermore, increased vacuolar lipid droplet association and internalization was found in 




lipid vacuolar targeting, including vesicular trafficking and autophagy (Fig 3-22).  Autophagy 
serves as a mechanism for protein and lipid recycling during periods of starvation and has been 
shown to function in mammalian lipid droplet homeostasis through regulating levels of lipolysis 
[91].  In many cases, autophagy is specific in targeting whole organelles for degradation, as seen 
in mitophagy (mitochondria), reticulophagy (endoplasmic reticulum) and lipophagy (lipid 
droplets) [91].  During lipophagy, LDs are taken up into the autophagosomes for lysosomal 
(vacuolar) degradation and lipid lipolysis.  In the get3Δ dga1Δ double mutant, internalized 
membranes were observed within the vacuole (Fig 3-7) reminiscent to that seen in autophagic 
conditions [89, 291].   As taken with the defects in vacuolar hydrolysis characteristic of GET3 
mutants, these results indicate that the reduction in LDs characteristic of the GET3 DGA1 double 
mutant could occur through a combination of decreased vacuolar lipid turnover with increased 
basal lipophagy.   
So why would lipophagy increase in this double mutant?  Interestingly, the DGA1 single 
mutant also showed increased vacuolar lipid association similar to that in get3Δ dga1Δ.  
Furthermore, it was only with a DGA1 deletion that we saw a significant reduction in lipid 
droplet number in the get3Δ background.  Perhaps, the increased vacuolar lipid droplet levels are 
due to mechanistic differences in the two diacylglycerol acyltransferase genes DGA1 and LRO1.  
Dga1p is an acyl-coA dependent diacylglycerol acyltransferase and is most active during the 
stationary phase of growth [14].  Lro1p, on the other hand, has the highest enzymatic activity 
during the log phase and esterifies diacylglycerol from a phospholipid acyl donor [246].  The 
catalytic site of Dga1p faces the cytosol [292] where it synthesizes lipid droplet bound TG.  In 
contrast, topological analysis of the yeast Lro1p predicts that the active site of Lro1p may be 




lipoprotein particle formation, in which VLDL particles are lipidated in the ER lumen through 
the addition of neutral lipids to Apolipoprotein B.  Moreover, similar results have been shown in 
hepatocytes, with DGAT1 having a “dual toplogy” where it is able to synthesize triglyceride in 
the lumen or cytosol based on nutrient availability [294].  We propose that synthesis of luminal 
TG by Lro1p is packaged separately from that formed by Dga1p.  Increased vacuolar lipids in 
DGA1 mutants may be due to preferential movement of Lro1p synthesized luminal TG to the 
vacuole, through the autophagic machinery (Fig 3-24).  This would explain the normal lipid 
droplet number occurring in the get3∆ lro1∆ double mutant, since DGA1 synthesized TG would 
channel directly to the lipid droplet and would not require vacuolar lipid turnover.   We predict 
that unlike dga1∆, a knockout of LRO1 would not have any lipid accumulation in the vacuole.   
The reason for vacuolar turnover targeting of Lro1p synthesized TG is unclear, but may 
be related to the changing needs of the cell throughout the growth cycle.  During the initial phase 
of growth, TG degradation is high in order to release lipid precursors for rapid membrane growth 
[188].  Lro1p is most active during this growth phase, and may synthesize a more accessible TG 
pool for cellular growth in the form of membrane building blocks.  In contrast, during saturated 
growth, LD numbers rise and cells presumably use FA released from TG for energy and not for 
cellular proliferation.  As the primary TG synthesis gene during saturated growth, DGA1 likely 
synthesizes a more stable lipid droplet pool in the cytosol for energy storage.   
In summary, a double deletion in GET3 DGA1 results in a 75% reduction in lipid droplet 
number, without a significant decrease in neutral lipid mass.  We propose that this is due to 
GET3 dependent defects in vacuolar hydrolysis, potentially through slowed Atg15p trafficking to 
the vacuole, and DGA1 dependent increases in vacuolar lipid trafficking.  This combination 




GET3 DGA1 double deletion (Fig 3-23 and Fig  3-24).   In light of the palmitoleate sensitivity 
occurring in GET3 mutants, decreased neutral lipid synthesis [7, 22, 23, 151, 187] and defects in 
vacuolar lipolysis [91] and lipophagy [184] have both been shown to cause major impacts on 
cellular function during lipid load.  It is therefore not surprising that loss of Get3p sensitizes 







Figure 3-24: Role of GET3 and DGA1 in lipid droplet homeostasis under 
normal conditions and with deletions in DGA1 and GET3. Under normal 
conditions, nutrient recycling of vacuolar proteins and lipids continues under 
basal conditions and with nutrient deprivation.  Lro1p derived triglyceride is more 
likely to target to the vacuole for lipolysis.  In a GET3 DGA1 double deletion, 
inefficient targeting of Atg15p may decrease vacuolar hydrolysis and 
autophagosome breakdown, resulting in decreased lipid droplets and reduced 














Mammalian ASNA1 is involved in palmitate-induced 
apoptosis and nutrient amplification of insulin release in 






 Lipotoxicity is a major contributor to obesity related disorders such as type 2 diabetes and 
nonalcoholic fatty liver disease.  We completed a yeast palmitoleate sensitivity screen to identify 
new pathways important in mammalian lipotoxicity.  Identification of Get3p as an important 
regulator of lipid metabolism and fatty acid sensitivity in yeast led us to its mammalian ortholog, 
ASNA1.  We hypothesized that knockdown of ASNA1 in mammalian cells would result in 
increased fatty acid induced apoptosis similar to that seen in the yeast GET3 deletion.  Consistent 
with our prediction, we found that apoptosis in the MIN6 pancreatic β-cell line following 
palmitate treatment was significantly increased upon ASNA1 knockdown compared to control. 
Furthermore, knockdown of ASNA1 has been shown to cause a defect in insulin secretion in 
pancreatic β-cells, though the mechanism of this defect is still unclear.  We determined that the 
defect in insulin secretion characteristic of ASNA1 knockdown cells could be normalized by 
palmitate or amino acid supplementation.  As a mediator of tail anchored protein insertion, 
knockdown of ASNA1 causes a mislocalization of proteins, such as SNARES, which can affect 
insulin granule docking and fusion.  Therefore, we propose that the defect in glucose stimulated 
insulin secretion resulting from reduced ASNA1 expression is due to the mislocalization of 
SNAREs necessary for insulin granule fusion.  The amplification of insulin secretion pathways 
by fatty acids and amino acids are likely to compensate for this defect by increasing the insulin 





  Chronically high levels of circulating free fatty acids (FFA) can occur through the 
combination of nutrient overload and insulin resistance, typically associated with obesity [105, 
106, 295-297].  In the context of pancreatic β-cells, excess intracellular lipids are associated with 
a reduction in insulin secretion and β-cell mass through increased apoptosis [298, 299] leading to 
the onset of type 2 diabetes (T2D) [300-303].  Though there is a clear association between 
obesity and T2D, a subset of the population is more vulnerable to T2D progression, likely due to 
genetic variation.  In order to determine gene polymorphisms responsible for this susceptibility, 
genome-wide association studies have been employed, and several novel genes identified [134, 
135, 304].  The known genes associated with T2D still only account for a small proportion of 
disease pathology, and additional research is needed to understand the details of disease 
progression.    
 In order to identify genes involved in eukaryotic lipotoxicity, we carried out a genome-
wide fatty acid sensitivity screen in yeast (chapter 2).  Of the 156 gene mutants identified, we 
found that a knockout of yeast GET3 caused increased sensitivity to the unsaturated fatty acid 
palmitoleate and a decrease in lipid droplet storage (chapter 3).  A major goal of our yeast FA 
sensitivity screen was to identify conserved genes that are involved in both yeast and mammalian 
lipotoxic pathways (chapter 2).  The high sequence conservation between yeast GET3 and human 
ASNA1 (46% identity) suggests a role for ASNA1 in cellular lipotoxicity. 
 Like GET3, ASNA1 is a member of the transmembrane domain recognition complex 
(TRC) that targets tail anchored (TA) proteins for ER protein insertion [305].  As seen with 
Get3p, the cytosolic ASNA1 recognizes transmembrane domains of TA proteins and delivers 




which are necessary for protein insertion.  Through sequence similarity, a mammalian GET1 
ortholog, CHD5 (congenital heart disease 5 protein) was recently identified, which has a similar 
topology to GET1, with 3 predicted transmembrane domains and an exposed cytosolic coiled-
coil domain.  CHD5 binds to ASNA1 in this coiled-coil domain and provides a docking site at 
the ER membrane [306] (Fig 4-1).   
 ASNA1 requires several other factors for efficient protein insertion.  The three protein 
complex consisting of the GET4 and GET5 orthologs, TRC35 and UBL4A, and the functional 
Sgt2 ortholog BAT3, were found to increase TA protein insertion efficiency through TA protein 
loading.  The TRC35-UBL4A-BAT3 complex provides a scaffold, bringing ASNA1 and the TA 
protein substrate in close proximity for transfer (Fig 4-1).  Only those proteins which have ER-
destined TA protein motifs actively bind to ASNA1, providing a key sorting step in this process 
[247].   
 Human ASNA1 is highly expressed in pancreatic beta cells and increased ASNA1 
expression promotes insulin secretion in the mouse insulinoma cell line, NIT-1, though the 
mechanism of this increase is still unclear.  Likewise, insulinoma clones with reduced ASNA1 
expression showed decreased insulin secretion with no change in the total cell content of 
proinsulin or insulin protein [233].  This data demonstrates that ASNA1 is not involved in the 
insulin synthesis pathway but instead likely promotes one of the steps leading to insulin release 
from β-cells, possibly ion channel regulation or the docking and fusion of insulin containing 
vesicles.   
 The role of ASNA1 in insulin secretion indicates that it may be an innovative target for 
the two contributors of type 2 diabetes; defects in pancreatic β-cell insulin secretion and lipid-




therefore we do not expect that loss of function mutations exist in the population.  Instead 
polymorphisms reducing function may sensitize cells to lipotoxicity.  For this reason, we chose 
to study the role of ASNA1 in lipotoxic disease using siRNA-induced knockdown of ASNA1 




Figure 4-1: Role of ASNA1 in tail anchored protein insertion. ASNA1 
recognizes newly synthesized tail anchored proteins and directs them to the ER 
membrane.  The putative docking site for ASNA1 is the GET1 ortholog WRB. 
Together these proteins insert the TA protein into the membrane and ASNA1 is 







Cell Culture.  The MIN6 mouse insulinoma cell line was a kind gift of Alan Attie.  MIN6 cells 
were maintained in Dulbecco’s modified Eagles Medium (DMEM) containing 25 mM glucose, 
15% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, 
100 g/ml L-glutamine and 5 100 l/L -mercaptoethanol [308].  Cells between passages of 25-
40 were used for knockdown.   McArdle RH7777 cells were obtained from ATCC and were 
maintained in DMEM with 10% FBS, 10 % Horse Serum, 100 units/ml penicillin, and 100 g/ml 
streptomycin. Cells were grown in humidified 5% CO2, 95% air at 37°C.  For fatty acid studies, 
cells were incubated for 0-20 hours in DMEM with 10% FBS containing oleate palmitate or 
palmitoleate (Sigma-Aldrich) bound to 1% fatty acid free BSA (Sigma-Aldrich).  Control 
incubations contained only BSA.   
 
siRNA knockdown.  ASNA1 expression was specifically silenced using prevalidated duplexes 
(Stealth
TM
 Select RNAi, Invitrogen) directed against mouse ASNA1 
 (siRNA 92: sense 5’-GGACGUGAGAGUGUUCUGAUCAUUU , siRNA 94: sense 5’-
CCUGGACCAGAUGGAAGACCUAUA ).   Stealth
TM
 Select RNAi negative control duplexes 
based on GC content (Invitrogen) were used as a non-specific control.  Transfection was 
completed using Lipofectamine 2000 according to the manufacturers protocol.   Cells were 
treated with a final concentration of 100 pM siRNA in a total of 2 mL media per dish for 24 
hours in normal culture conditions.  When specified fatty acids were added to culture 24 hours 





Lipid Analysis and Metabolic Labeling.  For lipid labeling, cells were pulse labeled with 0.5 
μCi/ml [9,10-
3
H] Oleic acid (Perkin Elmer) for 6 hours in serum free DMEM with 1% fatty acid 
free BSA plus 0.25 mM cold oleate.   Glycerol labeling was completed with 20 μCi/ml of [
3
H] 
Glycerol (PerkinElmer) in 1.5% fatty acid free BSA in serum free DMEM.  Cells were pulse 
labeled for 2 hours at 37°C followed by a 4 hour chase (serum free DMEM with 1.5% BSA, no 
label).  Lipid were extracted with 2 ml of hexane:isopropanol (3:2) was added to each well of a 6 
well plate and incubated at room temperature for 1 hour, after which the supernatant was 
removed and the extraction repeated.  Supernatant was dried with nitrogen, resuspended in 
chloroform:methanol (2:1) and lipids were separated on a TLC plate [309].  
 
Quantitative PCR.   RNA was isolated using the Qiagen RNAeasy kit as specified by the 
manufacturer and used to generate first strand cDNA (SuperScript first strand synthesis system, 
Invitrogen).   Quantitative real time PCR was performed with the MyiQ single color real time 
PCR detection system (Bio-Rad), SYBR Green 2X supermix (Bio-Rad) and the indicated 
primers (Table 4-1).  Expression levels were calculated relative to mouse GAPDH.   
 
Immunoblotting.  Cells were washed twice with PBS and lysed using SDS buffer (2% SDS, 62.5 
mM Tris-HCL (pH 6.8), 10% glycerol, 10% β-mercaptoethanol, and 0.01% bromophenol blue) 
and boiled for 5 minutes.  Protein extracts were prepared in a lysis buffer containing 25 mM 
Tris-HCL (pH 7.4), 2 mM Na3VO4, 10 mM NaF, 10 mM Na4P2O7, 1 mM EGTA, 1 mM EDTA, 
1% NP-40, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 10 nM okaidic acid and 1 mM 
phenylmethylsulfonylfluoride.  Equal amounts of protein extract were separated on a 12% SDS-




laboratories mini-transfer tank.  Membranes were blocked for 1 hour at room temperature with 
5% non-fat milk in Tris-Buffered Saline with 0.1% Tween 20 (TBST) and incubated with 
primary antibodies overnight at 4°C.  Protein bands were detected with HRP-conjugated 
secondary antibodies and SuperSignal West Pico enhanced chemiluminescent solution (Pierce).  
Membranes were stripped with Restore Western blot stripping buffer (Pierce) for 10 minutes at 
room temperature and reprobed with β-actin primary antibodies to control for loading 
differences.  Primary antibodies used were anti-GRP78, anti-phospho-eIF2α (Stressgen, Victoria, 
British Columbia) and anti-β-actin (Sigma).  Immunoblots were quantified by densitometry.  
 
Oil Red O staining. Cells were fixation was carried out in 10% neutral-buffered formalin for 1 
hour at room temperature followed by 5 minute incubation in 60% isopropanol.  Cells were 
stained in 0.5% Oil Red O solution in isopropanol:water (3:2) for 30 minutes followed by several 
washes with distilled water.  Cells were dried overnight and visualized using light microscopy.   
 
Apoptosis Assays.  Apoptosis levels were quantified using Invitrogen Vibrant Apoptosis Assay 
Kit #5 (V13244) by manufacturer’s directions.  Briefly, cells were incubated with 5 μg/ml 
Hoechst 33342 and 1 μg/ml propidium iodide (PI) for 30 minutes on ice.  Apoptotic cells are 
characterized as having condensed chromatin, which is stained by blue-fluorescent Hoechst 
3342, and stains the nuclei of apoptotic cells more brightly than that seen in normal cells.  Dead 
cells were identified as having internalization of PI, and apoptotic cells were considered as cell 
stained positive for Hoechst-33342 and negative for PI.  Ten frames per condition were captured 
and cells within these frames were counted in order to obtain a percentage of apoptotic cells 





Insulin Secretion.  Cells (5 x 10
5
 cells/well, 12 well plate) were seeded and cultured as 
described.  The cells were preincubated for 1 hour in HEPES-balanced Krebs-Ringer bicarbonate 
buffer (119 mM NaCl, 4.74 mM KCL, 2.54 mM CaCl2, 1.19 mM MgCl2, 1.19 mM KH2PO4, 25 
mM NaHCO3 and 10 mM HEPES, pH 7.4) containing 0.5% BSA with 5 mM glucose and 
incubated for 1 hour with various concentrations of glucose or KCL.  Released insulin was 
measured by rat insulin radioimmunoassay (Millipore) and the cellular DNA content was used to 
normalize the amount of insulin secretion.   
 
 
ApoB immunoprecipitation.  Cells were incubated in methionine/cysteine-free DMEM with 
1.5% fatty acid free BSA for 2 hours followed by [
35
S] methionine labeling for 2 hours.  After 
labeling, media was transferred into eppendorf tubes and a mixture of protease inhibitors 
(30μl/ml protease inhibitors, 1 mM benzamidine, 5 mM EDTA, 100 units/ml aprotinin, 50 μg/ml 
leupeptin, 50 μg/ml pepstatin A and 10 mM Hepes, pH 8.0) and 0.86 mM freshly added 
phenylmethylsulfonyl fluoride.  Immunoprecipitation of apoB in medium and cells was carried 
out according to the method described by Dixon et al [310] Antibodies against apoB 
(Calbiochem, San Diego, CA) and rProtein G Agarose (Invitrogen) was added to the reactive 
solution to precipitate apoB.  ApoB was precipitated by boiling for 5 minutes in sample buffer 
(0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol and 10% β-mercaptoethanol).  Proteins were 
separated by SDS-PAGE and gels were then treated with autofluor (Natioal Diagnostics, Atlanta 
GA) and after drying exposed to X-ray film (Kodak, X Omat AR) at -80°C for 1-3 days.  
Incorporation of [
35
S] into apoB48 and apoB100 was quantified by autoradiography and bands 






 In order to determine the role of ASNA1 in pancreatic β-cell lipotoxicity, we used the 
MIN6 insulin secreting mouse pancreatic β-cell line [308].  ASNA1 expression is known to be 
particularly high in mouse and human pancreatic islet cells [233, 312], which we validated by 
real time PCR compared to expression levels in the mouse liver (Fig 4-2).  We also found 
significant levels of ASNA1 expression in the MIN6 and McA-RH7777 rat hepatoma cell line 




Figure 4-2: Tissue specific mRNA expression of ASNA1. Real time PCR 
measurements of ASNA1 mRNA in mouse pancreatic islet cells, the mouse 
pancreatic β-cell line MIN6 , the rat hepatoma cell line McA-RH7777 and mouse 
liver.  Differences of mean fold induction (ΔΔCt) relative to mouse liver (mean ± 
s.d., n=3). Asterisks denote statistical significance (*p<0.05) compared to liver by 
unpaired t-test.  
 
For gene knockdown, MIN6 cells were transfected with ASNA1 specific or control 
siRNA oligonucleotides and grown at 37°C for 48 hours.  Treatment with ASNA1 siRNA 






Figure 4-3: ASNA1 knockdown in MIN6 mouse pancreatic β-cells. MIN6 cells 
were treated with 100 pM ASNA1 or control siRNA for 48 hours after which our 
follow up studies were completed. Total RNA was isolated and quantitative RT-
PCR was performed to assess mRNA levels of ASNA1 (mean ± s.d., n=3). 




Levels of lipid-induced apoptosis are significantly altered in MIN6 cells with ASNA1 
knockdown. Treatment of yeast get3Δ with 0.5 mM palmitoleate causes a significant increase in 
apoptosis compared to the control strain (chapter 3).  Due to the conservation of both sequence 
and function between yeast GET3 and mammalian ASNA1 we expected that knockdown of 
ASNA1 would also increase sensitivity of cells to fatty acid induced apoptosis.  We grew control 




palmitoleate (0.5 mM and 1.0 mM) or 0.5 mM oleate for 20 hours and assayed apoptosis by 
Hoechst 33342 and propidium iodide (PI) staining (Fig 4-4 A,B).  
We quantified percentage of cells undergoing apoptosis, including both early apoptotic 
(Hoechst +/PI -) and late apoptotic (Hoechst +/ PI +), and necrotic (Hoechst -/ PI +) cells as a 
percentage of the total cells within each frame (Fig 4-4 C).  Knockdown of ASNA1 resulted in a 
significant increase in the percent of apoptotic cells at 1.0 mM palmitate, which was not seen at 
lower concentrations of palmitate (0.5 mM) or with treatment with the unsaturated fatty acids 
palmitoleate and oleate (Fig 4-4 B).  In fact, cells treated with 0.5 mM palmitoleate had reduced 
apoptosis in the ASNA1 knockdown cells compared to control.  The differential sensitivity of 
MIN6 cells with reduced ASNA1 expression to UFA versus SFA is interesting.  UFA and SFA 
induced β-cell lipotoxicity are known to occur through independent pathways, with SFA causing 
cellular dysfunction through increased ceramide biosynthesis  [110, 111] and increased reactive 
oxygen species [125],  and UFA induced lipotoxicity involving the 
phosphorylation/dephosphorylation of protein phosphatase type 2C proteins [116, 130].  Both 
UFA and SFA mediated cell dysfunction can occur through altered ER stress activation [129, 
182].  Therefore, ASNA1 may alter these pathways conversely, leading to the contrasting 











Figure 4-4: Knockdown of ASNA1 in MIN6 cells increases sensitivity to 
palmitate-induced apoptosis.  Apoptosis rate of MIN6 cells was measured by 
Hoechst 33342 and propidium iodide staining after 16 hours of fatty acid 
treatment in DMEM + 10% FBS with 0.5 mM fatty acid free BSA  (A) 
Fluorescent microscopy images of Hoechst 33342 and propidium iodide (PI) 
staining of fatty acid treated cells.  (B) Quantification of apoptotic (Hoechst +) 
cells as a percentage of total cells. (mean ± s.e., 7 frames with at least 150 cells 
per frame)   Asterisks indicate statistical significance (*p<0.05, **p<0.01) 
compared to control siRNA by two tailed t-test.  (C) Example of early apoptotic 




Knockdown of ASNA1 in mouse pancreatic β-cells does not alter levels of lipid synthesis.  
Neutral lipid synthesis serves not only as a mechanism for energy storage during periods of 
nutrient deprivation, but also as a protective mechanism against an accumulation of intracellular 
fatty acids [114].  As such, ablation of neutral lipid storage capacity results in sensitivity of 
eukaryotic cells to fatty acid induced apoptosis [7, 22, 23].   
As described in chapter 3, knockout of GET3 in yeast results in decreased neutral lipid 
synthesis and a significant reduction in lipid droplet number per cell.  For this reason, and 
because lipoapoptosis was significantly increased with ASNA1 knockdown, we predicted that a 
reduction in ASNA1 expression would result in a decrease in neutral lipid storage capacity.  In 
order to measure neutral lipid levels in these strains, we used radiolabeled oleate incorporation 
and Oil Red O, which stains the neutral lipids, cholesterol ester and triglyceride.   
In contrast to the decreased neutral lipid levels occurring in yeast get3Δ there was no 
change in lipid synthesis detected in the ASNA1 knockdown, as measured by [
3
H]oleate 
incorporation in mammalian cells.  We separated several lipid species (sterol ester (SE), 
triglyceride (TAG), free fatty acid (FFA), diacylglycerol (DAG) and phospholipids (PL)) by thin 
layer chromatography followed by scintillation counting in order to determine the synthesis of 
each during a 4 hour growth period (Fig 4-5).  Consistent with the lipid labeling results, Oil Red 
O staining indicated no change in lipid droplet morphology in ASNA1 siRNA treated cell 







Figure 4-5: A reduction in ASNA1 expression in MIN6 cells does not alter 
levels of lipid synthesis. Lipid extraction and species separation through thin layer 
chromatography (TLC) was completed on MIN6 cells after 4 hours pulse with 
[
3
H]-Oleate incorporation after 4 hour pulse.  
 
 
Figure 4-6: ASNA1 knockdown in MIN6 mouse pancreatic β-cellsdoes not 
change lipid droplet number or size.  Oil Red O staining of neutral lipids in 







ASNA1 knockdown has increased basal ER stress, as measured by GRP78 protein expression.  
Increased levels of ER stress are commonly associated with lipoapoptosis [129, 131] and 
pancreatic β-cells are particularly vulnerable to lipid induced ER stress due to the protein load 
associated with their role in insulin secretion [313].  We went on to determine if the differences 
in lipotoxicity with ASNA1 knockdown could be explained by altered ER stress response by 
measuring mRNA and protein levels of the ER stress marker, GRP78 [314].  Gene expression 
levels of GRP78 were increased in response to 0.5 mM palmitate in both control and ASNA1 
siRNA treated cells, consistent with the known role of palmitate in ER stress activation [128, 
142].  Oleate treatment did not cause any increase in GRP78 mRNA expression in either siRNA 
condition (Fig 4-7C).    
 In line with the mRNA expression levels, incubation of MIN6 control cells with palmitate 
resulted in an increase in GRP78 protein levels (Fig 4-7B).  GRP78 protein expression in the 
control was also increased when treated with 1.0 mM oleate (Fig 4-7B), a result which was not 
seen in the mRNA expression but one which has been previously reported in other studies [124, 
128].  As protein levels are more relevant to ER stress induction, we used the protein expression 
as the more accurate readout of ER stress.   
Interestingly, GRP78 protein expression in ASNA1 knockdown was significantly 
increased under no treatment conditions (0.5% BSA) compared to control, at levels similar to 
that seen following palmitate treatment in the control condition (Fig 4-7B).   Growth of ASNA1 
knockdown cells with fatty acids did not induce a further elevation in GRP78 expression 
compared to the high basal levels, and the GRP78 protein levels remained constant regardless of 




protein expression and this expression level is not further increased upon fatty acid treatment in 
the ASNA1 knockdown (Fig 4-7B).  The significant increase in GRP78 expression under normal 
conditions (0.5% BSA) indicates that cells with reduced ASNA1 expression have elevated basal 
ER stress, a condition that may influence the cells ability to handle exogenous fatty acids.   
 
Figure 4-7:  Altered GRP78 levels in ASNA1 knockdown indicates increased 
ER stress activation under basal conditions. In order to determine ER stress 
levels, protein and mRNA was isolated from MIN6 cells treated with fatty acids 
for 16 hours.  Protein levels of GRP78 were determined through Western blotting 
(A) and quantified relative to the housekeeping gene β-Actin (B).  Gene 
expression of GRP78 was quantified through real time PCR relative to 0.5 % BSA 
control.  Statistical significance was determined through unpaired t-test (mean ± 
s.d., n=3).  Asterisks indicate statistical significance (*p<0.05) compared to 
control within the same treatment condition, + indicates statistical significance 






ASNA1 is required for insulin secretion in response to glucose.  Kao et al, described a defect in 
insulin release and glucose stimulated insulin secretion in clones of the mouse insulinoma cell 
line NIT-1 with decreased ASNA1 expression.  This was not due to decreased pro-insulin or 
insulin production [233] and therefore, ASNA1 likely affects the fusion of insulin granules with 
the membrane.   
 Acute exposure of pancreatic β-cells to long chain fatty acids promotes insulin 
secretion through several potential mechanisms, including increased insulin granule fusion with 
the membrane [315] and activation of the G-protein coupled receptor (GRP40) which stimulates 
insulin secretion through increased cytosolic Ca
2+
 [316] (Fig 4-8).   In order to determine if the 
ASNA1 dependent defect in insulin secretion also occur in response to acute free fatty acid 
treatment, we challenged MIN6 cells in buffer containing glucose with and without the fatty acid 
palmitoleate or palmitate for 1 hour and measured insulin secretion (Fig 4-9A). 
 Consistent with the previously reported results [233], we found a reduction in insulin 
release in ASNA1 siRNA treated cells in both low (2.8 mM) and high (20 mM) glucose 
conditions compared to the siRNA control.  We also measured insulin secretion in these cells 
when challenged with buffer containing both fatty acids and glucose.  Co-supplementation of 
glucose at low levels (2.8 mM) with 0.5 mM palmitate resulted in an increase in insulin secretion 
in MIN6 cells in both the control and ASNA1 siRNA groups, to an equal extent.  In other words, 
challenge of ASNA1 cells with an acute palmitate treatment resulted in an amplification of insulin 
release to the same level of the control (Fig 4-10).  Therefore, palmitate amplification of glucose 
stimulated insulin secretion (GSIS) was able to compensate for the ASNA1 dependent secretion 





Figure 4-8: Nutrient modulation of insulin secretion in pancreatic β-cells. 
Interaction of glucose, fatty acids and amino acids (arginine) in stimulation and 
potentiation of the insulin release.  Glucose uptake through the GLUT2 insulin 
independent glucose transporter increases glycolysis and ATP synthesis.  
Increased intracellular ATP inhibits potassium channel, causing a subsequent 
membrane depolarization and the opening of voltage gated calcium channels.  
Increased intracellular calcium resulting in insulin secretion.  Fatty acids and 
amino acids, such as Arginine, are able to amplify these pathways through 
increased fusion (fatty acids and lipid intermediates), increased intracellular 
calcium through FA binding to GRP40 and increased membrane polarization 








Figure 4-9: Schematic of glucose stimulated insulin secretion methods.  (A) 
Tests for acute fatty acid exposure or amino acid treatment were completed after 
48 hour knockdown with 1 hour of Krebs-Ringer bicarbonate buffer (KREB) pre-
incubation followed by 1 hour GSIS treatment with indicated concentration of 
glucose ±fatty acid or amino acid in the same buffer. (B) Tests for chronic fatty 
acid exposure were completed following 28 hours of incubation and 20 hours of 
0.5 mM palmitoleate treatment.  One hour of Krebs-Ringer bicarbonate buffer 
(KREB) pre-incubation and 1 hour of GSIS treatment with indicated 
concentration of glucose in the same buffer.  Insulin was collected from the media 
and quantified using the insulin RIA kit to determine secretion levels.   
 
 Acute palmitoleate treatment with low (2.8 mM glucose) and high (20 mM glucose) 
treatment resulted in a robust increase of insulin secretion in both control and ASNA1 knockdown 
cells.   In contrast to that seen with palmitate treatment, the levels of insulin secretion after a 1-
hour stimulation with buffer containing both palmitoleate and glucose were significantly reduced 
in ASNA1 knockdown cells compared to control in the same treatment conditions (Fig 4-10).   
Therefore, the insulin secretion defect occurring with decreased ASNA1 expression continues 
even with palmitoleate stimulation of GSIS, but is completely normalized with acute palmitate 




 Generally, fatty acids are unable to stimulate insulin secretion alone, and instead 
amplify glucose stimulation of insulin release [317].   Since palmitate was able to normalize 
insulin secretion in the ASNA1 knockdown cell line, this fatty acid is likely involved in a 
compensatory pathway to that blocked by ASNA1 knockdown.  Unlike palmitate, palmitoleate 
was unable to completely normalize the insulin secretion levels in the ASNA1 knockdown to 
levels of the control, but did cause a significant amplification of insulin release in these cells.  In 
summary, fatty acid treatment was able to amplify the GSIS in the ASNA1 knockdown, with a 2 
fold increase insulin release following palmitate exposure and a 3 fold increase in insulin release 
following palmitoleate treatment compared to the glucose treatment alone.   This suggests that 
the fatty acid potentiation of GSIS is not entirely through an ASNA1 dependent pathway.  
 
Amino acid and glucose stimulated insulin secretion.  In addition to fatty acids, amino acids 
such as L-arginine are also able to amplify the glucose stimulation of insulin release from 
pancreatic β- cells through alteration of plasma membrane permeability [317] (Fig 4-8). Since 
palmitate treatment was able to offset the insulin secretion defects upon ASNA1 knockdown, we 
treated cells with L-Arginine to determine if amino acid treatment would have a comparable 
effect (Fig 4-9A). Similar to that seen with palmitate supplementation, treatment of MIN6 cells 
with L-Arginine resulted in a significant increase in GSIS in both ASNA1 and control siRNA 
treatments.  The level of insulin secretion was equal for both control and ASNA1 knockdown 
under these conditions (Fig 4-10).  Therefore, amino acid supplementation was also able to 
compensate for the loss in ASNA1 expression.  From this study and others [233], it is clear that 




the nutrient challenge conditions. Supplementation of ASNA1 knockdown cells with fatty acids 
and amino acids is able to amplify and in some cases normalize insulin secretion.   
 
 
Figure 4-10: ASNA1 knockdown decreases glucose stimulated insulin 
secretion.  ASNA1 knockdown was carried out in MIN6 cells using ASNA1 
specific siRNA oligos and a control siRNA.   Insulin secretion was assayed after 
pretreatment with KREBS Insulin secretion was measured using an insulin 
radioimmunoassay (RIA) and normalized to total cellular DNA.  Glucose-
stimulated insulin secretion (GSIS), amino acid-stimulated insulin secretion 
(AASIS), and fatty acid stimulated insulin secretion (FASIS) were assayed in 
MIN6 cells after 48 hours of knockdown challenged with 2.8 to 20 mM glucose, 
10 mM arginine or a combination of glucose and 0.5 mM palmitoleate. Fatty acid 
(FA), amino acid (AA).  
  
 
Chronic fatty acid exposure in ASNA1 siRNA treated MIN6 cells.  Though acute treatment (1-3 




hours) causes cellular dysfunction through pathways of lipotoxicity [142].   Long-term fatty acid 
exposure not only increases levels of β-cell apoptosis, but also causes cellular dysfunction, 
particularly in the cells insulin secretion capacity. Diabetic subjects have increased levels of 
intracellular fatty acids [318], which have been shown to cause major defects in sensitization of 
pancreatic beta cells to glucose stimulated insulin secretion (GSIS) [319].   ASNA1 is involved 
in both sensitization of pancreatic β-cells to exogenous lipids as well as insulin release, and thus 
may be involved in glucose responsiveness under chronic fatty acid conditions.   
 In order to assess the role of ASNA1 in glucose stimulation of pancreatic β-cells grown 
in the presence of fatty acids, we treated MIN6 ASNA1 knockdown and control cells with 0.5 
mM palmitoleate overnight and tested insulin secretion with low (2.8 mM) and high (20 mM) 
glucose (Fig 4-9B).  As expected, the overnight fatty acid treatment resulted in a significant 
reduction in insulin release in both high and low glucose compared to the untreated condition 
(Fig 4-11A).  The insulin secreted following overnight FA exposure was equivalent in both 
control and ASNA1 siRNA treated MIN6 cells.  Therefore the defect in glucose stimulation due 
to chronic FA exposure was not exacerbated in the ASNA1 knockdown, with equally low 
secretion levels for both siRNA conditions (Fig 4-11).   This data suggests that more than one 
pathway is involved in fatty acid amplification of GSIS, and ASNA1 plays a role in at least one 





Figure 4-11: Effect of overnight fatty acid exposure on insulin secretion in 
ASNA1 knockdown cells.  GSIS of knockdown cells grown overnight (20 hours) 
in 0.5 mM palmitoleate and challenged with glucose stimulation with and without 
0.5 mM palmitoleate.   Values are mean ± SD from 2 separate experiments, each 
in triplicate.  * indicates significant difference from control values in the same 
condition (p<0.05) and + indicates statistical significance compared to control 
siRNA in 2.8 mM glucose challenge with no fatty acids.   
 
 
Knockdown of ASNA1 in rat hepatoma cells does not alter lipid metabolism or ApoB 
secretion.  Since knockdown of ASNA1 caused significant defects in insulin secretion, we 
questioned whether ASNA1 played a role in other secretion pathways, particularly those 
involved in the progression of lipotoxic disease.  Defects in very low density lipoprotein (VLDL) 
secretion from the liver are associated with nonalcoholic fatty liver disease (NAFLD) 
characterized by a hepatic lipid accumulation.  To study the effects of ASNA1 knockdown on 
hepatocytes, we used the rat hepatoma cell line McA-RH7777, treated with ASNA1 specific 




MIN6 cell line (Fig 4-2B).  Treatment of McA cells with ASNA1 siRNA resulted in a greater 
than 95% reduction in ASNA1 expression compared to control (Fig 4-12A).  As seen with ASNA1 
knockdown in MIN6 cells, this reduction was not associated with any change in fatty acid 
synthesis levels, as measured by [
14
C]oleate incorporation (Fig 4-112B).   
 VLDL is necessary for the transport of TG out of the liver to peripheral tissues for energy 
and storage [320, 321].  VLDL assembly and secretion are stimulated by increases in hepatic TG 
[322] and this assembly occurs through lipidation of apoB100 in the ER lumen followed by 
secretion into the circulation [321].  ApoB48 is a truncated product of the APOB gene found only 
in human intestine for chylomicron assembly (though ApoB48 is synthesized in murine and rat 
liver) [322].  Defects in VLDL secretion result in an accumulation of TG in hepatocytes [323-
325] , a disorder which can progress into the more inflammatory steatosis and cirrhosis.  We 
tested ApoB secretion levels by labeling cells with [
35
S]methinone and monitoring radiolabeled 
ApoB.  We found no change in ApoB-100 or Apo-48 levels in either the media or cells for 
ASNA1 knockdown compared to control siRNA (Fig 4-13).   Consistent with normal levels of 
ApoB secretion, we see no change in TG (Fig 4-12C) or PL (Fig 4-12D) in the hepatoma cells, 
after a 2-hour pulse or after a 4 hour chase.  This demonstrates that ASNA1 knockdown in the 





Figure 4-12: ASNA1 knockdown in McA-RH7777 rat hepatoma cells does not 
alter radiolabeled oleate or glycerol incorporation.  All studies were completed 
following 48 hour knockdown of ASNA1 in McA-RH7777 cells.  (A) Total RNA 
was isolated and quantitative RT-PCR was performed to assess mRNA levels of 
ASNA1 relative to housekeeping gene GAPDH. Lipid extraction and species 
separation through thin layer chromatography (TLC) was completed on  McA-
RH7777 cells after either (B) 4 hour pulse with [
14
C]-Oleate incorporation or 
[
3
H]-Glycerol incorporation into TAG (C) and PL (D) after 4 hour pulse (T = 0 
hr) and 4 hour chase (T = 4 hr). Asterisks denote statistical significance (p<0.05) 






Figure 4-13: ApoB secretion in McA-RH7777 with ASNA1 knockdown. To 
determine levels of ApoB secretion, cells were labeled with [
35
S]methionine for 2 
hours with.  Cells and media were collected, apoB immunoprecipitated and run on 
an SDS-PAGE gel followed by development via autoradiography (A).  
Quantification of [
35
S]methionine incorporation into ApoB100 (B) and ApoB48 












 Insulin resistance is a common consequence of obesity, due in part to high levels of 
circulating free fatty acids and ectopic fat deposition.  In order to compensate for peripheral 
insulin resistance and the resulting hyperglycemia, pancreatic β-cell mass and insulin production 
capacity increase. Speculation from T2D subject autopsies indicates that those predisposed to 
type 2 diabetes are unable to increase β-cell expansion in response to these conditions.   A major 
reason for the deficient compensation is due to the negative impacts of chronically high 
circulating free fatty acids on β-cell health.  Exposure of pancreatic β-cells to free fatty acids 
results in lipotoxicity, characterized by defects in insulin secretion, increased ER stress and 
apoptosis.  Consistent with these known FA-mediated effects, we found that treatment of the 
MIN6 pancreatic β-cell line with palmitate and palmitoleate induced lipotoxicity, with increased 
levels of apoptosis (Fig 4-4), ER stress (Fig 4-7) and decreased glucose stimulated insulin 
secretion (Fig 4-11).  In this study, we identified ASNA1 as an important protein affecting both 
fatty acid mediated cell death and insulin secretion.  
 ASNA1 is involved in two compensatory pathways associated with T2D progression, β-
cell expansion and increased insulin release and is therefore, a compelling target in diabetes 
prevention.   In vitro studies have shown that exposure of cultured β-cells to long chain saturated 
fatty acids (SFAs) decreases viability within only a few hours due to cytochrome c release and 
caspase activation [326].  Treatment of MIN6 cells with palmitate significantly increased 
apoptosis in both control and ASNA1 siRNA treated conditions but the percentage of apoptotic 




(Fig 4-4) demonstrating that decreased ASNA1 expression sensitizes MIN6 cells to SFA induced 
apoptosis.  
 For many years, only SFAs were believed to be toxic and unsaturated fatty acids were 
considered protective against pancreatic β-cell dysfunction and death.  This idea is based on in 
vitro studies, in which treatment of cultured β-cells with monounsaturated fatty acids (MUFAs) 
such as oleate and palmitoleate have minimal signs of dysfunction [130, 327, 328] and could 
protect against SFA induced apoptosis [329].    Higher levels of UFA (>0.8 mM) induce ER 
stress response and apoptosis in mammalian cells [128, 182, 311] and we found 1.0 mM 
palmitoleate was able to activate apoptosis in both control and ASNA1 siRNA treated cells.  In 
contrast to that seen with palmitate treatment, knockdown of ASNA1 did not sensitize cells to 
palmitoleate induced cell death (Fig 4-4). The differential effect of palmitate versus palmitoleate 
on β-cell survival with ASNA1 knockdown can be explained through alternative pathways for 
saturated and unsaturated fatty acid metabolism.  After cellular uptake, UFAs are preferentially 
incorporated into pathways of triglyceride storage [7] whereas SFAs are more likely to enter into 
other metabolic pathways including ceramide and phospholipid biosynthesis [111].  As a result 
of the independent channeling, SFA induced lipotoxicity occurs through pathways separate from 
UFAs.  Our studies indicate that ASNA1 has alternate effects on these pathways, though the 
mechanism of this interaction is unclear.  
Pancreatic β-cells are particularly vulnerable to lipid induced ER stress due to the role of 
these cells in insulin secretion.  Insulin synthesis accounts for more than half of the total protein 
synthesis in the pancreatic β-cell, and the subsequently high protein load at the ER is balanced 
with an increase in ER folding capacity [128, 142, 330].  For this reason, lipid induced ER stress 




expression as a marker for ER stress, we found an expected increase in GRP78 protein 
expression following overnight palmitate and oleate treatment in the control (Fig 4-7).  Upon 
knockdown of ASNA1 GRP78 levels were elevated in no treatment conditions and stayed at this 
level despite fatty acid treatment (Fig 4-7).   This demonstrates that basal ER stress is increased 
in the ASNA1 knockdown strain, and may be a potential mechanism for palmitate-sensitivity in 
these cells.  
  In addition to altering the vulnerability of pancreatic β-cells to lipid induced apoptosis, 
knockdown of ASNA1 causes a major defect in glucose stimulated insulin secretion (GSIS) 
[233].  In order to clarify the role of ASNA1 in GSIS, we challenged cells with glucose and either 
fatty acids (acute or chronic) or the amino acid, L-arginine, which have known effects on glucose 
stimulatory pathways [317].   Glucose is the only nutrient able to promote the release of insulin 
without additional stimulants, whereas amino acids and fatty acids, are able to amplify the 
glucose response but do not act independently from glucose in insulin stimulation [317].  
Glucose stimulates the release of insulin through an increase in oxidation and a rise in the 
ATP/ADP ratio, which closes ATP-sensitive K
+
 channels and depolarizes the membrane.  
Membrane depolarization opens voltage-gated Ca
2+ 
channels, increasing intracellular calcium 
and triggering the exocytosis of insulin granules into circulation [331, 332] (Fig 4-9).   
 Fatty acids are able to potentiate this response through several mechanisms.  The first is 
through an increase in intracellular long chain-CoA (LC-CoA) levels due to a glucose stimulated 
inhibition of carnitine palmitoyl-transferase (CPT1) dependent fatty acid oxidation. The defect in 
FA oxidation results in a rise in LC-CoA within the cell which can act on insulin granules and 
increase levels of exocytosis [333].  The second mechanism occurs through increased TG/FFA 




molecules and effect insulin granule release [333].   The last pathway acts through stimulation of 
the G-protein coupled receptor, GRP40, by fatty acid binding.  This binding leads to 
phospholipase C (PLC) activity at the plasma membrane resulting in hydrolysis of 
phosphatidylinositol 4-5 biphosphate (PIP2) to inositol 4,5-triphosphate (IP3) and diacylglycerol 
(DAG).  The stimulation of insulin release after GRP40-FA binding occurs through IP3 
movement to the ER where it stimulates Ca
2+
 release, and activation of insulin secretion through 
DAG signaling cascades [334].   In addition to fatty acids, proteins and amino acids are also to 
regulate insulin secretion [335-337].  For instance, L-Arginine, a cationic-charged amino acid, 
enhances insulin secretion by depolarization of the plasma membrane [335] (Fig 4-9) .  
 Knockdown of ASNA1 caused decreased glucose stimulated insulin release (Fig 4-10), 
consistent with previously published results [233].   Amplification of the insulin secretion 
pathway with acute fatty acid or protein treatment increased insulin secretion in both siRNA 
groups, with a significant secretion defect remaining following palmitoleate treatment in the 
ASNA1 knockdown (Fig 4-10).   Despite this defect, insulin secretion levels were three times that 
seen with glucose alone in cells with reduced ASNA1 expression.  From these results we propose 
that fatty acid and protein amplification pathways do not rely on ASNA1 mediated insulin 
secretion mechanisms.  If these pathways were driven through ASNA1, a knockdown in this gene 
would block the associated amplification.  
 Defects in insulin secretion resulting from reduced ASNA1 are not due to decreased 
insulin or proinsulin production [233].  Therefore, a likely explanation for the reduced insulin 
secretion occurring with ASNA1 knockdown is a defect in insulin granule docking and/or fusion.  
Like GET3, ASNA1 mediates tail anchored protein insertion into the ER membrane and a 




protein, Sed5 [338].  Therefore, it is possible that that several other SNARE proteins are 
mislocalized in the ASNA1 knockdown, which would result in slowed insulin granule docking 
and fusion (Figure 4-14).   Currently, there are eight SNARE proteins and 11 accessory factors 
which have been implicated in -cell insulin secretion, specifically in insulin vesicle targeting 
and fusion [339].   Moreover, numerous studies have linked T2D and insulin resistance with 
decreased SNARE protein levels in rodents and humans [340-342].  We propose that increased 
levels of exocytosis through fatty acid or L-arginine supplementation compensates for the 
SNARE insertion defect occurring with ASNA1 knockdown by increasing docking and fusion 
efficiency despite decreased SNARE protein levels (Figure 4-14).  
 The inability of palmitoleate to completely rescue the ASNA1 dependent insulin secretion 
defect may be due to differences in palmitate and palmitoleate mediated GSIS amplification.  For 
example, activation of GRP40 depends on the fatty acid type, with the highest induction of Ca
2+
 
occurring with the SFA between 12-16 carbons and a lower activation following oleate treatment 
[343].  Though palmitoleate was not tested by these methods, it is possible that the difference in 
insulin secretion following palmitoleate challenge in ASNA1 knockdown cells is due to the 
differential stimulation of GRP40 by palmitate versus palmitoleate.     
 In conclusion, this study has shown that the lipid sensitivity phenotype occurring in a 
GET3 deletion in yeast has been conserved in mammals, with decreased ASNA1 expression 
resulting in increased palmitate induced apoptosis.   Not only is this a proof of principle for our 
yeast genome-wide screen, but it also indicates that many other genes identified by our screen 
may have similar lipotoxicity phenotypes.  Therefore additional yeast to human translational 
research is required to determine if the other 67 mammalian orthologs identified by our screen 




demonstrate that fatty acid and amino acid amplification of GSIS is able to partially rescue the 
insulin secretion defects due to reduced ASNA1 expression and provides insight into the role of 
ASNA1 in insulin granule release.   
 
 
Figure 4-14: Model for ASNA1 mediated insulin secretion defects in pancreatic 
β-cells. ASNA1 functions in tail anchored protein insertion into the ER 
membrane.  The membrane fusion SNARE proteins are all tail anchored proteins, 
and loss of ASNA1 results in reduced insertion and misolicalzation these SNARE 
proteins.  Insulin grandule docking and fusion requires SNARE proteins.  
Therefore the SNARE protein mislocalization characteristic of reduced ASNA1 




















The role of ARV1 in lipotoxicity of the pancreatic β- cell 







 A portion of this body of work was previously submitted by Ying Liu for his doctorate 
thesis in 2004 [156].  After our identification of ARV1 in the yeast palmitoleate sensitivity screen 
(chapter 2) we continued his work in the context of lipotoxicity. Contributions by Dr. Liu include 
knockdown (Fig 5-6 and 5-7) and overexpression (Fig 5-10 and 5-11) of ARV1 in HEK293 cells 
and ARV1 overexpression studies in mice (Fig 5-12 and 5-13, Table 5-1 and 5-2).  My work 
focused instead on the effect of decreased ARV1 expression with respect to lipid synthesis and 
lipid induced apoptosis in yeast (Fig 5-1, 5-2 and 5-3) and mouse pancreatic β-cells (Fig 5-4, 5-5, 
5-8 and 5-9).  Human ARV1 overexpression studies in McA-RH7777 cells (Fig 5-14, Fig 5-15 









 The most sensitive strain identified by our yeast palmitoleate sensitivity screen was in the 
deletion of ARE2 Required for Viability gene, ARV1.  ARV1 is a putative sterol transporter which 
localizes to the ER membrane, deletion of which results in an accumulation of sterols at the ER 
and constitutively active unfolded protein response (UPR), likely due to the sterol buildup.  
Orthologs of ARV1 exist in all eukaryotic systems queried, and expression of human ARV1 is 
able to rescue lipid related phenotypes in the yeast ARV1 deletion, demonstrating functional 
homology.  We found that knockdown of ARV1 in the MIN6 pancreatic β-cell line caused a 
similar fatty acid sensitivity phenotype to that in the yeast arv1Δ, with increased apoptosis in 
response to both palmitate and palmitoleate.  In addition, reduced ARV1 expression in MIN6 and 
HEK293 cells resulted in decreased neutral lipid synthesis.  In order to determine the role of 
ARV1 in vivo, we used a human ARV1 adenovirus (AdhARV1) to induce hepatic ARV1 
overexpression.  Mice injected with the AdhARV1 saw a significant increase in triglyceride mass 
and an accumulation of lipid droplets within the liver, with no change in plasma lipid levels.  
Gene expression levels of the triglyceride synthesis enzyme, DGAT1, were significantly 
increased in these livers compared to control, with no significant changes in other lipid synthesis 
enzymes.  These results suggest that mammalian ARV1 is involved in the regulation of neutral 
lipid synthesis in both pancreatic β-cells and in the liver, and therefore may be a factor in genetic 












In order to identify gene deletions resulting in increased sensitivity to exogenous free 
fatty acids, we completed a genome-wide fatty acid sensitivity screen in yeast (chapter 2).  The 
goal of this screen was to find novel genes required for protection against the negative effects of 
lipid accumulation in eukaryotic cells, focusing primarily on those which have been conserved 
across evolution.  A deletion in ARV1 resulted in the most severe growth defect in response to 
the unsaturated fatty acid palmitoleate compared to all other single deletions tested (chapter 2), 
making it an appealing gene for follow up studies.  
The ARE2 Required for Viability gene, ARV1, was first identified in yeast as essential in 
cells lacking all sterol esterification capacity due to deletions in the two ACAT related enzymes, 
ARE1 and ARE2.  In yeast ARV1 deletion strains, free sterol levels in the ER dramatically rise at 
the expense of the plasma membrane (PM).  Thus, ARV1 has been proposed to act as a sterol 
transporter, involved in free sterols export out of the ER membrane.  Yeast arv1Δ has a robust 
induction of the UPR under basal conditions, likely due to the sterol accumulation in the ER 
[206].   These sterol localization defects characteristic of yeast ARV1 mutants are complemented 
by expression of human ARV1, indicating a functional conservation throughout evolution [205].   
ARV1 has been identified in all eukaryotic organisms queried thus far [239, 344, 345], 
with sequence conservation occurring primarily in a 61-residue ARV1 homology domain (AHD) 
at the N-terminal region of the protein.  This region is made up of a putative zinc binding motif 
and a block of 33 conserved residues [205].  Human ARV1 is expressed in most tissues, but is 






maximum expression levels in the lung [239].  Similar to the yeast ARV1 deletion, knockdown of 
ARV1 in mouse liver using antisense oligonucleotides results in an accumulation of free sterol in 
the liver resulting in a 2-4 fold increase in hepatic and plasma bile acid levels through an 
increase in FXR activation [239].    
Despite the recognized role of ARV1 in sterol metabolism, no known phenotypes 
connecting ARV1 and fatty acid homeostasis have been reported [344].  Due to its high 
evolutionary conservation, we predict that decreased mammalian ARV1 expression will sensitize 
cells to lipid-induced apoptosis, similar to that seen in yeast.   Furthermore, we propose that 
ARV1 is integral in the progression of the lipotoxic diseases, type 2 diabetes (T2D) and 
nonalcoholic fatty liver disease (NAFLD), due to its role in lipotoxicity.  
Overall, our results show that ARV1 expression is positively correlated with triglyceride 
synthesis in mouse pancreatic  cells and mouse liver, due, at least in part, to increased DGAT1 
levels.  Additionally, ARV1 is protective against lipid induced pancreatic β-cell lipotoxicity and 







MATERIALS AND METHODS 
 
Yeast General.  Molecular biology and yeast procedures were performed according to 
conventional methods [177]. Complete (YPD; yeast extract, peptone, dextrose), synthetic 
complete (SC) and selective media were prepared as described previously [177].  All yeast 
strains used in this study were derived from s288C (Open Biosystems), with the exception of 
SCY2021 (are1::HIS3 are2::LEU2 dga1::URA3 lro1::URA3) which is derived from 
W303[178].   All single mutants were obtained from the Open Biosystems Yeast Knock Out 
Strain collection (Cat # YSC1053).  When indicated, fatty acids (Sigma) were added to media in 
0.6% ethanol:tyloxapol (5:1, v/v) with the designated quantity of fatty acid (palmitoleate and 
oleate as a 10% w/v stock in ethanol).  For liquid growth assays, overnight cultures were used to 
inoculate liquid media such that the starting optical density was 0.1 (OD600 nm) and growth 
curves were obtained using a Microbiology Workstation Bioscreen C (Thermo Electron Corp.) 
and Research Express Bioscreen C software (Transgalactic Ltd).  Three isolates per genotype 
were normalized to an absorbance (OD600) of 0.1 and 10 μl of each strain was added to 290 μl 
of media per well and grown at 30° for 4 days and averaged in order to produce the final growth 
curve.  
 
Cell Culture. The MIN6 mouse insulinoma cell line [346] was a kind gift of Dr. Alan Attie 
(Madison, WI).  MIN6 cells were maintained in Dulbecco’s modified Eagles medium DMEM) 
containing 25 mM glucose, 15% heat-inactivated fetal bovine serum (FBS), 100 units/mL 
penicillin, 100 ug/ml streptomycin, 100 ug/ml L-glutamine and 5 ul/L β-mercaptoethanol.  






Collection (ATCC, Manassas, VA) and cultured in Dulbecco’s modified Eagle’s Medium 
(DMEM) medium containing 10% fetal bovine serum (FBS), L-glutamine and antibiotics.  
McArdle RH7777 cells were obtained from ATCC.  McA-RH7777 cells were maintained in 
DMEM with 10% FBS, 10 % Horse Serum, 100 units/ml penicillin, and 100 g/ml streptomycin. 
Cells were grown in humidified 5% CO2, 95% air at 37°C.  Fatty acids were prepared using fatty 
acid free bovine serum albumin (BSA) (Invitrogen).  Cells were incubated for 0-20 hours in 
DMEM with 10% FBS containing oleate, palmitate or palmitoleate (Sigma-Aldrich) bound to 
1% fatty acid free BSA (Sigma-Aldrich).  Control incubations contained only BSA.   
 
Lipid Analysis and Metabolic Labeling. Mammalian lipid labeling was performed on cells 
seeded overnight in a 6 well plate.  For oleate labeling, cells were pulse labeled with 0.5 μCi/ml 
[9,10- 
3
H] Oleic acid for 6 hours in serum free DMEM with 1% essentially fatty acid free BSA + 
0.25 mM cold oleate.  Labeling with 0.5 μCi/ml [
3
H]acetate and 3μCi/ml [
3
H] glycerol was done 
with cells grown to 95% confluence for 8 hours at 37°C [156].  For lipid extraction, 2 ml of 
hexane:isopropanol (3:2) was added to each well and incubated at room temperature for 1 hour, 
after which the supernatant was removed and the extraction repeated.  Samples were dried with 
nitrogen gas, resuspended in chloroform:methanol (2:1) and lipids were separated on a TLC plate 
[309]. Total cholesterol levels were measured by Gas Liquid Chromatography (GLC) as 
described [309].  TG content was determined by enzymatic assay using Trig/GB from Roche.  
Lipid levels were quantified as described previously and normalized to protein level using a 







Fluorescence Microscopy. Yeast cells were grown in specified media to saturation.  For lipid 
droplet analysis, cells were stained with Nile Red (1 μg/ml) (Sigma-Aldrich) and visualized with 
a long pass GFP filter (excitation 440 nm).  For quantification, 10 confocal frames 0.25 μm apart 
were captured and displayed as maximum intensity projections.  Lipid droplets were counted for 
6 frames per strain, with 15-30 cells per frame.  Statistical analysis was carried out by comparing 
variation within frames. All microscopy was performed using a Zeiss Axiovert 200 M using a 
63x oil immersion objective and images taken using a Hamamatsu Orca-ER camera.   
  
Apoptosis Assays. Yeast apoptosis was assessed using Annexin V binding and propidium 
idodide staining using the FITC Annexin V/Dead Cell apoptosis kit (Molecular probes V13242).  
Cells were washed with sorbitol buffer (1.2 M Sorbitol, 0.5 mM Magnesium Cloride, 35 mM 
Potassium Acetate ph 6.8), digested with 5.5% glusulase and 15 U/ml lyticase in sorbitol buffer 
and resuspended in Annexin/PI for 20 minutes [257].  MIN6 apoptosis levels were quantified 
using Invitrogen Vibrant Apoptosis Assay Kit #5 (V13244) as described by manufacturer.  10 
frames per condition were captured and cells within these frames were counted in order to obtain 
a percentage of apoptotic and dead cells within the population.   
 
siRNA and ASO transfection. Murine ARV1 specific and negative control ASOs were provided 
by Isis Pharmaceuticals, Inc (Carlsbad, CA).  The ASOs are chimeric 20-mer phosphorothioate 
oligonucleotides with 2’-O-Methoxyethyl (MOE) groups at positions 1-3 and 17-20.  ASOs were 
prepared as a 200 uM concentration in dH2O.  Transient transfection experiments were 






which media was changed to DMEM with 10% FBS for 24-48 hours.  When specified, fatty 
acids were added to culture 24 hours after knockdown.   
 
Immunoblots. Cells were washed twice with PBS and lysed using SDS buffer (2% SDS, 62.5 
mM Tris-HCL (pH 6.8), 10% glycerol, 10% β-mercaptoethanol, and 0.01% bromophenol blue) 
and boiled for 5 minutes.  Protein extracts were prepared in a lysis buffer containing 25 mM 
Tris-HCL (pH 7.4), 2 mM Na3VO4, 10 mM NaF, 10 mM Na4P2O7, 1 mM EGTA, 1 mM EDTA, 
1% NP-40, 5 μg/ml leupeptin, 5 μg/ml  aprotinin, 10 nM okaidic acid and 1 mM 
phenylmethylsulfonylfluoride.  Equal amounts of protein extract were separated on a 12% SDS-
PAGE gel and electrotransferred to a 0.45 μm nitrocellulose membrane using a Bio-Rad 
laboratories mini-transfer tank.  Membranes were blocked for 1 hour at room temperature with 
5% non-fat milk in Tris-Buffered Saline with 0.1% Tween 20 (TBST) and incubated with 
primary antibodies overnight at 4°C.  Protein bands were detected with HRP-conjugated 
secondary antibodies and SuperSignal West Pico enhanced chemiluminescent solution (Pierce).   
 
ApoB immunoprecipitation.  Cells were incubated in methionine/cysteine-free DMEM with 
1.5% fatty acid free BSA for 2 hours followed by [
35
S] methionine labeling for 2 hours.  After 
labeling, media was transferred into eppendorf tubes and a mixture of protease inhibitors 
(30μl/ml protease inhibitors, 1 mM benzamidine, 5 mM EDTA, 100 units/ml aprotinin, 50 μg/ml 
leupeptin, 50 μg/ml pepstatin A and 10 mM Hepes, pH 8.0) and 0.86 mM freshly added 
phenylmethylsulfonyl fluoride.  Immunoprecipitation of apoB in medium and cells was carried 
out according to the method described by Dixon et al [310].  Antibodies against apoB 






solution to precipitate apoB.  ApoB was precipitated by boiling for 5 minutes in sample buffer 
(0.125 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol and 10% β-mercaptoethanol).  Proteins were 
separated by SDS-PAGE and gels were then treated with autofluor (National Diagnostics, 
Atlanta GA) and after drying exposed to X-ray film (Kodak, X Omat AR) at -80°C for 1-3 days.  
Incorporation of [
35
S]methionine into apoB48 and apoB100 was quantified by autoradiography 
and bands were cut and radioactive incorporation was quantified by liquid scintillation counting 
[311]. 
 
Miscellaneous.  The following methods were completed as described by Dr. Ying Liu [156]: 
SRE-luciferase Activity Assay, Recombinant  Adenovirus Construction, Gene Expression 










Deletion in ARV1 results in robust palmitoleate sensitivity.  Of the 156 deletion strains 
identified in the palmitoleate sensitivity screen (chapter 2), the most sensitive based on growth 
curve analysis and colony density was arv1Δ.  This gene mutant was the only deletion tested 
having similar levels of sensitivity to that of the are1Δ are2Δ dga1Δ lro1Δ neutral lipid deficient 
yeast strain, and is similarly unable to grow in the presence of 0.05 mM palmitoleate (a 
concentration 10 fold lower than used in the screen) (Fig 5-1).    
 
Figure 5-1: Deletion of ARV1 results in severe fatty acid sensitivity and 
increased lipid droplet number.  Wild Type and arv1Δ growth in YPD liquid 
media with indicated concentrations of palmitoleate.  n=3 for each condition   
 
In order to determine if this sensitivity was due to fatty acid induced apoptosis or 
necrosis, we treated wild type and the ARV1 deletion with 0.1 mM palmitoleate for 16 hours, 






respectively.  We considered any cells staining positive for Annexin V to be undergoing 
apoptosis, either as late stage apoptosis (Annexin+/ PI+) or early stage apoptosis (Annexin +/PI) 
[257].  Consistent with its growth sensitivity phenotype (Fig 5-1), we saw a significant increase 
in apoptotic cells in the ARV1 deletion after palmitoleate treatment, which did not occur in the 
wild type strain (Fig 5-2).  Even in YPD media alone, arv1Δ had significantly higher levels of 
Annexin V and PI staining compared to the control, indicating that ablation of ARV1 results in 
increased apoptosis under basal conditions (Fig 5-2).  Since the cell death percentage in the 
ARV1 deletion was increased even under normal growth conditions, we also compared the 
apoptotic cell percentage of arv1Δ in YPD versus the palmitoleate treatment condition and found 
that fatty acid supplement significantly increased apoptosis levels (Fig 5-2B).  Therefore, 
knockout of ARV1 results in increased cell death under basal conditions and a further increase in 
apoptotic induction when treated with palmitoleate, compared to control (Fig 5-2).  
Since neutral lipid (NL) synthesis is a cell’s primary defense against lipotoxicity, we 
considered if the increased fatty acid (FA)-sensitivity was due to insufficient lipid storage.  
Images of lipid droplets, stained with Nile Red, were captured and quantified in the wild type 
and ARV1 mutant in YPD +/- 0.1 mM palmitoleate to obtain the average number of droplets per 
cell (Fig 5-3A).  We saw no significant difference in lipid droplet number between strains when 
grown in YPD, but in the presence of palmitoleate there was a significant increase in lipid 
droplet number in arv1Δ (8.06 droplets/cell) compared to wild type (5.23 droplets/cell) (Figure 
5-3 A-B).  A similar increase in lipid droplet number was seen in cholesterol treated ARV1 
mutants [205, 206].  Interestingly, activation of ER stress in yeast through tunicamycin or 
Brefeldin A treatment results in lipid droplet accumulation [347].  Since ARV1 mutant strains 










Figure 5-2: Mutation in ARV1 increases levels of fatty acid induced apoptosis. 
(A) Annexin/Propidium iodide staining of wild type and arv1Δ cells after 
incubation in YPD ± 0.1 mM palmitoleate for 16 hours (B-C) and quantified based 
on proportion of total cells stained for externalization of phosphatidylserine 
(Annexin V +) and propidium idodide (PI) internalization.  (mean ±s.e, 10 fields of 
cells, at least 60 cells per field).  Asterisks denote statistical significance compared 









Figure 5-3: Deletion of ARV1 results in increased lipid droplet number with 
palmitoleate treatment. (A) Strains grown for 24 hours in YPD ± 0.1 mM 
Palmitoleate and stained for lipid droplets with Nile Red (1µg/ml).  (B) Lipid 
droplets per cell quantified for each strain and condition, (mean ±s.e., 10 fields of 
cells, at least 60 cells per field).   Asterisks denote statistical significance 
compared to the wild type control in the same condition (*p<0.05).   
 
Decreased expression of mammalian ARV1 increases fatty acid induced lipotoxicity of 
pancreatic β-cells. Human ARV1 is a functional ortholog of yeast ARV1, and as such is able to 
rescue sensitivity and lipid phenotypes associated with yeast arv1Δ.  Due to this conservation, 
we hypothesized that altering expression levels of ARV1 in mammalian systems would affect 
lipid homeostasis and FA-sensitivity similarly to that seen in yeast. The identification of ARV1 in 
the yeast lipotoxicity screen indicates that mammalian ARV1 may also play an integral role in 






to focus on ARV1 in the context of TG homeostasis and obesity related diseases, such as type 2 
diabetes and nonalcoholic fatty liver disease.  
As a deletion in yeast ARV1 results in robust apoptosis in response to FA treatment, we 
predicted that knockdown of mammalian ARV1 would confer a similar sensitivity.  Lipid induced 
apoptosis of pancreatic β-cells is associated with altered glucose metabolism and T2D 
progression [126, 348-350].  In order to elucidate the role of ARV1 in -cell health, we used the 
MIN6 mouse pancreatic β-cell line to test for levels of lipoapoptosis upon specific gene 
knockdown.  Cells were treated with murine ARV1 specific antisense oligonucleotides (ASOs) 
for 48 hours to induce a significant reduction in gene expression. This treatment caused an 
approximate 40% decrease in ARV1 expression compared to control ASO treatment (Fig 5-4).   
 
 
Figure 5-4: ARV1 knockdown in MIN6 pancreatic β-cells. Mouse ARV1 mRNA 
expression levels with 0.25 μM ASO treatment for 48 hours measured by 






wild type control in the same condition (*p<0.05) by unpaired t-test of differences 
of the mean fold induction (ΔΔCt) ±s.d. (n=3).  
 
 
Levels of apoptosis were measured after 24 hours of fatty acid treatment by the 
fluorescent apoptotic marker stain, Hoechst 33342, and the cell death marker, propidium iodide 
(PI) (Fig 5-5).  Condensing chromatin, characteristic of apoptotic cells, is stained brightly with 
blue-fluorescent Hoechst 33342 dye compared with a dim nuclear stain of normal cells.  
Apoptotic cells were identified as cells staining positive for Hoechst 33342 and negative for PI 
[351].    
Treatment of MIN6 cells with the saturated fatty acid (SFA) palmitate (at both 0.1 and 
0.5 mM) and the unsaturated fatty acid (UFA) palmitoleate (at 0.5 mM), induced a significant 
increase in apoptosis in both control and ARV1 siRNA groups compared to the apoptosis 
percentage under no treatment conditions (Fig 5-5).   Similar levels of apoptosis have been 
demonstrated in pancreatic β-cell models following chronic fatty acid exposure [202, 352].   
When comparing control and ARV1 siRNA treatments, we saw a significant increase in 
apoptosis in ARV1 knockdown following the addition of both palmitate (at 0.1 and 0.5 mM) and 
palmitoleate (Fig 5-5).   Incubation of either control or ARV1 siRNA treated cells with oleate or 
low levels of palmitoleate (0.1 mM) did not increase apoptosis in either group.  However, in the 
no treatment condition (0.5% BSA), ARV1 knockdown caused a significant increase in the 
apoptotic cell percentage compared to the no treatment control (Fig 5-5B).  This mirrors the 
increase in basal apoptosis occurring with yeast arv1Δ grown in rich media (YPD) and indicates 
that knockdown of ARV1 in either model results in a decrease in cellular viability (Fig 5-2).  






palmitate and palmitoleate induced apoptosis, which is consistent with the FA-sensitivity 









Figure 5-5: Decreased ARV1 expression in MIN6 cells increases sensitivity to 
fatty acid induced apoptosis. (A) Hoechst/PI staining and of MIN6 cells treated 
with 0.5 mM Oleate, Palmitoleate and Palmitate for 16 hours.  (B) Quantification 
of the average number of apoptotic cells.  (mean ±s.e., 7 fields with 70-200 cells 
per field).  Asterisks denote statistical significance (*p<0.05) compared to Control 







Neutral lipid synthesis is directly correlated to ARV1 expression levels. A reduction in neutral 
lipid (NL) synthesis and storage in both yeast and mammalian systems is associated with 
increased levels of fatty acid induced apoptosis, ER-stress and cellular dysfunction [22, 186].   
Obesity related diseases such as type 2 diabetes (T2D) are due in part to these lipid-induced 
cellular defects [353, 354].   In order to test for alterations in NL synthesis resulting from ARV1 
knockdown, we used two model systems, human embryonic kidney (HEK293) cells and MIN6 
cells.  HEK293 cells were chosen due to their minimal level of TG mass under normal growth 
conditions, making any small increase in TG and lipid droplets easier to detect.  Stable HEK293 
cell lines with suppressed ARV1 expression were constructed using ARV1 specific siRNA 
followed by clone selection.  A stable cell line with a >85% reduction in ARV1 expression was 
chosen for the subsequent experiments (Fig 5-6).   
 
 
Figure 5-6: Knockdown of ARV1 in HEK293 cells. (A) Selection of HEK293 
stable cells with suppressed hARV1 expression. After antibiotic selections, 






Signals were measured by phospho-imaging.  Relative abundance of ARV1 
mRNA was expressed as a ratio to housekeeping gene G3PDH.  Control (CT) 
stably transfected with pSilencer-scrambled  
 
Triglyceride synthesis in HEK293 cells were determined by [
3
H]acetate incorporation 
and expressed in terms of radioactivity incorporation (DPM) per milligram (mg) of protein.  
Knockdown of human ARV1 in HEK293 cells resulted in a 55% decrease in [
3
H]acetate 
incorporation into triglyceride and a 70% reduction in cholesteryl ester (Fig 5-7 A-B), 
implicating ARV1 in the regulation of NL synthesis.   Consistent with these results, Tong et al., 
demonstrated that liver TG was significantly reduced in mice with decreased hepatic ARV1 
expression [239].    
 
Figure 5-7: Knockdown of ARV1 in HEK293 cells results in a reduction in 
neutral lipid levels. Lipid labeling in ARV1 siRNA cells has reduced levels of 
(A) triglyceride and (B) cholesterol ester synthesis.  There was no change in 
[
3
H]acetate incorporation into free cholesterol (FC) or phospholipid between 
control and ARV1 knockdown cells (data not shown).    Astrisks demotes 










As knockdown of ARV1 in MIN6 cells resulted in a robust sensitivity to fatty acid 
induced apoptosis, we also measured NL synthesis levels in this pancreatic β-cell line.  Lipid 
synthesis levels in MIN6 cells were measured by average percent [
3
H]oleate incorporation into 
lipid species following 4 hour label.  Like that seen in HEK293 cells, triglyceride synthesis was 
decreased with ARV1 knockdown compared to control (Fig 5-8A).  All other lipid species 
measured (free fatty acid, diacylglycerol and cholesterol ester) had normal incorporation with the 
exception of phospholipids, which showed a significant increase (Fig 5-8 B).   
 
Figure 5-8: ARV1 knockdown in MIN6 pancreatic β-cells results in decreased 
triglyceride and increased phospholipid synthesis.  Lipid synthesis measured by 
[
3
H]oleate incorporation into triglyceride (A) and phospholipid (B) as a 
percentage of total lipid species. No changes were seen in any other species 
synthesis (SE, FFA, DAG).  Astrisks demotes statistical significance (*p<0.05) as 








 The neutral lipids, triglyceride and cholesterol ester, are stored in the core of the lipid 
droplet, where they can be used as membrane building blocks or as a source of energy [30].  
Since NL synthesis levels were significantly reduced in HEK293 and MIN6 cells following 
ARV1 knockdown, we expected a similar decrease in lipid droplet number and/or size following 
decreased ARV1 expression.  In order to determine if this was the case, we grew siRNA treated 
cells overnight in 0.5 mM oleate, and stained for lipid droplets with Oil Red O.  Despite the 
reduction in NL synthesis, we saw no obvious change in LD morphology upon ARV1 
knockdown in MIN6 cells (Fig 5-9).  Moreover, in contrast to yeast arv1Δ, which had an 
increase in lipid droplets following palmitoleate treatment (Fig 5-3), knockdown of ARV1 in 
MIN6 cells with overnight FA treatment had no effect on lipid droplet number or morphology 
(Fig 5-9).  This may be due to differences in lipid droplet homeostasis in yeast and MIN6 cells, 
or perhaps to the differences in a full deletion versus a gene knockdown, which still has ~60% 







Figure 5-9.  Reduced ARV1 expression in MIN6 cells does not alter lipid 
droplet morphology. Cells were grown overnight in oleate for 20 hours followed 
by Oil Red O staining.   
 
Human ARV1 overexpression alters lipid levels independent of SREBP.  In order to 
further elucidate the role of ARV1 in mammalian lipid metabolism, we used a constitutively 
active human ARV1 vector to determine the effects of ARV1 overexpression in lipid synthesis.  
Stable HEK293 monoclonal cell lines transfected with human ARV1 (hARV1-EGFP) were 
selected using fluorescent microscopy and western blot analysis to identify clones with the 
highest levels of hARV1-EGFP expression (Fig 5-10 A-C).  Since decreased ARV1 expression 
resulted in a reduction in TG synthesis, we tested for altered TG synthesis levels with increased 
ARV1 expression.  Corresponding to that seen with ARV1 knockdown, ARV1 overexpression 
resulted in a dramatic increase in [
3
H]glycerol labeling of both triglyceride (TG) (163%) and 
phospholipid (109%) in hARV1-EGFP cells compared to control (Fig. 5-10 D-E).  Taken 
together with ARV1 knockdown data, these results indicate that ARV1 expression directly 






 In mammals, levels of cholesterol and fatty acids within the cell are controlled, in part, 
by the sterol regulatory element-binding protein (SREBP) family of transcription factors [355].  
These proteins are localized at the ER membrane and are cleaved in response to intracellular 
lipid levels, releasing mature forms of the SREBPs that bind to the sterol regulatory elements 
(SRE) of genes involved in cholesterol and fatty acid synthesis [356].   Mice with hepatic ARV1 
knockdown showed increased ER cholesterol and a downregulation of SREBP cleavage and 
activation in the liver.  We therefore reasoned that the increased TG synthesis in hARV1-EGFP 
transfected HEK293 cells could be explained by a rise in SRE-mediated gene expression.  To test 
for a potential role for SREBP in hARV1-EGFP cells we used a pSyn-SRE vector to measure 
luciferase activity.  In all conditions tested, there were no significant changes in SRE-mediated 
gene expression between control and hARV1-EGFP cells (Fig 5-11), suggesting that increased 









Figure 5-10: Overexpression of ARV1 in HEK293 cells causes increases 
triglyceride and phospholipid synthesis[156] (A-B) Stable transfection of 
HEK293 cells with hARV1-EGP and control EGFP. hARV1-EGFP cells were 
labeled for 8 hours with [3H]glycerol and lipid species were separated by TLC.  
TG (D) and PL (E) are expressed as DPM/mg of protein.  Asterisks denote 








Figure 5-11. Increased lipid synthesis levels in HEK293 cells with ARV1 
overexpression is independent of the sterol regulatory element binding protein 
(SREBP) [156].  SRE-mediate gene expression measured by transfection with 
pSyn-SRE and pRL-CMV and treated for 16 hours with serum free (SF) DMEM 
+ 1% BSA, SF DMEM + 1% BSA with 10 µg/ml cholesterol and 1 µg/ml 25-OH-
cholesterol, DMEM with 10% fetal bovine serum (FBS) and SF DMEM + 1% 
BSA with 0.3 mM oleate. Relative SRE activity expressed as a ratio of firefly to 
Renilla luciferase activity.  
 
Overexpression of Human ARV1 in Mice Increases Heptatic Triglyceride Levels.   Altered NL 
synthesis can have profound effects on cellular health in the face of caloric excess.  For instance, 
ablation of the TG synthesis enzyme, DGAT1, results in increased UFA induced toxicity in 
mouse fibroblasts [7] and overexpression of TG synthesis enzymes is able to decrease lipotoxic 
phenotypes in vivo [25].  In agreement with these studies, we demonstrate that decreased NL 
synthesis in MIN6 cells following ARV1 knockdown is associated with increased FA-induced 
apoptosis.  In addition to a reduction in NL synthesis, lipid deposition in the liver, which can 
occur through increased TG synthesis, is associated with cellular dysfunction categorized as 


































with obesity related disorders.  A protein like ARV1, which has obvious effects on TG synthesis, 
may be an important regulator of lipotoxic pathways.  
In order to assess the role of ARV1 in mammalian physiology, we induced ARV1 
overexpression in mouse liver and monitored hepatic and plasma lipid levels.  In order to 
increase hepatic ARV1 expression we injected C57BL/6 female mice with a human ARV1 
specific adenovirus (AdhARV1) or a control adenovirus (AdNull) for 4 days, after which serum 
was collected and tested for total cholesterol, triglyceride and HDL and mice were sacrificed for 
hepatic lipid analysis [357, 358].  As expected, mRNA expression levels of hepatic hARV1 were 
consistently increased in ARV1 adenovirus injected mice (AdhARV1) compared to control 
(AdNull) (Fig 5-12A).   This did not cause any change in the serum lipid profile between the two 
groups (data not shown) but did result in a significant increase in hepatic TG compared to control 
(Fig 5-12C).  This is consistent with our in vitro studies showing increased TG synthesis with 
higher ARV1 expression (Fig 5-10D).  Both free cholesterol and phospholipids also showed a 
significant increase in the livers of the AdhARV1 injected mice compared to control, with a 33% 
and 21% increase respectively (Fig 5-12C).  To confirm the hepatic lipid accumulation, we 
stained the livers with Oil Red O and observed large neutral lipid droplets in AdhARV1 infected 







Figure 5-12:  Overexpression of human ARV1 in mice causes fatty liver [156].  
Mice injected with AdhARV1 or AdNull for 4 days, sacrificed and livers were 
perfused and homologized (A) mRNA levels of hARV1 gene expression in mouse 
livers (B) Ethidium bromide staining of 18s and 18s rRNA to show equal loading 
of RNA samples.   Samples 1-7, RNA from livers of AdhARV1 infected mice; 8-
14, RNA from lives of AdNull Infected mice; 15-18 RNA samples from livers of 
PBS injected mice (C) Liver lipids were measured enzymatically  (D) Neutral 
lipid staining in livers with Oil-red-O stain. 
   
Increased liver TG can be associated with hepatic insulin resistance and ER stress and 
occurs due to an imbalance between TG liver influx (de novo biosynthesis, diet or adipose tissue) 






lipid changes observed in AdhARV1 infected mice, we used gene expression profiling with an 
Affymetrix GeneChip.  Using high stringent criteria (student t test P<0.001 between AdhARV1 
and AdNull, fold changes either >1.5 or <0.5) we identified 27 upregulated (Table 5-1) and 9 
downregulated genes in the AdhARV1 livers (Table 5-2).  The triglyceride synthesis gene, 
DGAT1, was found to be upregulated 1.6 fold in and this increase was confirmed by real-time 
PCR (Fig 5-13).   There is little known about the regulation of DGAT1 transcription, but DGAT1 
contains a Peroxisomal Proliferator-Activated Receptor (PPAR) binding site and its mRNA 
expression increases in response to the PPARγ activators, thiazolidinediones, in adipose tissue 
[361].  Furthermore, gene expression analysis of biopsy samples taken from patients with 
nonalcoholic fatty liver disease (NAFLD) have a significant increase in expression of both 
DGAT1 and PPARγ [362].  Other enzymes involved in triglyceride or sterol ester synthesis did 
not have altered gene expression in these livers including downstream targets of SREBP.  This 
result is consistent with our previous observation in the HEK293 cell model, showing no major 
















Table 5-1.  Genes with increased expression in AdhARV1 treated mice [156].    
Genes upregulated (fold change 1.5 or more P<0.001) in livers with hARV1 
overexpression. Results calculated based on data of 6 sets of Affymetrix 









Table 5-2.  Genes with decreased expression in AdhARV1 treated mice[156].  
Genes downregulated (fold change 0.5 or less, P<0.001) in livers with hARV1 
overexpression. Results calculated based on data of 6 sets of Affymetrix 












Figure 5-13:  DGAT1 expression levels are significantly increased in AdhARV1 
treated mice [156].  DGAT1 mRNA expression levels from AdhARV1 injected 
mouse livers compared to AdNull control.   Asterisks denotes statistical 
significance as determined by unpaired t-test (*p<0.05) compared to control.    
 
 
ARV1 overexpression in rat hepatoma cell line McA-RH7777.  There are several mechanisms 






fatty acid uptake from circulation, decreased fatty acid oxidation or a reduction in very low 
density lipoprotein (VLDL) secretion can all result in a rise in hepatic TG mass.  These 
mechanisms can occur simultaneously or independent from one another [68] and therefore, in 
addition to the increase in hepatic TG synthesis seen with ARV1 overexpression, any of these 
defects could exacerbate the fatty liver phenotype.    
 In order to test for altered TG secretion we transfected rat hepatoma McA-RH77777 cells 
with the same control (AdNull) and human ARV1 (AdhARV1) adenoviral constructs used in our 
mouse study and assessed TG clearance using [
3
H]glycerol labeling.   McA-RH7777 cells were 
treated with the adenovirus constructs for 48 hours to induce ARV1 overexpression (Fig 5-14A) 
and pulse labeled with [
3
H]glycerol for 2 hours.  In contrast to the mouse studies, there was no 
difference in triglyceride levels in AdhARV1 infected cells compared to control (Fig 5-14B). 
Following the 2 hour pulse, fresh media without label was added to a subset of cells for 4 hours, 
after which lipids were extracted.  An accumulation of lipids due to defects in TG secretion 
would result in increased [
3
H]glycerol labeled intracellular TG after this 4 hour chase.  We did 
not see any difference in TG levels post-chase with human ARV1 overexpression compared to 
control (Fig 5-14C), indicating that it is unlikely that VLDL secretion is affected by altered 
ARV1 expression.   
 In order to be certain, we went on to quantify VLDL synthesis and secretion levels in 
adenoviral treated McA-RH7777 cells.  VLDL is assembled in the liver through lipidation of 
apolipoprotein B (ApoB) and secreted into the circulation where it delivers lipids to peripheral 
tissues [68].  ApoB synthesis and secretion were quantified by protein labeling of McA cells with 
[
35
S] methionine in serum free DMEM ± oleate for 2 hours.  Media and cells were collected and 






antibody (Fig 5-15) [311].  Oleate was included in this study because short term incubation of 
McA cells with oleate induces an increase in apoB100 secretion compared to secretion in without 
oleate [124].   We found that overexpression of human ARV1 in McA-RH7777 cells did not 
change apoB100 or apoB48 secretion in either treatment condition (Fig 5-15).  Together with the 
[
3
H]glycerol studies, these results indicate that there is no change in TG synthesis or TG 
















Figure 5-14:  ARV1 overexpression in McA-RH7777 cells does not change 
levels of lipid synthesis (A) human ARV1 expression levels as measured by 
quantitative RT-PCR relative to GAPDH internal control (B)[3H]glycerol 
labeling of triglyceride in adenoviral treated McA-RH7777 cells after 2 hour 
pulse with label in serum free (SF)  DMEM + 1.5% BSA and after 4 hour pulse in 









Figure 5-15:  ApoB secretion is unchanged with human ARV1 overexpression 
in McA-RH7777 cells.  To determine levels of ApoB secretion, cells were labeled 
with [
35
S]methionine for 2 hours with (D-F) and without (A-C) oleate.  Cells and 
media were collected, apoB immunoprecipitated and run on an SDS-PAGE gel 








S]methionine incorporation into ApoB100 (B and E) and ApoB48 (C and F) 
relative to AdNull control.  
 The significant increase in TG synthesis occurring in AdhARV1 injected mice was not 
recapitulated in the McA-RH7777 cell line.  We measured mRNA expression levels of basal 
ARV1 in mouse liver and McA-RH7777 cells to determine if the contradictory results were due 
to a difference in ARV1 expression in untreated cells.  Using quantitative RT-PCR we found that 
mRNA expression of ARV1 was significantly elevated, by more than 50 fold, in McA-RH7777 
cells compared to levels in mouse liver (Fig 5-16).  ARV1 expression in pancreatic islets and 
MIN6 cells were also significantly lower than those in McA-RH7777 cells by more than 15 fold 
(Fig 5-16).  Therefore, the contradictory results between rat hepatoma cells and the mouse liver 
could be due to the naturally higher ARV1 expression levels in McA-RH7777 cells compared to 
mouse liver, which would confound any further increase in ARV1.   
 
Figure 5-16:  ARV1 mRNA expression is increased in MIN6 and McA-RH7777 
cell lines compared to mouse liver and pancreatic islet cells.  Real-time PCR 
measurements of ARV1 expression  in mouse liver and pancreatic islet cells, the 






MIN6.   Mean fold induction relative to mouse liver expression.  Asterisks denote 
statistically significant (p<0.05) differences in the mean fold induction (ΔΔCt) 
compared to liver by unpaired t-test (n =3). 
DISCUSSION 
In these studies, we demonstrate a role for eukaryotic ARV1 in triglyceride synthesis and 
lipotoxic pathways in both yeast and mammalian cells.   Our major finding was that the role of 
ARV1 in lipotoxicity has been conserved between yeast and mammalian systems, with decreased 
expression resulting in increased fatty acid sensitivity.   Additionally, mammalian ARV1 
expression is directly correlated with levels of TG synthesis in several mammalian models, 
including MIN6 pancreatic β-cells, HEK-293 embryonic kidney cells and mouse liver.  In 
AdhARV1 injected mice, hepatic ARV1 overexpression resulted in lipid droplet accumulation 
(Fig 5-12D) and upregulation of the TG synthesis gene DGAT1 (Table 5-1).  Lipid accumulation 
in nonadipose tissue, such as the liver, is associated with fatty acid induced cellular dysfunction, 
through increased toxic fatty acid metabolites (ie, ceramides, FFA, DAG) [68, 161, 184, 354, 
363].   
DGAT1 expression has been implicated in fatty liver phenotypes in both rodent models 
and human subjects.  Gene expression analysis of biopsy samples taken from patients with 
nonalcoholic fatty liver disease (NAFLD) have a significant increase in DGAT1 expression 
[362].  Furthermore, DGAT1 deficient hepatocytes are protected against hepatic steatosis and 
inhibition of DGAT1 protects against high fat diet induced fatty liver in mice [364].   Our 
findings indicate that overexpression of human ARV1 in mouse liver is able to induce DGAT1 
dependent fatty liver implicating ARV1 as a central regulator of hepatic TG metabolism.  
The mechanism by which ARV1 overexpression drives DGAT1 mediated TG synthesis is 






driven luciferase promoter activity in HEK-293 ARV1 overexpressing cell lines (Fig 5-11) 
demonstrate that the lipid accumulation is independent of SREBP activity.  Previous ARV1 in 
vivo studies have focused on sterol phenotypes resulting from a reduction in hepatic ARV1 
expression.   The ARV1 liver knockdown results in increased bile acid production in response to 
an accumulation of intracellular cholesterol [239].  In yeast, a deletion in ARV1 also causes sterol 
accumulation, which activates ER stress and UPR induction [206].  In both cases, ARV1 
functions to detoxify the ER of sterol accumulation, though a precise mechanism for sterol 
movement remains elusive.  As a result of these studies, and others, the proposed function for 
ARV1 is as a sterol transporter, lack of which results in free sterol accumulation in the ER 
membrane [205, 206, 239].  
Multiple studies have shown that ARV1 is integrally involved in general lipid trafficking 
and homeostasis [58, 205, 344, 365].   The pleiotropic phenotypes exhibited in arv1Δ have made 
it difficult to assess primary and secondary response to the lipid transport defects and have made 
the determination of ARV1 function challenging.  We propose that the defects in TG homeostasis 
resulting from altered ARV1 expression can be explained as a secondary effect to its function as a 
sterol transporter.   
As a mediator of sterol detoxification from the ER, overexpression of ARV1 would likely 
result in free sterol deficiency in the ER membrane and a subsequent increase in plasma 
membrane (PM) cholesterol (Fig 5-17 (1)).   Plasma membrane localized cholesterol causes an 
increase in the lateral ordering of the membrane, decreasing membrane fluidity [366].  This 
fluidity is integral in cellular health, and extreme membrane fluidity or rigidity can result in 
broad cellular defects [367-369].   For example, high levels of cholesterol at the membrane cause 






membrane-binding capabilities [370].  The accumulation of free cholesterol in the plasma 
membrane due to increased ARV1 expression would result in a rigid membrane architecture and 
require cellular maintenance in order to regain normal membrane structure (Fig 5-17 (2)).  
A cell is able to balance decreased fluidity through alterations in phospholipid acyl chain 
composition.   The ratio of saturated to unsaturated fatty acyl chains in membrane phospholipids 
has a major impact on membrane fluidity, with increased unsaturated fatty acyl chains increasing 
membrane fluidity.  Feedback mechanisms likely exist to increase unsaturated fatty acid 
production and normalize membrane fluidity in instances of increased free cholesterol.  Fatty 
acid biosynthesis genes, acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS) and stearoyl-
CoA desaturase (SCD), contain sequences which indicate that they may be regulated by sterols 
and likely explain the coupling of sterol-FA levels at the membrane [371, 372].  We propose that 
following hepatic ARV1 overexpression, increased plasma membrane cholesterol upregulates 
UFA biosynthesis in order to maintain membrane architecture (Fig 5-17 (3) and (4)).  The 
increase in intracellular UFA could channel not only into PL acyl chains but also into other 
pathways, particularly triglyceride synthesis (Fig 5-17(5)).  Therefore, the continuous 
biosynthesis of unsaturated fatty acids through a membrane fluidity feedback mechanism could 








Figure 5-17: Model for increased DGAT1 driven triglyceride synthesis with 
ARV1 overexpression. (1) As an ER sterol transporter, overexpression of ARV1 
would result in increased transport of free cholesterol from the ER to the plasma 
membrane (PM) causing a cholesterol deficient ER and an accumulation of sterols 
at the PM.  (2) Increased cholesterol levels within the membrane changes 
membrane properties and increases rigidity.  A large change in membrane fluidity 
affects protein movement within the membrane and is involved in general cellular 
health. (3) In order to restore normal fluidity, de novo FA synthesis is 
upregulated, particularly UFA synthesis.  (4) Increased UFA incorporation into 
phospholipid (PL) acyl chains increases membrane fluidity to preserve membrane 
structure and function. (5) The increase in cellular UFA can also channel into TG 
synthesis through DGAT1 dependent esterification, resulting in lipid droplet 








Our study not only identified a novel pathway involved in lipotoxic disease, but also 
further demonstrates the power of yeast genetics in the identification of human disease modifiers.  
A primary goal of our UFA sensitivity screen in yeast (chapter 2) was to find conserved genes 
that are involved in lipotoxicity in both yeast and mammals.  As expected from the screen, we 
found a significant increase in apoptosis in response to fatty acid treatment in the yeast ARV1 
deletion compared to control (Fig 5-2).   We also demonstrate that knockdown of ARV1 in MIN6 
cells increases vulnerability of pancreatic β-cells to lipoapoptosis. Therefore, our screen was 
successful in the identification of a currently unreported mammalian lipotoxicity pathway 
through sequence and functional homology.   
The role of neutral lipid synthesis as a protective mechanism against the formation of 
toxic lipid metabolites has been well established [7, 22, 23, 373].  It is therefore not surprising 
that decreased TG synthesis in MIN6 cells upon ARV1 knockdown increases cell sensitivity to 
FA-induced apoptosis (Fig 5-5).   The reduction in TG synthesis occurring with decreased ARV1 
expression may occur through a mechanism similar to that described in its overexpression (Fig 5-
17), with feedback mechanisms attempting to correct for changes in membrane properties and 
having secondary lipid homeostatic consequences.   
Yeast ARV1 mutants have a multitude of lipid related phenotypes, many of which involve 
defects in sterol and ceramide metabolism [205, 344].   Strains lacking ARV1 have increased 
sensitivity to the polyene antibiotic nystatin, a decrease in sterol uptake, and an increase in the 
propapoptotic sphingolipid, ceramide [205, 344].  In addition, deletion of ARV1 results in a 
significant increase in ER stress and unfolded protein response (UPR) under basal conditions 






stress response [378, 379] as playing an integral role in pathways of lipotoxicity and insulin 
resistance.  The accumulation of ceramide and the constitutively active UPR characteristic of 
ARV1 mutants are two potential mechanisms explaining FA sensitivity in yeast arv1Δ.   
Alternatively ARV1 knockdown in the mouse liver did not result in increased UPR 
activation, due to the hepatocytes ability to channel excess cholesterol into bile acid production 
[239].  Pancreatic β-cells lack this detoxification pathway, and likely deal with sterol 
accumulation in a mechanism more similar to yeast.  Therefore, the increase in lipotoxicity in 
MIN6 cells with knockdown of ARV1 likely occurs through UPR induction and increased 
ceramide synthesis driven by ER sterol accumulation, though further research is needed to 
substantiate this claim. 
In conclusion, we have demonstrated a role for mammalian ARV1 in the progression of 
two major lipotoxic disorders, nonalcoholic fatty liver disease and lipid-induced pancreatic β-cell 
failure.   Altered expression of ARV1 causes major changes in neutral lipid synthesis and overall 
lipid homeostasis.  Though no known ARV1 gene polymorphisms have been associated with 
disease states, it is possible that slight changes in ARV1 expression in humans contributes to a 
predisposition to obesity related disorders and thus, future research is necessary to understand the 
















 The aim of this thesis was to identify new pathways of lipotoxicity in eukaryotic cells 
using the model organism S. cerevisiae.   Lipotoxicity occurs through lipid accumulation in cells, 
inducing cellular dysfunction associated with increases in reactive oxygen species [125, 139, 
211, 380, 381], ceramide biosynthesis [111, 382], ER stress [129, 164, 182] and altered 
membrane fluidity [23, 113].  Loss of all neutral lipid synthesis in yeast (are1Δ are2Δ dga1Δ 
lro1Δ) results in robust sensitivity to unsaturated fatty acid (UFA) treatment [22, 23].  In order to 
identify single deletions inducing similar lipotoxicity, we completed a genome-wide sensitivity 
screen with the unsaturated fatty acid, palmitoleate.  This screen identified 156 gene deletions 
resulting in significant sensitivity to growth on fatty acid containing media. 
Of these genes, many are involved in vesicular trafficking defects, mitochondrial 
respiration, and translational regulation.  In addition to palmitoleate sensitivity, we found the 
majority of these gene deletions to be sensitive to the sterol targeting polyene antibiotic, nystatin 
and growth in cold temperature (16°C).  Over forty percent of the genes identified by our screen 
have mammalian orthologs and several have been previously reported to be involved in 
phenotypes associated with type 2 diabetes.  
Three members of the vesicular trafficking, Golgi to ER Transport (GET) complex, were 
found to be sensitive to palmitoleate upon deletion.  In order to gain insight into the role of the 
GET complex in UFA metabolism, we focused on the well-conserved member of the complex, 
GET3, and its role in lipotoxicity and lipid homeostasis.   Deletion of GET3 results in a decrease 






synthesis gene, DGA1.   This LD defect was not due to decreased neutral lipid mass, but NL 
synthesis in GET3 mutants was significantly lower than control.  Additionally, electron 
microscopy of the GET3 DGA1 double deletion shows increased vacuolar lipid accumulation and 
membrane invaginations reminiscent of autophagic bodies.   
In order to determine if the increase in vacuolar associated lipids was due to defects in 
hydrolysis, we tested for vacuolar proteinase activity, autophagic flux and survival rates under 
conditions of nitrogen starvation (SD-N).  Autophagic flux, as measured by GFP-Atg8p 
cleavage, and survival in SD-N media were decreased in both get3Δ and get3Δ dga1Δ, indicating 
a GET3 dependent defect in vacuolar nutrient turnover.  Protease activity and vacuolar pH were 
both normal, as measured by cleavage of the fluorescent marker protein conjugate, CMAC-Arg.  
The increased vacuolar-lipid association is found in the DGA1 single deletion as well, and thus is 
likely due to differences in trafficking of LRO1 versus DGA1 produced triglyceride.  From this 
data we hypothesize that defects in GET3 cause decreased vacuolar lipolysis, potentially through 
defective trafficking of the vacuolar lipase, Atg15p, from the endosome through the MVB 
pathway.  This appears to be independent of mis-insertion of tail-anchored proteins characterized 
by mutations in the GET complex, and we propose that these defects can be explained by the role 
of Get3p in phophatidylinositol-3-phosphate production at the endosomal membrane and early 
endosome maturation.  
Since a main goal of the original screen was in the identification of genes involved in 
lipotoxic disease, we followed up two mammalian orthologs of yeast genes found by our screen.  
The two orthologs we chose to focus on were the GET3 ortholog, mammalian ASNA1 and 






lipid induced apoptosis and lipoid homeostasis in the mouse pancreatic β-cell line, MIN6, and 
the rat hepatoma cell line, McA-RH7777.   
Due to the major effects of GET3 deletion in lipid droplet homeostasis and lipotoxicity, 
we hypothesized that knockdown of ASNA1 in MIN6 cells would increase susceptibility of these 
cells to fatty acid induced cell death.  Apoptosis levels in ASNA1 knockdown cells were 
significantly increased after palmitate treatment at 1.0 mM but palmitoleate, oleate and lower 
levels of palmitate (0.5 mM), did not result in a higher apoptotic level in ASNA1 knockdown 
cells compared to control.  Basal levels of ER stress were also significantly elevated in the 
ASNA1 knockdown cells compared to control, a condition which may sensitize these cells to both 
lipoapoptosis [142] and defects in insulin secretion [128, 313].  
In addition to β-cell apoptosis, cellular dysfunction following chronic fatty acid treatment 
is a major contributor in the progression of type 2 diabetes [142, 383, 384].  Previous work 
identified ASNA1 as a regulator of glucose stimulated insulin resistance, with decreased ASNA1 
levels resulting in reduced insulin secretion [289].   In order to gain insight into the mechanisms 
of this secretion defect, we supplemented cells with fatty acids and amino acids, and tested for 
ASNA1 dependent defects in glucose stimulated insulin secretion.  From this study, we found that 
acute exposure of MIN6 cells to palmitate or L-Arginine was able to normalize the insulin 
secretion defects characteristic of cells with reduced ASNA1 expression.  These studies 
demonstrate that amplification of glucose stimulated insulin secretion by palmitate and L-
arginine are able to compensate for the insulin secretion defect with knockdown of ASNA1, and 
likely operate within a parallel cellular pathway.  We propose the defects in insulin secretion 
resulting from reduced ASNA1 expression are due to decreased insertion of SNARE proteins 






docking and fusion.  Fatty acids supplementation was able to increase insulin secretion, 
potentially through GRP40 binding, despite the ASNA1 dependent defects.   
The second ortholog we examined was mammalian ARV1, which is homologous to the 
yeast ARV1, particularly in a 61 residue ARV1-homology domain.  We chose ARV1 for several 
reasons.  Deletions in yeast ARV1 caused the most dramatic palmitoleate sensitivity of all single 
mutants tested.  Additionally, unpublished work in the Sturley Lab demonstrated a role for ARV1 
in lipid biosynthesis and the progression of nonalcoholic fatty liver disease in mice [156].  We 
used rat hepatoma McA-RH7777 cells with adenoviral vectors containing human ARV1 to study 
the effects of ARV1 overexpression in very low density lipoprotein (VLDL) secretion and found 
no change in VLDL secretion in these cells compared to a GFP control.  We predict that the 
increase in neutral lipid synthesis with ARV1 overexpression is a secondary effect based on its 
role as an ER resident sterol transporter.  Upregulation of ARV1 likely result in cholesterol 
accumulation at the plasma membrane, and a subsequent increase in membrane ridgity.  
Increased unsaturated fatty acid synthesis for incorporation into phospholipid acyl chains is a 
primary cellular response to increased membrane fluidity [371], and thus a rise in intracellular 
UFA could channel not only into phospholipid synthesis but also into the DGAT1 triglyceride 
synthesis pathway.  
Additionally, knockdown of ARV1 in MIN6 pancreatic sensitized cells to apoptosis under 
basal conditions and with palmitoleate or palmitate treatment. Neutral lipid synthesis was 
decreased in with reduced ARV1 expression, which is consistent with increased lipoapoptosis.  
Deletion of ARV1 in yeast results in an accumulation of the toxic lipid metabolite, ceramide, and 
a constituitely active unfolded protein response (UPR)[205, 206, 344].  Both ceramide and UPR 






cells with a knockdown in ARV1 occurs through these mechanisms. Together, these results 
indicate that ARV1 is involved in disease progression of two lipotoxic disease, type 2 diabetes 
and nonalcoholic fatty liver disease, through its role in fatty acid biosynthesis.   
 
CONCLUDING REMARKS 
Genetic make-up is well recognized as an important variable determining susceptibility to 
lipotoxic disease in the face of nutrient overload.   Genome-wide lipid droplet morphology 
screens and genome-wide association studies have identified several genes involved in cellular 
lipid metabolism [56-60] or polymorphisms associated with disease phenotypes [65, 134, 235, 
236, 304, 342, 385], but there is much to be determined in terms of the cellular mechanisms of 
lipotoxicity.  The goal of our screen was to identify genes involved in not only yeast lipotoxicity, 
but also potential targets for mammalian lipotoxic disease treatment.   We found 68 new 
mammalian genes, which may confer sensitivity to fatty acids in mammalian cells, based on their 
sequence homology to yeast genes identified by our palmitoleate sensitivity screen.  
We demonstrate that knockdown of two of these orthologs, ASNA1 and ARV1, in MIN6 
pancreatic β-cells increases levels of fatty acid induced apoptosis and demonstrate a role for both 
of both genes in lipotoxic pathways leading to T2D.     These studies demonstrate that our yeast 
sensitivity screen was successful in the identification of mammalian lipotoxicity genes based on 
gene sequence identity.  Therefore, it is likely that our list of 66 unstudied human orthologs 
contains more genes that are integrally involved in the pathways of lipotoxicity, and these genes 










 In order to further characterize the role of yeast Get3p and mammalian ASNA1 and 
ARV1 in lipotoxicity, we can continue to utilize both yeast and mammalian model systems.  
Future studies complementing this work include additional studies on GET3 in lipid lipase 
activity and lipid droplet homeostasis, the unique effects of a DGA1 deletion on TG localization, 
and the function of mammalian ARV1 and ASNA1 in pancreatic β-cell health in vivo.  
 
1. Determine the role of yeast vacuolar lipase activity in whole cell lipid homeostasis.   
We propose that the decreased lipid droplet number occurring in GET3 mutants is due to defects 
in vacuolar lipase activity and decreased TG turnover.  Likewise, studies in hepatocytes have 
shown that lipid stores can be mobilized by lysosomal lipases and an inhibition of autophagy 
results in lipid droplet accumulation [91].   In order to decipher the role of vacuolar lipase 
activity in yeast lipid metabolism, we could block autophagy, either chemically or genetically, 
and look for a neutral lipid accumulation and alterations in other pathways of lipid metabolism.   
 Further study in the GET mutant may also provide insight into the role of the yeast 
vacuolar lipase, Atg15p, in lipid recycling.  Localization of Atg15, using a fluorescent tag such 
as GFP, in a GET3 deletion would determine if the localization of this protein was in fact altered 
due to protein sorting defects.  Additionally, we would expect specific blockage of PtdIns-3-P 
synthesis at the endosome would result in a similar defect in vacuolar lipase localization and 
activity.  Together these studies would clarify the role of lipophagy and vacuolar lipid recycling 
in cellular lipid homeostasis.  






2. Further elucidate the role of Get3p in lipid metabolism.  In order to determine if the 
lipid phenotypes characteristic of Get3p are due to its role in G protein activation or TA protein 
insertion, these mechanisms must be isolated.   Structural analysis studies of Get3p have 
determined protein domains integral for tail anchored protein insertion, particularly the 
nucleotide hydrolase domain (NDH) and a hydrophobic patch, which binds TA proteins [386].  
One approach to separate out the two Get3p pathways is to mutate specific amino acids within 
the TA binding domain of Get3p.  This would hypothetically block TA protein insertion without 
affecting its guanine exchange function.  Lipid metabolism studies similar to those completed in 
this thesis could then be repeated in strains containing these TA protein point mutants, in order to 
determine if the decrease in LD number and neutral lipid synthesis are dependent on TA protein 
misinsertion.    
 Get3p strains with targeted mutations in the guanine nucleotide exchange domain would 
also be useful in clarification of the connection between Get3p and lipid metabolism.  
Unfortunately, no known signature sequence or domain exists that is able to predict activity of 
nonreceptor exchange factors, like Get3p [217]. Thus, additional research into the interaction 
between Get3p and Gpa1 is necessary to determine the protein domains important in nucleotide 
exchange.   
 
3.  Identify if pools of triglyceride synthesized by Dga1p or Lro1p are differentially 
localized within the cell.   The diverse phenotypes seen with deletion of LRO1 and DGA1 in a 
strain lacking GET3, indicates that the TG synthesized by these enzymes exists in separate pools 
at the ER membrane.    Topographical studies of Lro1p have indicated that the active enzymatic 






Similar results have been demonstrated in hepatocytes, which demonstrate that DGAT2 activity 
occurs in the cyosol whereas DGAT1 is able to synthesize TG in the lumenal compartment 
[294].     
Furthermore, clarification of the differential metabolism of cytosolic and lumenally 
synthesized TG in yeast may explain the increased vacuolar lipid association occurring in DGA1 
mutants.   Electron microscopy of single deletions in LRO1 or DGA1, and triple deletions lacking 
all sterol ester synthesis (are1Δ are2Δ) with an additional deletion in one of the TG synthesis 
genes could provide valuable insight into TG localization and flux based on enzymatic origin.   
 
3. Selective knockdown of ASNA1 and ARV1 in mouse pancreatic β-cells and liver.  In 
order to determine the role of ARV1 and ASNA1 in pancreatic β-cell lipotoxicity and type 2 
diabetes progression, conditional knockouts of either gene in mouse pancreatic β-cells would 
provide insight into cellular function and phenotypes related to type 2 diabetes and obesity 
related disease.  Loss of ARV1 in nematodes is embryonic lethal [387], and it is likely that a 
knockout of ARV1 in a germ line would be inviable.  Similarly, knockout of ASNA1 in mice is 
embryonic lethal [307].  Therefore, use of the Cre/LoxP system [388] for tissue specific 
knockout of ARV1 and ASNA1 is a useful alternative to the whole body knockout model.   
Studies of pancreatic β-cell function in these mice, particularly when maintained on a high fat 
diet, would clarify the increased lipoapoptosis and altered glucose stimulated insulin release 
demonstrated in our tissue culture studies.  
 
4. Complete an ARV1 overexpression and knockdown study in mice fed a high fat diet.  






accumulation through increased TG synthesis [156].  These mice were maintained on a normal 
diet, and additional studies of hepatic ARV1 overexpression in the face of high fat diet (HFD) 
challenge may uncover additional lipid related phenotypes.  It would be particularly interesting 
to see if HFD in ARV1 overexpressing mice resulted in the progression of noninflammatory 
nonalcoholic fatty liver disease (NAFLD) to more advanced nonalcoholic steatohepatitis 
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Figure S2-1: Sensitivity of vacuolar protein sorting (VPS) mutants to palmitoleate. Serial 
dilution plating of 61 VPS mutants on 0.5 mM palmitoleate for 2 days at 30°C. + indicates 










Figure S3-1: Growth curves of GET complex and triglyceride synthesis enzyme knockouts in 
palmitoleate.  Strains grown in 0.5 mM palmitoleate for 3 days with cell density as measured by 
absorbance (OD600).  (A) GET1 and LRO1 deletions (B)  GET2 and LRO1 deletions (C) GET3 







Table S2-1:  Growth Curve Validation of significant palmitoleate sensitive screen hits.  
Growth curve variables “Max Rate”, “Time” and “Max OD” relative to wild type control.  
Strains are ranked first by the severity of their phenotype upon deletion.  This severity was 
determined by summation of the three relative growth values (“Max Rate” + “Max OD” +  
“Time”).   “Max Rate” and “Max OD” value is 1 for normal growth the higher the value to 
slower the growth.  Normal growth for “Time” is 0 and .increased value indicates slow growth.  















































































































































Table S2-2: Palmitoleate sensitive gene functions and human orthologs.  Functional 
information on yeast genes obtained from Saccharomyces genome database (SGD). Human 
percentage values indicated refer to percent sequence identity.  Ortholog conservation and 
function obtained from National Center for Biotechnology (NCBI) and Biobase PROTEOME 




































































































































Table S2-3:  Additional phenotypes of palmitoleate sensitive strains.  Breakdown of additional 
lipid related phenotypes in single deletion mutants based on lipid droplet screen (Table 2-3) 
nystatin and myriocin sensitivity vulnerability to low (16°) or high (37°) temperatures and 
identification in genome-wide screen for altered basal unfolded protein response (UPR) (Jonikas 
et al).  Sensitivity levels on a scale of 0-4 0 being no sensitivity and 4 being complete inviability.  
Blank values for Nystatin Myriocin Cold and Heat columns indicate that strain was not tested.  
Blank values for UPR column indicate that no significant change was evident.  Yeast genes 















































































































Table S3-1: Yeast Tail-Anchored (TA) proteins and sensitivity to palmitoleate.  List of yeast 
tail anchored proteins, their cellular localization and function and their sensitivity to palmitoleate 
based on the palmitoleate screen, or a retesting on solid media (solid + palmitoleate) and liquid 
media (liquid + palmitoleate).  Blank wells indicate that the mutant was not tested.  ’0’ indicates 
no sensitivity, ‘+’ slight sensitivity and ‘++’ completely inviable.  
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